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Resumo 
 
Desde 1993 que a OMS declarou a Tuberculose (TB) como uma emergência de saúde pública 
global. É, atualmente, responsável por quase 2 milhões de mortes por ano, sendo a nona 
principal causa de morte em todo o mundo. O principal obstáculo para o controlo efetivo da TB 
é a resistência aos antibacilares, havendo assim a necessidade de implementação de novas 
tecnologias de diagnóstico rápido que possam traduzir-se no início precoce do tratamento e 
bloqueio das cadeias de transmissão. 
Considerando os constrangimentos para o isolamento e tempo de crescimento das estirpes de 
M. tuberculosis, o principal objetivo desta dissertação consistiu em avaliar o potencial do uso de 
metodologias baseadas na Sequenciação Total do Genoma (WGS) para o diagnóstico de rotina 
e vigilância epidemiológica. Procedeu-se à avaliação de várias plataformas bioinformáticas para 
previsão in silico dos perfis de resistência aos antibacilares, bem como ao desenvolvimento de 
“pipelines” bioinformáticas para vigilância epidemiológica. Estas abordagens revelaram uma 
elevada sensibilidade quando comparadas com as metodologias tradicionais, tendo sido já 
implementadas na rotina laboratorial do Laboratório Nacional de Referência (LNR). 
Adicionalmente, demonstrámos a possibilidade de usar essas mesmas metodologias 
diretamente em amostras clínicas, diminuindo o tempo de resposta para cinco a oito dias. Além 
disso, e de acordo com as novas recomendações para o tratamento da TB, iniciámos estudos 
para identificação de mutações associadas à resistência aos fármacos recentemente adotados, 
de forma a enriquecer as bases de dados e, consequentemente, a performance do diagnóstico 
genotípico. 
Concluindo, acreditamos ter contribuído para a validação das metodologias baseadas em WGS 
como ferramentas para ultrapassar as dificuldades do diagnóstico e vigilância fenotípica da TB 
em particular, na sua capacidade de fornecer informações muito mais rápidas sobre previsão de 
resistência e transmissão. Por último, este trabalho esteve na base da transição tecnológica 
iniciada no LNR para a vigilância da tuberculose. 
 
Palavras-chave 
Tuberculose, Multirresistência, Whole-genome sequencing, Vigilância, Mutações associadas a 
resistência, Epidemiologia 
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Abstract 
 
Tuberculosis (TB) has been declared as a global public health emergency by the WHO since 1993. 
It still accounts for almost 2 million deaths each year, making it the ninth leading cause of death 
worldwide. The major obstacle for an effective TB control is antimicrobial resistance, thus, to be 
successful, new strategies must be addressed, for instance, the implementation of new rapid TB 
diagnostic technologies that could translate into early treatment initiation and blocking of 
transmission chains.  
Considering the major constraints regarding the isolation and time of growth of M. tuberculosis 
strains, the main goal of this PhD dissertation was to acknowledge the potential of the use of 
WGS-based methodologies for routine diagnostic and epidemiological surveillance. We 
evaluated several software for in silico prediction of antibiotic resistance and developed 
bioinformatics pipelines for surveillance purposes, in particular for the identification of 
transmission chains. As they revealed high sensitivity, these approaches are already 
implemented in the routine of the Portuguese National Reference Laboratory (NRL). We also 
recognised the possibility to use these same approaches directly to samples collected from TB 
patients, lowering the time-to-results, for a complete drug resistance pattern and phylogeny 
analysis, for five to eight days. The validation of this methodology is ongoing and will be 
implemented in a near future. Additionally, and according to the new recommendations for TB 
treatment, we have initiated studies to identify new mutations associated with resistance to the 
recently adopted drugs, in order to enrich the available databases and improve the performance 
of the genotypic diagnostics pipelines.  
This PhD dissertation highlights WGS-based methodologies as powerful tools to surpass the 
difficulties of phenotypic TB diagnosis and surveillance and to provide a much more rapid 
information regarding resistance prediction and eventual transmission chains. It also supported 
the technological transition performed at the NRL for TB surveillance. 
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Tuberculosis, Multidrug resistance, Whole-genome sequencing, Surveillance, Resistance-
associated Mutations, Epidemiology 
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Notes of the author: thesis organization, format and outline 
 
This PhD dissertation is composed of seven chapters, including an Introduction, several research 
studies (either published or ongoing), and a final discussion. Its core is based on three 
manuscripts (listed below) that are presented as individual chapters and two additional chapters 
that include a proof of concept of methodologies to be soon implemented and submitted to a 
journal  and an undergoing study with the major breakthroughs at the moment. The manuscripts 
have already been published in peer reviewed international journals, and the corresponding 
chapters essentially represent what was published. The chapters were organized so that they 
follow a rational order taking into account the objectives delineated for this PhD work. Each 
manuscript-based chapter is preceded by a title page describing the reference of the publication, 
the specific contributions of the author of the present PhD thesis, and, when applicable, the 
alterations that were performed regarding what is published (referred as "minor changes"). In 
brief, each chapter includes the following contents: 
Chapter I. This chapter consists of a general introduction that intends to provide the reader with 
the state of the art in the subjects addressed in this doctoral dissertation around Tuberculosis, 
the first cause of death from an infectious disease. It includes a global overview of the major 
aspects of M. tuberculosis taxonomy, biology, molecular epidemiology and impact on human 
health, followed by insights into the genetic diversity and some already established 
genotype/phenotype associations. It ends with the description of the main objectives of this PhD 
project, which includes the specific research questions that drove the investigations carried out 
on behalf of each chapter. 
 
Chapter II. Genetic prediction of antibiotic resistance 
This chapter corresponds to the following published manuscript: “Rita Macedo, Alexandra 
Nunes, Isabel Portugal, Sílvia Duarte, Luís Vieira, João Paulo Gomes. Dissecting whole-genome 
sequencing-based online tools for predicting resistance in Mycobacterium tuberculosis: can we 
use them for clinical decision guidance? 2018. Tuberculosis. 110: 44–51”. It evaluates the use of 
several bioinformatics pipelines for in silico prediction of antibiotic resistance in M. tuberculosis 
aiming at overcoming the time-consuming laboratory procedure underlying the antibiotic 
susceptibility tests. The ultimate goal of this study was to implement one of the evaluated 
bioinformatics-based approaches in the routine practice of the National Reference Tuberculosis 
Laboratory at INSA. 
 
xx 
 
Chapter III. Epidemiology of multidrug resistant tuberculosis in Portugal 
This chapter corresponds to the following manuscript: “Rita Macedo, Raquel Duarte. Trends of 
MDR-TB clustering in Portugal. 2019. ERJ Open Research 5: 00151-2018”. In general, this study 
focus on understanding the dynamics of MDR-TB emergence and transmission, to establish the 
rate of recent transmissions against newly developed resistant strains, to pinpoint the 
emergence of new cases in the population and to identify associated risk factors. 
 
Chapter IV. Development of genomic-based surveillance methodologies 
 This chapter corresponds to the following manuscript: “Rita Macedo, Miguel Pinto, Vítor 
Borges, Alexandra Nunes, Olena Oliveira, Isabel Portugal, Raquel Duarte, João Paulo Gomes. 
Evaluation of a gene-by-gene approach for prospective whole-genome sequencing-based 
surveillance of multidrug resistant Mycobacterium tuberculosis. 2019. Tuberculosis 115: 81-88”. 
This study ultimately aimed to implement a whole-genome-sequencing-based approach for 
surveillance purposes at the National Reference Tuberculosis Laboratory at INSA, following the 
recommendations of the international health authorities. 
 
Chapter V. Whole-genome-sequencing of Mycobacterium tuberculosis directly from clinical 
samples 
This chapter corresponds to an ongoing study enrolling the PhD student and the team of the 
Bioinformatics Unit of the Department of Infectious Diseases at INSA. It aims at developing and 
optimizing a laboratory procedure to capture M. tuberculosis genomes directly from the clinical 
samples without the need for culture propagation of the infecting strains. If this approach turns 
out to be a feasible method, it could be applied upstream of the use of the bioinformatics 
pipeline to predict antibiotic resistance (described in Chapter II). Using these two approaches in 
a tandem fashion would tremendously decrease (i.e., in several weeks) the time necessary to 
determine the suitable antibiotic therapy. 
 
Chapter VI.  Disclosing the genetic basis of antibiotic resistance 
This chapter corresponds to a long-term ongoing study enrolling the same teams as the previous 
study. By using in vitro selective pressure scenarios (i.e., antibiotic pressure using sub-MIC) 
during M. tuberculosis propagation, this study intends to identify the mutations responsible for 
the emergence of clones with decreased susceptibility to a specific antibiotic, and thus enrich 
xxi 
 
the available genetic databases. Ultimately, it may contribute to the accuracy improvement of 
the software platforms used for in silico prediction of antibiotic resistance (described in chapter 
II). 
 
Chapter VII. This chapter provides a global overview of the subjects addressed throughout the 
chapters, highlighting the main results and conclusions achieved in this PhD dissertation. 
Considering that each chapter focusing a research study contains its own “Discussion”, only the 
most relevant results are discussed in this final chapter in order to avoid redundancy. New 
research questions raised with this work that can be addressed in the future follow-up of these 
investigations are also presented. 
 
Considering the dissimilar layouts and in-text reference styles adopted by different journals 
where the manuscripts were published, all chapters were formatted in a unique style, with all 
references being cited by sequential numbers (in parentheses) and listed in the "References" 
section according to the order in which they appear in the text. In this regard, a single section of 
"References" is presented. 
Similarly, all the supplemental material is presented at the final of this PhD thesis, enumerated 
accordingly with the chapter they concern to. 
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1. General Introduction 
 
1.1 The genus Mycobacteria 
 
Lehmann and Neumann first introduced the genus Mycobacterium to the scientific community 
in 1896 (1). The subsequent history of the genus has been profoundly influenced by the fact that 
only very few of the almost 200 currently recognized species 
(http://www.bacterio.net/mycobacterium.html) have been a cause of human disease, above all, 
M. tuberculosis. Thus, studies of microbial physiology, structure, genetics and diagnostic tools 
have mainly focused on M. tuberculosis. 
Mycobacterium is the only genus in the family of the Mycobacteriaceae, as it is defined in 
Bergey’s Manual of Systematic Bacteriology (2), but it is considered to be closely related to other 
mycolic acid-containing genera: Caseobacter, Corynebacterium, Nocardia and Rhodococcus (3). 
All mycobacteria are aerobic (though some species are able to grow under a reduced oxygen 
atmosphere), nonspore-forming, nonmotile, slightly curved or straight rods (0.2–0.6 × 1.0–10 
μm). Many species form whitish or creamcolored colonies, but especially among the rapid 
growers, there are also many bright yellow or orange species containing carotenoid pigments 
(4). In some cases, the pigments are only formed in response to light (photochromogenic 
species), but most pigmented species also form these pigments in the dark (scotochromogenic 
species). The classification of Runyon separates the genus Mycobacterium into four groups 
(photochromogens, scotochromogens, nonphotochromogens, and rapid growers) and was 
introduced in the late 1950s as a systematic base for the description of mycobacteria (5). This 
division, based on pigmentation and growth rate, is still of use to the clinical mycobacteriologist 
and the separation of the genus into two major groups on the basis of the growth rate of the 
individual species forms the basis of the mycobacterial taxonomy. The most prominent feature 
of mycobacteria that is uniformly present and distinctive of the genus is the lipid-rich cell 
envelope (1). Indeed, it is the complex cell envelope of mycobacteria that confers these bacteria 
the property of ‘acidfastness’ (i.e. resistance to decolourization when stained with carbolfuchsin 
and decolorized with dilute hydrochloric acid). Uniformly, they do not stain well with Gram stain 
and should be considered gramneutral. Mycobacteria possess a cell wall polysaccharide that 
resembles that of gram-positive bacteria; however, the mycobacterial peptidoglycan contains 
lipids in place of proteins and polysaccharides (1). Furthermore, the mycobacterial envelope 
contains a plasma membrane that is quite similar in structure and function to the plasma 
membrane of other bacteria, except for the presence of lipoarabinomannan (LAM), lipomannan 
and phosphatidylinositol mannosides. As a whole, the cell wall component of the envelope 
4 
 
confers size, shape, protection against osmotic pressure and probably protects the plasma 
membrane from deleterious molecules present in the environment of the cell. In summary, the 
peptidoglycan confers cell shape while the next layer of the envelope, arabinogalactan esterified 
to the mycolic acids, provides a hydrophobic permeability barrier. Other important fatty acids 
are waxes, phospholipids and mycoserosic and phthienoic acids, and tuberculostearic acid (10-
R-methyl-octadecanoic), a unique cell component within the Actinomycetales, including the 
mycobacteria (1). 
In 1947, Middlebrook first described growth of tubercle bacilli in the shape of serpentine cords 
(‘cording’). For many years, cording was correlated with virulence and considered a distinctive 
feature of M. tuberculosis. However, it is now known that several mycobacterial species display 
cording and the correlation with virulence, if any, is unclear (1). 
 
 
1.1.1 Taxonomy 
 
The number of Mycobacterium species has increased from about 40 in 1980 (6) to over 180 in 
2018 (http://www.bacterio.net/mycobacterium.html). The description of novel species is 
paralleled by the development of molecular methods and by the increased recognition that slow 
growing mycobacteria are clinically important and fast-growing mycobacteria are ecologically 
important. By the end of 1983, there were 52 described species, only six new species were added 
between 1984 and 1991, about four new species per year between 1992 and 2003 and most of 
the non-tuberculous mycobacteria (NTM) species were identified in recent years. 
Currently the genus is broadly divided into “slow growers” and “rapid growers”. Rapid growers 
are those species that under optimal solid culture conditions grow visible colonies within seven 
days. The slow growers exceed this time, in some cases, in several additional weeks. The most 
notable members of the slow growers belong to the M. tuberculosis complex (MTBC), which 
cause tuberculosis (TB) in both humans and animals. Another slow-grower is M. ulcerans, which 
is the cause of the Buruli Ulcer, a neglected tropical disease with its highest incidence in sub-
Saharan Africa (7). Also of note is M. avium subsp. paratuberculosis, which causes Johnes disease 
in cattle and has long been suspected (but not yet proven) to be a contributor to Crohn’s disease 
in humans (8). M. leprae causes leprosy, a disabling disease which is still endemic in isolated 
pockets of the world (9). All of the known rapid growing Mycobacteria are primarily 
environmental, with some having the ability to become opportunistic pathogens. The most 
5 
 
virulent and clinically relevant of these is M. abscessus, which can cause both wound and 
respiratory infections (10). 
 
 
1.2 The Mycobacterium tuberculosis complex 
 
The species M. tuberculosis belongs to the “M. tuberculosis complex” (MTBC), which is a group 
of closely related species that can cause TB disease in animals. Although currently defined as 
different species, they fall short of the minimum standard to be considered true species (i.e., 
more than 5% nucleotide divergence). Nevertheless, there are clear phenotypic and 
epidemiological differences between the members of the complex: M. tuberculosis is strictly a 
human pathogen; M. bovis and M. caprae can infect a wide range of animals, but of primary 
concern is its burden in cattle; M. africanum is mostly found in humans but it seems to be 
restricted geographically to West Africa (11); M. canettii is the most divergent species, differing 
from M. tuberculosis by at least 2% at the nucleotide level. It has unusual smooth colony 
morphology and a lower virulence (12). More recently, additional species of the MTBC were 
identified. One of those has emerged in banded mongooses (Mungos mungo) in Botswana and 
was named mongoose bacillus, or M. mungi sp. nov. This pathogen causes high mortality rates 
among banded mongooses that live in close association with humans because these animals live 
in human-made structures and scavenge human waste, including feces (13). Another new 
species is M. suricattae, isolated from free-living meerkats (Suricata suricatta) from the Kalahari 
Desert, South Africa, and was first reported in 2002 (14). Finally, Oryx bacilli, M. oryx, have been 
isolated from members of the Bovidae family, i.e., oryxes, gazelles, deer, antelope, and 
waterbucks, although their exact host range remains unsettled (15). However, for these novel 
subspecies, no cases of human disease have yet been reported to date. 
The completion of the first M. tuberculosis reference genome (16) provided the opportunity to 
detect large sequence polymorphisms (LSPs). These LSPs were used as markers to reflect the 
deep evolutionary relationships between the members of the complex. Remarkably, they 
provided evidence that refuted the commonly proposed idea that human TB evolved from a 
bovine progenitor, as M. bovis was found to have diverged more recently than the other human 
strains (17). 
Our knowledge of the MTBC was increased by sequence-based analyses of genes (18), and, more 
recently, by whole-genome sequencing analysis (19). This revealed the presence of seven human 
lineages, and one animal lineage, which includes M. bovis (Figure 1.1). M. africanum is split into 
two distinct lineages, West African 1 and 2. The other lineages are comprised of geographically 
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structured M. tuberculosis strains; Lineage 4, the Euro-American lineage, is the most widespread 
and commonly isolated (20) and Lineage 2, the East-Asian lineage, is split into Beijing and non-
Beijing strains. The Beijing clone is of particular concern as it is typically highly drug resistant and 
it is supposed to have spread from East-Asia into Eastern-Europe (21,22). 
In addition, these studies indicated that the MTBC had a highly clonal population structure (18) 
and that there was an absence of inter-genomic recombination occurring within the complex. 
MTBC is devoid of horizontal gene transfer, thereby exhibiting a closed genome, coupled with a 
low mutation rate (23). Consequently, is recognized as monomorphic bacteria, but, still, a 
successful pathogen that has subsisted as such since the dawn of humankind (19,24). M. canettii 
is an exception, as there is some evidence of recombination both within this species and with 
other members (12). The absence of recombination in the rest of the complex is currently 
unexplained, but could possibly be due to a loss of the required molecular mechanisms or a lack 
of opportunity due to its facultative intracellular lifestyle. 
 
 
Figure 1.1. Phylogenetic relationships of the different MTBC lineages, based on SNPs of 261 mycobacterial 
genomes, adapted from the work from (25) - L1 correspond to East-African-Indian (EAI) strains, L2 to 
Beijing strains, L3 to Dehli/Central Asian strains (Dehli/CAS), L4 to Euro-American strains (T, Haarlem, LAM, 
S, X), L5 to M. africanum 1 and L6 to M. africanum 2 strains. L7 strains are restricted to Ethiopia and the 
Horn of Africa region (26). 
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1.3 History of Tuberculosis 
 
Tuberculosis is considered an ancient disease, and evidence for TB-like disease, confirmed by 
both morphological and molecular methods, has been found in skeletons dating to the Neolithic 
era, approximately 9,000 years ago, in the Eastern Mediterranean (27). However, some 
estimates place the origin of the disease much earlier – 70,000 years old – when humans first 
started emerging from Africa (19). 
TB is thought to have killed more people than any other microbial disease throughout history 
(28). Its significant impact on human society is reflected by the multiple designations that were 
attributed to this disease throughout the centuries.  Hippocrates first described it as 
“consumption” (or Phthisis in Greek), probably relating to the “wasting away” and weight loss 
experienced by the patients (29). The term “White Plague” was used during the epidemics that 
spread throughout Europe during the 17th and 18th centuries (30), and presumably referred to 
the pale complexion given by the disease. TB incidence is thought to have reached its peak in 
the 19th century when it is estimated that a quarter of Europeans have died from the disease 
(29). It is against this catastrophic scenario and prognosis that Robert Koch made his famous 
presentation to the Physiological society of Berlin in 1882, where he demonstrated that the 
tubercle was the causative agent of TB. Not only was this one of the first pathogenic bacteria to 
be described, but he also established the “Koch’s postulates”, which set the standard of 
infectious diseases’ etiology, still of relevance nowadays (28). 
With the advent of antibiotics and improved public health measures, many in the western world 
have considered TB a disease of the past. Incidence declined gradually during the early and mid-
19th century almost until the present day, although the exact reasons for this phenomenon 
remain unclear (28). Despite this, a third of the population is thought to be infected, and today, 
TB remains a disease of poverty in high and low/middle income countries, with the global burden 
mostly centralized in Africa, Asia and South America, where the majority of the infected people 
can be found (31,32). 
 
 
1.4 Tuberculosis: pathogenesis, clinical features and diagnosis 
 
1.4.1 Pathogenesis 
 
Tuberculosis can develop through progression of recently acquired infection (primary disease), 
reactivation of latent infection, or exogenous reinfection (33). In immunocompetent individuals, 
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about 90% of those with TB infection never develop the disease; approximately 3-10% will 
develop the disease in the first 1-2 years after infection (34) and another 5% during their 
lifetime. The risk depends on the age of acquiring infection, being lowest in the age range of 5 
to 9 years (35). Exogenous reinfection is thought to be uncommon in immunocompetent people, 
but life-style-related factors and chronic diseases, such as active or passive smoking (36,37), 
nutritional status (38) and diabetes mellitus (39) may significantly affect the risk of reactivation. 
In the setting of Human-Immunodeficiency Virus, HIV-1, infection, the risk of progressing rapidly 
to disease, once infected with M. tuberculosis, the risk of reactivation, and the risk of exogenous 
reinfection are all increased compared to seronegative persons (40–42). 
The “life cycle of TB” starts with the inhalation of infectious droplets that reach the alveoli 
(Figure 1.2). They are phagocytised by the alveolar macrophages and, at this point, the immune 
system either manages to confine the mycobacteria, leading to a latent asymptomatic infection 
and the formation of granulomas, which happens for the majority of the cases, or failure can 
lead to an active infection (43,44). In order to control the infection, the macrophages induce 
production of proteolytic enzymes and cytokines that attract T lymphocytes to the site. This 
initial control phase can last between two to 12 weeks (45). If this is successful, a granuloma will 
eventually be formed, which is a nodular type lesion formed of T lymphocytes and macrophages 
intended to confine the mycobacteria. This primary pulmonary granuloma and associated 
draining lymph nodes are known as the “Ghon complex” and can be detected radiologically (46). 
This environment is characterised by low oxygen and pH, in which the mycobacteria are able to 
survive in a dormant state. The lesion can then undergo calcification and fibrosis in order to keep 
the infection confined. Approximately 90% of those infected with M. tuberculosis maintain the 
infection in this dormant state for the rest of their lives (47). Of the remaining 10%, the 
granuloma fails to contain the bacilli allowing them to spread to a bronchus or nearby blood 
vessel (45). This allows the infection to spread throughout the respiratory system where 
progressive lung damage occurs through the formation of cavities. In some cases it spreads to 
other organs such as the lymphatic system, bones and meninges and a reactivated TB can affect 
almost any anatomical site (48). However, only pulmonary TB is transmissible and ensures the 
evolutionary success and adaptation of the bacteria. 
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Figure 1.2. Phases of human tuberculosis. After inhalation of the bacteria, there is a blood-borne stage 
where the immune system attempts to control the infection. In 5-10% of individuals, this will lead to active 
or cavitary tuberculosis, which can allow M. tuberculosis ongoing transmission through aerosols 
production. Adapted from (44). 
 
 
1.4.2 Clinical features 
 
Most TB cases occur as pulmonary disease with only about 17% occurring at an extrapulmonary 
site. However, about 70% of HIV-1 infected patients will have evidence of extrapulmonary 
disease or mycobacteremia and these co-infected patients are more likely to present atypically, 
potentially delaying TB diagnosis (1).   
The classical symptoms of early and progressive active TB disease can be unspecific but the most 
common are fevers, night sweats, fatigue, weight loss and a chronic cough (45,49). Additionally, 
the disease reveals localized symptoms according to the form it takes. If untreated, the 
estimated fatality rate of smear positive and negative pulmonary TB is about 70% and 20%, 
respectively (50). Some extrapulmonary manifestations, such as milliary TB or meningitis are 
universally fatal in the absence of treatment (49,51). Patients with pulmonary disease, of whom, 
those with cavities that function as open reservoirs of large numbers of bacilli, are the most 
infectious and more prone to transmit the disease (52). This happens when droplets are coughed 
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up from the bronchus, aerosolised, and remain airborne for minutes to hours allowing spread 
to other persons. These droplet nuclei are tiny ranging from 2–5 μm in diameter and containing 
as few as 1–3 cells (53). The timing of the development of active TB can vary greatly from weeks 
to decades after infection, is most often caused by a compromised immune system, and can 
later become latent, and then be reactivated multiple times throughout life. 
 
 
1.4.3 Diagnosis 
 
Although TB shares many clinical and radiological features with other respiratory diseases, 
symptoms remain an important tool to facilitate passive case-finding (54). Radiology (X-ray) is 
generally used in a first evaluation for TB diagnosis. In patients with progressive primary or 
postprimary TB, computed tomography scanning is often performed, in addition to chest 
radiography. Magnetic resonance imaging may also be used to evaluate complications of 
thoracic disease, such as the extent of thoracic wall involvement, but is of limited value in the 
evaluation of patients with pulmonary TB. These chest abnormalities are merely suggestive and 
can be used to rule out the disease but not for confirmative diagnostic purposes (55,56). 
Patients suspected of having pulmonary TB should have at least two sputum specimens 
examined for microscopic evidence of acid-fast bacilli (AFB) (57). Fluorescence microscopy is 
faster to visualize and shows a higher sensitivity when compared to conventional Ziehl-Neelsen 
(ZN) smear microscopy (58). However, it has lower specificity than ZN smear microscopy for 
diagnosis, thereby suggesting a need for appropriate training, quality management, monitoring 
of performance and confirmation testing with ZN staining (59). In addition, specimens should be 
cultured in order to identify the specific mycobacterial species and for drug susceptibility testing. 
Mycobacteria of the MTBC are slow growers, dividing every 15 to 20 hours (60), and thus it can 
take over 3 weeks to see visible growth on standard culture media (61).  This has significant 
clinical implications because therapy must be initiated before TB diagnosis is confirmed. In 
addition, drug susceptibility testing (DST) results are rarely available at the initiation of 
treatment. On the other hand, clinically significant disease can be present even in the absence 
of a positive culture, due to poor specimen collection, contamination and/or low bacillary count 
(54). 
Nucleic acid amplification tests (NAAT) allow the rapid identification of MTBC (61). Several NAAT 
are commercially available for the laboratory-based diagnosis of TB and some of them also allow 
the detection of resistance to rifampicin and some other first- and second-line drugs (54).  Using 
culture as the reference procedure, most of them reveal similar high sensitivity and specificity 
11 
 
for the detection of M. tuberculosis among sputum smear-positive patients (62,63). However, 
unlike culture isolation, detection by NAAT does not necessarily imply viability of the detected 
bacteria. Nevertheless, the WHO recommends that Xpert MTB/RIF should be used rather than 
conventional microscopy, culture and DST as the initial diagnostic test in adults and children 
suspected of having MDR-TB or HIV-associated TB (64). 
 
 
1.4.4 Drug susceptibility testing 
 
Drug susceptibility testing (DST) of M. tuberculosis should be performed on an initial isolate from 
all patients with TB (61). If the patient’s culture remains positive after 3 months of therapy, a 
new DST should be performed. Testing is done using a standard methodology such as the 
recommended by the National Committee for Clinical Laboratory Standards (NCCLS) (65). 
Drug resistance can be detected by a variety of in vitro methods that are usually contingent on 
demonstrating growth of the organism in the presence of a "critical" concentration of an 
antituberculosis drug. The two most commonly used qualitative methods are the proportion 
method and the BACTEC method. The agar proportion method has been proposed as the 
reference method for all antituberculosis drugs except pyrazinamide for which BACTEC is the 
reference method (65). With the proportion method, plates of drug-free agar and agar 
containing critical concentrations of antituberculosis drugs are inoculated with the isolate. For 
most drugs, resistance is determined by comparing the number of colony forming units (CFU) 
on drug-containing versus drug-free media, with clinically significant resistance being defined as 
greater than 1% growth on drug-containing media relative to drug-free media (65). Rapid broth-
based methods (e.g., BACTEC, MIGIT, etc.) are recommended for initial susceptibility testing of 
first-line agents. The BACTEC method allows a more rapidly determination of minimal inhibitory 
concentrations (MICs), as the growth is facilitated by the addition of enhancing growth 
supplements. 
The short turnover time of genotypic methods offers an attractive potential for rapid detection 
and characterization of drug resistance. However, genome sequencing of M. tuberculosis 
isolates revealed a large number of new genes, intergenic regions and nonsynonymous single 
nucleotide polymorphisms (SNP) showing consistent associations with drug resistance. This 
indicates that the genetic basis of drug resistance is more complex than previously anticipated 
(66) and that the available commercially and routinely used NAAT do not target all the necessary 
genes.   
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1.5 Tuberculosis treatment 
 
Although TB is an ancient disease, effective drugs were not available for centuries. The pre-
antibiotic therapy initially consisted of isolation of the patients in sanatoria to reduce the 
transmission to healthy contacts, with rest, adequate nutrition, and sunlight exposure (67–69). 
The first evidence of a potential anti-TB drug was made in 1940, when a dapsone-derivative 
compound, known as promin, was administered to a sample of infected guinea pigs. However, 
that compound was never subjected to human clinical trials (70–72). In 1944, Schatz and 
Waksman stated that streptomycin (STR), a natural substance isolated from Streptomyces 
griseus, had bactericidal activity and thus could be prescribed for TB treatment. However, only 
few years later, the first resistant cases arose, compromising the use of a streptomycin-based 
monotherapy (73). Four years later, a new synthetic drug, called para-aminosalicylic acid (PAS), 
was presented as an alternative drug. Following the poor results of the monotherapy, in 1952, 
the first regimen based on the combination of STR, PAS, and isoniazid (INH) was proposed 
(71,72,74). 
In 1954, pyrazinamide (PZA) was discovered and ethambutol (EMB) and rifampicin (RIF) were 
introduced in 1961 and 1963, respectively. At this time, the duration of therapies could last two 
years. In 1970, trials on RIF-including regimens showed good results with a therapy of 9 months, 
and in 1974, the inclusion of RIF and PZA at lower dosages demonstrated the efficacy of a 6-
month treatment (71,72,75,76). 
The choice of the antituberculosis drugs in the different phases is not random, but it is based on 
the epidemiology and on the specificity of action of the drugs, which are molecules with two 
different mechanisms of action—bactericidal and sterilizing effect (77). The first group is crucial 
in the intensive phase and allows a relevant reduction of the bacterial load; the indirect 
consequence of this activity is the reduction of the probability of selecting drug-resistant strains. 
The most important drugs prescribed for that aim are INH, PZA, RIF, and STR. The sterilizing 
activity is performed mostly in the continuation phase because it is oriented to kill mycobacteria 
in a dormancy state. Antituberculosis drugs of this group are PZA and RIF (77). These general 
principles are accepted worldwide and the WHO defined standardized regimens (78). As such, 
new cases of TB in patients that were never exposed to drugs have to be treated for 6 months. 
The intensive phase lasts two months and should be administered a combined regimen that 
includes EMB, INH, PZA, and RIF. The four-months continuation phase only includes INH and RIF 
(77,78). Previously treated cases require a different management and a rapid and conventional 
DST is required before the initiation of therapy, to ensure the most appropriate regimen to 
choose (77). 
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It is obvious that multidrug resistant cases (MDR, i.e., in vitro resistant to at least isoniazid and 
rifampicin) could represent a challenge because of the poorest therapeutic options. The so-
called second- and third-line antituberculosis drugs are less efficacious, more toxic, and more 
expensive than the first-line drugs. However, and because of the lesser effectiveness, to obtain 
a clinical and a microbiological cure it is mandatory to treat individuals with MDR-TB for longer 
periods. The WHO suggests the prescription of at least four active drugs during the intensive 
phase and should include PZA, one of the injectable second-line drugs (amikacin - AMK, 
capreomycin - CAP, or kanamycin - KAN), a new-generation fluoroquinolone (FQ), ethionamide 
- ETH (or prothionamide), and cycloserine (or PAS) (78,79). The duration of the first phase of the 
treatment should depend on the culture conversion, but it should last at least eight months, 
whereas the duration of the second phase should be longer than 20 months (77–79). 
With the emergence of more resistant cases, first described in 2007 in patients from Africa, new 
therapeutic options have been proposed (80). Extensively-drug resistant (XDR) TB (defined as 
MDR-TB with resistance to a FQ plus a second-line injectable drug) is a considerable threat, 
resulting in extremely poor treatment outcomes. In a recent study of XDR-TB in South Africa, 
46% of patients died after a two-year follow-up (81); the same outcome would be expected 
without treatment at all. As such, there is a desperately need for new or improved drugs to 
prevent further resistance (eventually leading to strains resistant to all drugs) (82). For this 
reason, several drugs approved for infectious diseases other than TB were screened and showed 
in vitro and in vivo antimycobacterial activity; among them, imipenem-cilastatin, linezolid, and 
meropenem-clavulanate have had a relevant role in individuals with drug-resistant TB in the last 
few years. The new molecules recently approved or in the last clinical trial phases are 
bedaquiline (a new diarylquinoline, previously called TMC 207), delamanid (previously called 
OPC-67683), sutezolid (PNU 100480), and PA-824 (79,83). 
 
 
1.6 Resistance to antituberculosis drugs 
 
In M. tuberculosis, drug resistance occurs through chromosomal mutations that confer 
resistance to individual antituberculosis drugs. These mutations occur spontaneously and at 
predictable rates (84). For example, mutations conferring resistance to INH and RIF occur with 
an estimated frequency of approximately 3 X 10-8 and 2 X 10-10 mutations per bacterium per 
generation, respectively (84). All populations of M. tuberculosis will therefore have a certain 
number of naturally occurring drug-resistant mutants and this probability will be influenced by 
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the size of the bacterial population and the replication rate. The probability that simultaneous 
resistance to INH and RIF will develop in nature is then extremely small, as it is the mathematical 
product of each of the separate probabilities (85). The process of development of resistance in 
M. tuberculosis is basically through the selection of de novo mutations, either SNPs or indels, at 
loci usually termed as resistance associated genes. There are basically four mechanisms 
responsible for this: i) drug target modification, as a result of non-synonymous mutations; ii) 
unsuccessful prodrug activation, due to mutations that prevent the prodrug of reaching its active 
form; iii) target overexpression, usually from mutations at the promoter region that controls the 
expression of the drug target; and, iv) overexpression of drug modifying enzymes, rendering the 
drug inactive (86). 
STR interferes with protein synthesis by inhibiting genetic translation (87). Minimum Inhibitory 
Concentration (MIC) range between 1.0-2.0 mg/L (1.0 mg/L for M. tuberculosis H37Rv) and this 
drug has a moderate bactericidal activity against susceptible isolates (88). Comparing with the 
two other aminoglycosides used in TB treatment, KAN and AMK, STR is the least toxic (89). 
Resistance is usually due to mutations in rpsL and are associated with high-level resistance, in 
particular, the K43R mutation (90). Another mechanism of STR resistance occurs through rrs 
gene mutations and usually yields a lower resistance level (90,91). gidB mutations have also 
been detected in clinical isolates, although its role in resistance is not yet fully understood. They 
appear in resistant and susceptible isolates (92,93), suggesting they could be phylogeny-related 
(93). This is the case for the endemic MDR/XDR-TB Q1 clade in Portugal that was defined based 
on the A80P mutation on gidB, which is simultaneously associated with an intermediate-level 
resistance to STR (94,95). 
INH is a synthetic prodrug that requires activation by the bacterial catalase peroxidase encoded 
by the katG gene and enters the cell by passive diffusion (96,97). Its efficacy is in part due to its 
low MIC: 0.02 mg/L for M. tuberculosis H37Rv and 0.02-0.05 mg/L in susceptible clinical isolates 
(88). INH has a bactericidal activity against rapidly growing mycobacteria and is bacteriostatic 
against slow-growers, although bactericidal activity is also observed in M. tuberculosis (98). 
Resistance usually develops as a consequence of katG mutations that decrease the ability of the 
catalase-peroxidase to convert INH to its active form. The most common mutation is a serine to 
threonine substitution at codon 315 (S315T), found in up to 93% of INH resistant isolates and is 
associated to high-level resistance (99–101). Another important mechanism of INH resistance, 
is the acquisition of mutations in the promoter region of the mabA(fabG1)-inhA operon (102–
104). These mutations usually lead to INH low-level resistance, and an unusual high-prevalence 
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of inhA promoter mutations (up to 91%) have been detected in Lisbon, Portugal, and in strains 
from M. africanum West-Africa 1 lineage (105,106). 
RIF is a semi-synthetic drug derived from rifamycin (107) and binds to the β-subunit of the DNA-
dependent RNA polymerase (encoded by rpoB) (108), physically blocking transcription (109). It 
has a bactericidal activity (110) against metabolically active bacteria, but also possesses some 
sterilizing activity against latent bacilli (111). RIF MIC ranges between 0.2-0.4 mg/L for 
susceptible clinical isolates (0.4 mg/L for M. tuberculosis H37Rv) (88) and the acquisition of 
resistance is usually the result of aminoacid substitutions in an 81-bp region of rpoB, named RIF 
resistance determining region (RRDR) (112,113). Besides aminoacid substitutions, deletions or 
insertions in rpoB have been reported in some studies (114). The most common substitutions 
occur in codons 450 (prevalence of 31.0-76.9% in RIF-resistant isolates), 445 (7.7-43.0%) and 
435 (3.4-28.6%), according to M. tuberculosis RpoB numbering (92,112,113,115–119). RIF 
resistance level depends on the mutation, e.g., S450L and H445D result in high-level resistance 
whereas D435V mostly results in an intermediate-level resistance (91,120,121). It is of most 
importance to note that resistance to RIF rarely emerges before resistance to other drugs, 
especially INH, and, for this reason, is considered a marker for prediction of MDR-TB cases (122). 
EMB is an antimycobacterial drug synthesized from ethylenediamine and targets the cell wall 
biosynthesis by inhibiting the arabinosylation of the cell wall arabinogalactan (AG) and 
lipoarabinomannan (LAM) (123). It has a bacteriostatic activity against metabolically active 
bacilli (124,125) and MIC range of 0.5-2 mg/L for susceptible isolates (0.5 mg/L for M. 
tuberculosis H37Rv) (88). EMB resistance is mainly associated with mutations in embB (126) and 
the most common ones occur in codon 306, usually involving the substitution of a methionine 
by a valine, leucine or isoleucine (103,127–129). Although strains bearing embB306 mutations 
have been associated with a higher level of resistance (130), the molecular basis of EMB 
resistance is not fully determined, as mutations at this site have been described to appear in 
both resistant and sensitive strains (91,103,129). 
PZA is a nicotinamide synthetic prodrug that enters the cell by passive diffusion where it is 
converted by the bacterial pyrazinamidase (PZase)/nicotinamidase into pyrazinoic acid (POA) in 
an acidic pH environment (131). However, there is recent evidence showing that PZA can also 
act on neutral pH conditions (132). Concerning resistance in clinical isolates, the main 
mechanism supporting PZA resistance is the acquisition of mutations in pncA, which have been 
identified by numerous other authors in about 72.0-99.9% of the PZA resistant isolates studied 
(92,131,133,134). 
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The second-line injectable drugs (SLIDs) for TB treatment are KAN, AMK and CAP. Although KAN 
and AMK are, such as STR, aminoglycosides and CAP is a macrocyclic peptide, these drugs share 
the same action mechanism and cross-resistance between the three has been well documented 
(135,136). KAN, AMK and CAP have shown in vitro bactericidal activities but CAP has also a 
bactericidal effect against latent M. tuberculosis bacilli (137). These three drugs act through the 
inhibition of the genetic translation due to ribosomal binding. Mutations in the 16S rRNA-
encoding rrs gene can mediate cross-resistance between CAP, KAN and AMK, being the most 
common mutation the A1401G, present in 49.3-88.6% of the resistant isolates (91,103,136). On 
the other hand, the C1402T mutation, mediates resistance to KAN, CAP, but not to AMK whereas 
the G1484T mutation also mediates resistance to the three drugs (KAN, AMK and CAP) 
(136,138). KAN resistance has also been linked with eis overexpression, which is responsible only 
for low-level KAN resistance (139). CAP resistance can also be mediated by tlyA mutations (140). 
Nevertheless, tlyA mutations in CAP resistant isolates are rare and it is more likely that CAP 
resistance develops because of KAN/AMK cross-resistance (140). 
FQs are quinolones fluorinated at the central ring system. These are broad-spectrum 
antibacterial drugs that target the bacterial DNA gyrase and topoisomerase IV, therefore 
inhibiting DNA replication (141). FQ resistance has been reported to be increasing as a result of 
previous exposure to FQ prior to TB diagnosis and treatment as it is commonly used for 
treatment to other bacterial infections (79). Gatifloxacin (GAT) and moxifloxacin (MXF) appear 
to induce FQ resistant mutants at a lower rate than ciprofloxacin (CIP) and levofloxacin (LVX) 
(142). Furthermore GAT and MXF are more effective (lower MIC) than CIP and ofloxacin (OFX) 
and can be used to treat FQ low-level resistant isolates (143). Von Groll et al has also observed 
almost complete cross-resistance between OFX, MXF and GAT (144). The molecular basis of FQ 
resistance has been associated with gyrA and gyrB mutations (145).  The most common 
mutations associated with FQ resistance occur in gyrA in codons 94 and 90, in 46.2-71.9% and 
4.0-43.0% isolates, respectively (103,143,144,146). Mutations occurring in gyrB have also been 
described, although at a lesser frequency and some with questionable role in FQ resistance 
(142,146). 
The molecular mechanisms responsible for the resistance to the remaining second and third-
line anti-TB drugs, e.g. linezolide, PAS and cycloserine, are still poorer investigated and, as such, 
the correlation between genotypic and phenotypic DST has low sensitivity. 
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1.7 Epidemiology of tuberculosis 
 
The WHO declared TB as a global public health emergency in 1993 and, at the present, almost 
three decades after, TB still accounts for almost 2 million deaths each year, making it the ninth 
leading cause of death worldwide (147,148). 
The major obstacle for an effective TB control is, undoubtedly, the antimicrobial resistance 
(149). The new WHO’s End TB framework is aiming towards TB elimination by 2035 but, to be 
successful, this new strategy must effectively address increasingly different challenges (148). 
One of them regards the use and the development of new anti-TB drugs and efficient vaccines. 
The other refers to the implementation of TB diagnostic technologies that could translate into 
proper care, early treatment initiation and blocking of the transmission chains. 
In 2017, 10 million people fell ill with TB, and 1.6 million died from the disease (including 0.3 
million among people with HIV) (31). WHO estimates that there were 558 000 new RIF-resistant 
cases, of which 82% were also MDR-TB. According to this, about 500 000 new MDR-TB cases 
have occurred in 2017 (31), which, accordingly to the latest estimates of 2014, will likely result 
in the death of approximately 78 400 of these patients (about 16%). XDR-TB associated mortality 
and treatment success are even lower than those for MDR-TB: 28% and 30%, respectively (148). 
Across the WHO European region alone, 15 363 (17.7%) new MDR-TB cases were reported in 
2017 (150). However, only approximately 40% of all RIF-resistant and MDR-TB cases are 
currently being detected in Europe, due to the lack of universal DST coverage or rapid testing, 
and, as such, the increase of primary MDR-TB transmission is being potentiated (150). Although 
it is estimated that 54 million lives were saved through TB diagnosis and treatment between 
2000 and 2017, the detection rate is still very far from the WHO established target of 85%, 
making the deployment of adequate molecular testing an urgent matter and the knowledge of 
the resistance targets a pressing need (31). 
In Portugal, TB incidence has been steadily decreasing in the last years, with an average of about 
5% per year and the proportion of patients with MDR-TB remained stationary with 1% of the 
cases (151). In 2017, the report of the Portuguese National TB program (NTP) reported 1607 
new cases of pulmonary TB with 12 MDR-TB cases (151). 
Considering that M/XDR-TB are more difficult and expensive to treat compared to drug sensitive 
TB, survival rates are poorer, and knowing that primary transmission is the major cause for this 
epidemic, controlling these cases is the key for successful TB control programs and for achieving 
the targets of the “End-TB Strategy” (148). 
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1.8 Molecular typing of M. tuberculosis strains 
 
The development of molecular techniques to differentiate strains within a species has been 
useful both as a public health and as a research tool. Over the last decades, several techniques 
have been developed taking advantage of the most variable loci in the M. tuberculosis genome. 
The first typing method developed was based on restriction fragment length polymorphism 
(RFLP) analysis using the insertion sequence element IS6110 as a probe (152). Another 
commonly used technique, spoligotyping, targets specific repeat sequences found in multiple 
copies at a single locus in the M. tuberculosis genome (the direct repeat locus) using a DNA probe 
(153). Variable number of tandem repeat (VNTR) typing is the most recently developed method, 
based on the presence and number of mycobacterial interspersed repeat loci (MIRU) and is 
currently recognised as the gold standard (154–156). The three methods vary in their reliability, 
resolution and time-on-hands, but there is no clear winner with different laboratories across the 
world preferring either one method or employing all of them at once. 
Despite the undeniable usefulness of these genotyping techniques, it is equally undeniable that 
they have their limitations. By design, these loci are at the extremes of variation so are 
unrepresentative of the genome as a whole. As such, they can only provide us with a basic idea 
of relatedness, and are difficult to resolve with temporal information. Their major issue for 
public health applications is that they can also lack discriminatory power as isolates with 
identical DNA fingerprints may not always be epidemiologically linked (157). 
 
 
 
1.9 Whole genome sequencing 
 
1.9.1. Illumina Sequencing technology 
 
In the last decade there have been major advances in the so called “next generation” sequencing 
technologies in order to allow sequencing to become more high throughput and affordable. 
There several technologies currently available, but the Illumina platforms currently dominate 
the high-throughput sequencing market, and have been used for all the sequencing analysis 
carried out for this thesis, so will be discussed in more detail. 
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Illumina sequencing is similar to the Sanger method in that it is based on a sequencing-by-
synthesis approach, where a polymerase is used to synthesise a complementary strand to the 
single stranded target DNA with terminator nucleotides used to halt the synthesis. However, the 
Illumina technology utilises reversible terminators so that the chain termination process is not 
permanent and synthesis can continue after each base is detected. Fluorescently tagged 
nucleotides are used to determine which base is being incorporated as the synthesis proceeds 
one base at a time. In order to achieve this, “libraries” of the target DNA need to be prepared. 
First, the genomic DNA is fragmented with an aim to produce lots of overlapping fragments 
within a specific size range (for bacterial genomes this is most often 250-500bp). Adaptors are 
attached to the fragments, which serve four functions: ligation to the flowcell, as primers for 
PCR amplification, sequencing primer-binding sites and as index tags to allow multiplexing of 
multiple libraries in a single run. After adaptor ligation, a PCR step is then typically used to enrich 
for DNA fragments with the adaptors in the correct orientation. The DNA is then denatured to 
produce single strands, which are then ligated to a flowcell, where each fragment is amplified 
to form clusters of clonal DNA, which will increase the intensity of the fluorescent signal. The 
sequencing reaction is carried out with modified versions of the four nucleotides (dATP, dGTP, 
dCTP, dTTP) with a different fluorescent dye and blocking group. When a base is incorporated 
as complementary to the template strand, the fluorescent dye is photographed and then 
removed. This allows the sequence of the millions of DNA fragments to be determined at once, 
one base at a time (158). 
 
 
1.9.2. Application of whole genome sequencing (WGS) to M. tuberculosis 
 
It took 13 years and 3.8 billion dollars (159) for the completion of the Human Genome Project 
in 2003 (160). Since then, advances in sequencing technology have made it possible to sequence 
an entire human genome in a few days and costing a few thousand dollars. As impressive as this 
is, bacterial genomes are megabases long as opposed to gigabases and WGS is starting to 
become a clinical reality for infection diagnosis. First, its higher resolution compared with the 
traditional genotyping technologies allows academic researchers to better understand bacterial 
population structure, mutation rates and evolutionary processes. Using genome wide SNP as 
the basis for these kinds of studies means we can start to understand temporal parameters, as 
these units of variation are likely to be more clock-like associated than those studied using 
traditional genotyping techniques. The second major advantage of WGS is that it can provide 
information on variants other than SNP. Both mapping and de novo assembly approaches can 
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be used to detect deletions, insertions and the acquisition of horizontally transferred elements. 
This allows us to understand the evolutionary dynamics of these elements and how they affect 
pathogenicity and antibiotic resistance. Finally WGS is becoming cheaper, meaning that 
irrespective of all the other advantages it provides, it can equally be, if not more, economically 
viable than current techniques. 
The first WGS study of a M. tuberculosis outbreak was published in 2011 (157), and described a 
putative outbreak involving 32 people in British Columbia, Canada. All the isolates from the 
outbreak were identical using MIRU-VNTR, but could be differentiated using the genome-wide 
data. The resultant phylogeny was combined with detailed epidemiological contact tracing, 
which together suggested that what was thought to be a single outbreak consisted of two 
different outbreaks. Similar studies on other tuberculosis outbreaks (161) or recent transmission 
(162,163) have provided further evidence to support the advantages of genome-analysis in 
determining transmission patterns over previous techniques. 
WGS has also enabled significant progress in our understanding of antibiotic resistance. Work 
by Sebastian Gagneux and colleagues provided the first convincing evidence for the existence of 
compensatory mutations in TB (164). Furthermore our knowledge of possible drug resistance 
causing mutations have also been expanded either through the identification of convergent 
mutations (165), or through more complex methods that identify evidence of diversifying 
selection in both genic and intergenic regions associated with drug resistant strains (66). 
More recently, advances have been made to achieve WGS results directly from clinical samples 
(166,167) making it possible to analyse M. tuberculosis strains’ epidemiology and genetic 
resistance markers without the constraints of the isolation in culture. This may provide faster 
results and the improvement of public health measures and proper therapeutic schemas. 
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1.10 Aims and general research plan 
 
With this PhD dissertation, we intended to demonstrate the usefulness of WGS-based 
methodologies in the diagnosis and monitoring of TB through the genomic analyses of M. 
tuberculosis strains isolated from patients with MDR-TB. The major question that drove this 
main objective was to address if we could use, or replace, some of the phenotypic testing with 
procedures based on WGS-sequencing that could allow more discriminatory and faster results 
to be sent to the clinician as well as to the public health authorities. As such, several specific 
aims were pursued in the course of this PhD work: 
i) to evaluate the use of specific and tailored platforms for the in silico prediction of known 
mutations associated with the resistance to anti-TB drugs using WGS-based methodologies after 
M.tuberculosis isolation in culture (Chapter II); 
ii) to evaluate the clustering rates and association with the epidemiological links using the 
traditional genotyping method, MIRU-VNTR, throughout the last five years, and after the 
establishment of specific reference centers for the managing of all the MDR-TB cases diagnosed 
in Portugal (Chapter III); 
iii) to establish a WGS-based molecular surveillance methodology,  in order to infer a more 
reliable association between the strains to be signalized as possible transmission cases to the 
health authorities (Chapter IV); 
iv) to surpass the time and constraints regarding the isolation of M. tuberculosis in culture, by 
applying the above defined WGS-based methodologies directly to sputum samples isolated from 
the TB patients. This would speed up even more the diagnostic/DST to be sent to the clinician 
and public health authorities (Chapter V); 
v) to contribute to a better knowledge regarding the mutations associated with the acquisition 
of phenotypic resistance, by using antibiotic selective pressure on fully susceptible M. 
tuberculosis strains to monitor the development of resistance. This would enrich the publicly 
available databases thus contributing to the improvement of the bioinformatics platforms 
evaluated in Chapter II (Chapter VI). 
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Genetic prediction of antibiotic resistance 
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2. Dissecting whole-genome sequencing-based online tools for 
predicting resistance in Mycobacterium tuberculosis: can we use 
them for clinical decision guidance? 
 
Abstract 
Whole-genome sequencing (WGS)-based bioinformatics platforms for the rapid prediction of 
resistance will soon be implemented in the Tuberculosis (TB) laboratory, but their accuracy 
assessment still needs to be strengthened. Here, we fully-sequenced a total of 54 multidrug-
resistant (MDR) and five susceptible TB strains and performed, for the first time, a simultaneous 
evaluation of the major four free online platforms (TB Profiler, PhyResSE, Mykrobe Predictor 
and TGS-TB). 
Overall, the sensitivity of resistance prediction ranged from 84.3% using Mykrobe predictor to 
95.2% using TB profiler, while specificity was higher and homogeneous among platforms. TB 
profiler revealed the best performance robustness (sensitivity, specificity, PPV and NPV above 
95%), followed by TGS-TB (all parameters above 90%). We also observed a few discrepancies 
between phenotype and genotype, where, in some cases, it was possible to pin-point some 
“candidate” mutations (e.g., in the rpsL promoter region) highlighting the need for their 
confirmation through mutagenesis assays and potential review of the anti-TB genetic databases. 
The rampant development of the bioinformatics algorithms and the tremendously reduced 
time-frame until the clinician may decide for a definitive and most effective treatment will 
certainly trigger the technological transition where WGS-based bioinformatics platforms could 
replace phenotypic drug susceptibility testing for TB. 
Abbreviations 
AMK, Amikacin; CAP, Capreomycin; CICLO, Cicloserine; DST, Drug Susceptibility Testing; EMB, 
Etambutol; ETH, Ethionamide; FLQ, Fluoroquinolones; IGV, Integrative Genomics Viewer; INH, 
Isoniazid; KAN, Kanamycin; LNZ, Linezolid; MDR-TB, Multidrug-resistant Tuberculosis; MOX, 
Moxifloxacin; MTBC, Mycobacterium tuberculosis complex; NPV, Negative Predicted Value; 
OFX, Ofloxacin; PAS, Para-aminosalicylic acid; PPV, Positive Predicted Value; PZA, Pyrazinamide; 
RMP, Rifampicin; SNP, Single Nucleotide Polymorphisms; SRA, Sequence Read Archive; STR, 
Streptomycine; TB, Tuberculosis; WGS, Whole genome sequencing; WHO, World Health 
Organization; XDR-TB, Extensively drug-resistant Tuberculosis. 
Keywords: Multidrug-resistant tuberculosis; Whole-Genome Sequencing; TB profiler; TGS-TB; 
PhyResSE; Mykrobe predictor. 
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2.1 Introduction 
 
Tuberculosis (TB) remains one of the leading causes of morbidity and mortality worldwide, with 
estimates of 10.4 million new cases (312 000 in Europe) and 1.7 million deaths in 2016 (148). 
Despite millions of people are successfully treated for TB each year, resistance to commonly 
used antituberculous drugs is increasing (168). 
Nowadays, multidrug-resistant TB (MDR-TB; resistant to at least the most powerful first-line 
anti-TB drugs, rifampicin and isoniazid) and extensively drug-resistant TB (XDR-TB; MDR-TB with 
additional resistance to any fluoroquinolone and one or more among amikacin, kanamycin or 
capreomycin) represent a major threat for global TB control. According to World Health 
Organization (WHO) estimates, there were 490 000 cases of MDR-TB in 2016, of which ~6.2% 
were also XDR-TB (148). Underlying this continuous multidrug resistance scenario is the 
mismanagement of TB treatment and person-to-person transmission. Since MDR- and XDR-TB 
are more difficult and expensive to treat and survival rates are poorer when compared to drug 
sensitive TB (estimates show that only 54% of the patients with MDR-TB and 30% with XDR-TB 
survive), the disease needs continuous vigilance (148). As most TB deaths could be prevented 
with early diagnosis and appropriate treatment, in 2015, the WHO proposed the expansion of 
rapid laboratory diagnosis as one of the five high priority actions to fight the global drug resistant 
TB crisis (169). Phenotypic testing of samples collected from possible TB patients, using 
conventional culture methods, can take up to eight weeks for the isolation of the strains and 
two to four additional weeks until the final report with the resistance profile is issued (170). The 
introduction of molecular-based diagnostic tools for the detection of drug resistance enables 
earlier diagnosis of MDR-TB, preventing the spread of these resistant cases and allowing 
effective therapeutic options (171). Nowadays, these PCR-based targeted molecular tests, in 
particular the WHO endorsed Cepheid Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) and 
the Hain line-probe assays (Hain Lifescience, Nehren, 64 Germany) (169,171), are generally 
being used, but only examine a limited number of both M. tuberculosis genomic regions and 
anti-TB drugs, being unable to provide a full “genetic drug resistance” result (170,172). Thus, the 
fight against M/XDR-TB still lacks more accurate, complete and comprehensive laboratory tests 
to ensure effective diagnosis with the correct treatment initiation and outcome and, 
consequently, reduction of TB transmission. 
In recent years, whole genome sequencing (WGS) has emerged as a very powerful tool for the 
surveillance, outbreak investigation and drug resistance monitoring of human pathogens, 
including M. tuberculosis. WGS can detect transmission events missed by epidemiological 
investigation, discriminate relapse TB from re-infection and it also allows the simultaneous 
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characterisation of the complete antimicrobial resistance profile of a given isolate (168,173–
177), which may be tremendously important for TB patients. Fortunately, this issue is 
particularly facilitated for M. tuberculosis as antibiotic resistance in this bacterial pathogen is 
known to be provided essentially by single nucleotide polymorphisms (SNPs) and sometimes 
small insertions or deletions (indels) rather than by the lateral acquisition of resistance genes 
(178–181). A potential barrier for the implementation of WGS methodologies in a routine 
diagnostic setting could be the lack of bioinformatics expertise among clinical microbiologists. 
In fact, the data generated is of great complexity and may hamper its use and full potential, so 
there is a need for user-friendly comprehensive and validated workflows, before the putative 
adoption of WGS-based laboratory diagnosis. However, major progress has already been 
achieved (182,183) as there are several tailor-made automated bioinformatics platforms for 
rapid prediction of antimicrobial resistance that can be used and implemented in a routine 
diagnostic setting (184,185,186). The most commonly used bioinformatics platforms are TB 
Profiler (184), PhyResSE (185), Mykrobe predictor (187) and TGS-TB (186), which are freely 
available online, user-friendly, can be run in a common desk/laptop computer, and accept raw 
data directly from the sequencer (FASTQ files). While the existing few studies have 
demonstrated a high sensitivity and specificity by using such platforms for the first line drugs 
isoniazid and rifampicin, on the other hand, there seems to exist a substantial variation with the 
remaining first and second line drugs (173–175,182,188–190). This may be of considerable 
importance when using WGS to guide clinical decisions so there is an urgent need for 
standardization of the laboratory methodologies and data interpretation, as previously 
suggested (191). Although it is now clear that WGS has the potential to revolutionize the 
detection of drug resistance in MTB strains, it is crucial to demonstrate that its use in the routine 
diagnostic setting will have an impact on patient outcomes. However, there is a lack of 
comprehensive and exhaustive studies on the use of these WGS-based analyses in order to guide 
clinical decision-making. In fact, the available published studies only used one or two of these 
platforms with a limited number of strains and potential resistance hits (183–185,190,192). 
Here, in order to contribute to the global picture regarding the usefulness of bioinformatics 
platforms to predict antimicrobial resistance in TB, we performed a comparative study of the 
most used freely available online platforms (TB Profiler (184), PhyResSE (185), Mykrobe 
predictor (187) and TGS-TB (186). We used the largest set of MDR-TB strains to date (enrolling 
about 300 phenotypic hits) that was simultaneously analysed by multiple platforms. 
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2.2 Materials and Methods 
 
2.2.1 Samples 
 
For the study purposes, 54 M/XDR- and five susceptible-TB strains were analysed. All MDR-TB 
strains isolated in Portugal are regularly sent to the TB National Reference Laboratory from the 
Portuguese National Institute of Health for drug susceptibility testing and genotyping. Drug 
susceptibility testing (DST) for first- (isoniazid-INH, rifampicin-RMP, etambutol-EMB, 
streptomycine-STR and pyrazinamide-PZA) and second-line (amikacin-AMK, kanamycin-KAN, 
capreomycin-CAP, ofloxacin-OFX, moxifloxacin-MOX, ethionamide-ETH, linezolid-LNZ, 
cicloserine-CICLO and para-aminosalicylic acid-PAS) antibiotics was performed using MGIT960 
system (Becton Dickinson), according to manufacturer´s instructions, or the proportion method 
using solid media (CICLO and PAS). The five susceptible-TB strains were retrieved from 
Chatterjee et al. 2017 (190), for which susceptibility testing for first- and second-line anti-TB 
drugs were performed using the same methodology as the one described in the present study. 
 
 
2.2.2 Whole genome sequencing (WGS) 
 
For each strain, WGS was performed as previously described (193). Total DNA was extracted 
from solid cultures using commercial extraction kits (QIAmp, Quiagen) after an initial step of cell 
inactivation where samples were subjected to 95ºC for 1h followed by enzyme digestion for 3h 
with proteinase K. Quantification and quality assessment of the purified DNA was performed 
using Qubit Fluorometer with hsDNA Assay Kit (Thermo Fisher Scientific) and agarose gel 
electrophoresis (0,8%), respectively. High-quality DNA samples were then used to prepare dual-
indexed Nextera XT Illumina libraries using the KAPA HiFi HotStart ReadyMix PCR Kit (KAPA 
Biosystems) in the indexing step to improve amplification of the GC-rich genome regions. 
Libraries were subsequently subjected to cluster generation and paired-end sequencing 
(2×250bp) on a MiSeq Illumina platform (Illumina Inc.), according to the manufacturer’s 
instructions. 
 
2.2.3 In silico prediction of drug-resistance using online tools 
 
For each strain, genotypic drug resistance was predicted using the freely available software 
platforms tailor-made for M. tuberculosis, namely: TB Profiler webserver v1 (184), PhyResSE v1.0 
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(185), Mykrobe Predictor v0.1.3 (187) and TGS-TB v2 (186). All of these online platforms analyse 
WGS data directly from uploaded raw sequence files (in FASTQ format). Basically, they map raw 
or trimmed (after pre-processing raw data) reads against a modified version of the H37Rv 
reference genome (GenBank accession number: NC_000962) that contains drug resistance and 
lineage specific mutations. After SNPs/indels calling using specific algorithms (contrarily to the 
remaining platforms, Mykrobe predictor algorithm only calls SNPs), the identified mutations are 
compared to a curated list/database to determine known and putative polymorphisms. 
Sensitivity, specificity, Positive Predicted Value (PPV) and Negative Predicted Value (NPV) were 
estimated for each platform in order to access their drug resistance predictability for all anti-TB 
drugs. 
 
 
2.2.4 Confirmation of genotypic drug prediction 
 
In parallel, for confirmation purposes we used bioinformatics pipelines established in our lab, in 
order to access both the accuracy of SNPs/indels calling performed by the above cited platforms 
as well as all genotypic/phenotypic discrepancies. This was evaluated by a reference-based 
mapping strategy using Snippy v3.1 software (https://github.com/tseemann/snippy), which 
included BWA, SAMtools, Freebayes, vcftools and snpEff. FastQC v0.11.3 tool 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) was applied to evaluate reads’ 
quality before and after quality improvement measures carried out by Trimmomatic v0.36 
software (http://www.usadellab.org/cms/?page=trimmomatic). Furthermore, as two of the 
four online tools (TB Profiler and Mykrobe Predictor) used for prediction of TB drug-markers do 
not pre-process the raw data prior to the analysis, Snippy confirmatory analyses were 
additionally performed using both raw and trimmed read sequences. For each isolate, after 
mapping the reads (both raw and trimmed) against the H37Rv reference genome, variants were 
called in sites that filled the following criteria: i) minimum mapping quality of 20; ii) minimum 
number of reads covering the variant position >10; and iii) minimum proportion of reads 
differing from the reference of 90%. The only exception occurred for three variant positions, 
where a minimum of five reads was accepted to support polymorphisms since they did not occur 
at sites with unusual low coverage. All putative SNPs/indels were carefully inspected and 
confirmed using the Integrative Genomics Viewer (IGV) v2.4.2 
(http://software.broadinstitute.org/software/igv/). 
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2.2.5 Data availability 
 
Raw sequence reads of all 54 Portuguese TB strains subjected to WGS were deposited in the 
Sequence Read Archive (SRA) (http://www.ncbi.nlm.nih.gov/sra) under the study accession 
number SRP131205 (detailed in Supplementary Table S1). The previously published sequence 
reads of the five susceptible-TB strains (190) used in the present study for comparative purposes 
were also downloaded from SRA (Run accession numbers: SRR5341263, SRR5341215, 
SRR5341214, SRR5341212 and SRR5341211). 
 
2.3 Results 
 
In the present study, we have performed a comparative evaluation of four free most used WGS-
based online tools to automatically predict drug resistance for a total of 12 anti-TB drugs 
(streptomycin, isoniazid, rifampicin, ethambutol, pyrazinamide, amikacin, capreomycin, 
kanamycin, quinolones, ethionamide, linezolide and para-aminosalicilic acid) for 54 MDR- plus 
five susceptible-TB strains (the latter were used in order to strength analysis of platforms’ 
specificity). Phenotypic DST was performed throughout the study period as soon as the liquid 
culture was positive for further analysis. Of the 54 MDR-TB strains, 8 (15%) were also XDR. 
Globally, a total of 293 phenotypic hits were achieved, which were subjected to genotypic 
prediction. 
Considering that the input of all online tools is the output of WGS apparatus, we started by 
evaluating the quality of the data used for genotype predictions. This was accessed by using both 
raw and trimmed reads since two of the four analyzed platforms do not pre-process the raw 
data prior to the analysis. Despite the variation on the number of paired reads across samples 
(median 2.1 and 1.8 million of raw and trimmed reads, respectively), the percentage of 
chromosome covered was homogeneous. On average, 98.8% of raw and 98.6% of trimmed reads 
mapped to the H37Rv reference genome (ranging across samples from 96.7% to 99.7% for raw 
reads and from 95.5% to 99.7% for trimmed reads). The median depth of coverage was 88.6-
fold using raw reads and 68.6-fold using trimmed reads. The majority of the genome (~96% with 
raw reads and ~94% with trimmed reads) was covered to at least tenfold depth. 
 
2.3.1 Genotypic/Phenotypic correlation 
 
Figure 2.1. summarizes both the phenotypic and genotypic results obtained per anti-TB drug and 
platform.
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Figure 2.1. Overview of the agreement between phenotypes and genotypes predicted by the four platforms under evaluation.  The figure shows the phenotypic results observed for each of 
the 54 MDR-TB strains enrolled in the present study, as well as the respective genotypic profile given per platform (TB profiler, TGS-TB, PhyResSE and Mykrobe predictor) and per anti-TB drug 
tested. MDR-TB strains are designated as TB1 to TB54 in the upper row. The anti-TB drugs were: Streptomycin (STR), Isoniazid (INH), Rifampicin (RMP), Ethambutol (EMB), Pyrazinamide (PZA), 
Ethionamide (ETH), Fluoroquinolones (FLQ), Capreomycin (CAP), Amikacin (AMK), Kanamycin (KAN), Para-aminosalicylic acid (PAS), and Linezolide (LZD). No phenotypic and genotypic hits were 
observed for LZD.
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
STR
INH
RMP
EMB 
PZA
ETH
FLQ
CAP
AM
KAN
PAS
LZD
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
T
b
p
ro
fi
le
T
G
S
-T
B
P
h
y
R
e
s
S
E
M
y
k
ro
b
e
STR
INH
RMP
EMB 
PZA
ETH
FLQ
CAP
AM
KAN
PAS
LZD
Resistant phenotype Resistant genotype
TB 52 TB 53 TB 54TB 50 TB 51TB 4 1 TB 4 2 TB 4 3 TB 4 4 TB 4 5 TB 4 6 TB 4 7 TB 4 8 TB 4 9
TB 6 TB 7 TB 8 TB 9 TB 10 TB 2 1 TB 2 2 TB 2 3 TB 2 4 TB 2 5 TB 2 6 TB 2 7
TB 2 8 TB 3 4 TB 3 5TB 2 9
TB 2 0TB 11 TB 12 TB 13 TB 14 TB 15TB 5 TB 16 TB 17 TB 18 TB 19
A
n
ti
-T
B
 d
ru
g
TB 3 1 TB 3 2 TB 3 3
TB 1 TB 2 TB 3 TB 4
A
n
ti
-T
B
 d
ru
g TB 3 0 TB 3 6 TB 3 7 TB 3 8 TB 3 9 TB 4 0
32 
 
The outputs were compared and further analysed in order to determine which platform yielded 
the best correlation with the phenotypic DST. Regarding the five full susceptible TB strains, no 
false positive results were found with any of the four platforms. Comparative analysis of 
phenotypic and genotypic drug resistances confirmed the MDR profile of the 54 strains. These 
phenotypic/genotypic correlation varied per anti-TB drug and platform used for the analysis 
(Figures 2.1 and 2.2). 
 
 
Figure 2.2. Performance values of the bioinformatics platforms for predicting antibiotic resistance. (A) 
Sensitivity, specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) estimates for 
each platform. The filled circles correspond to values considering DST as the gold standard, while the 
unfilled circles are corrected values after detailed analysis of false positives and negatives. All calculations 
were performed considering the anti-TB drugs that each platform can evaluate, since Mykrobe predictor 
does not analyze resistance to Ethionamide and Pyrazinamide. (B) Sensitivity of each online platform to 
predict resistance for each of the tested antibiotics: Streptomycin (STR), Isoniazid (INH), Rifampicin (RMP), 
Ethambutol (EMB), Pyrazinamide (PZA), Ethionamide (ETH), Fluoroquinolones (FLQ), Capreomycin (CAP), 
Amikacin (AMK), Kanamycin (KAN), and Para-aminosalicylic acid (PAS). First-line anti-TB drugs are marked 
with an asterisk (*). 
 
For simplification purposes, we considered only a single genotype for each observed phenotype, 
even when more than one hit was given by a platform (i.e., when, for some strains, more than 
one SNP/indel was identified for the same phenotype), leading to a maximum of 293 possible 
genotype predictions (or 227 for Mykrobe predictor, since it does not analyse resistance to ETH 
and PZA (174–176,187). 
 In order to evaluate the implementation of these platforms in the laboratory setting, it is of 
utmost importance to measure some performance parameters (like sensitivity, specificity, NPV 
and PPV) that will allow to better infer the most robust platform to be used for clinical guidance. 
As a first approach, considering the phenotypic DST results as gold standard, TB profiler showed 
33 
 
the highest sensitivity (92.5%) and NPV (95.0%), whereas Mykrobe predictor showed the highest 
specificity (97.7%) and PPV (96.0%) (Figure 2.2A). However, as shown in Figure 1, some 
discrepancies between genotypes and phenotypes were due to the absence of a resistance 
phenotype. As will be explained below, some of these were considered as phenotypic failures, 
so the performance of each platform was recalculated by taking into account this correction. 
With this approach, the sensitivity of resistance prediction ranged from 84.3% using Mykrobe 
predictor to 95.2% using TB profiler, while specificity was higher and homogeneous among 
platforms (varying from 93.0% with TGS-TB to 100% with Mykrobe predictor) (Figure 2.2A). 
Globally, TB profiler revealed the best performance robustness for drug resistance prediction 
(with all four parameters under evaluation above 95%), followed by TGS-TB (all parameters 
above 90%), PhyResSE and Mykrobe predictor. All these calculations took into account the 
number of anti-TB drugs analysed with each platform (Figure 2.2A). 
The analysis per anti-TB drug (Figure 2.2B) revealed that, with the exception of the major first 
line antibiotics (INH and RMP) and of the second-line quinolones, capreomycin, and para-
aminosalicylic acid, heterogeneous accuracy values were observed among platforms for the 
remaining eight antibiotics. In particular, for isoniazid and rifampicin resistance, all platforms 
showed a prediction accuracy rate above 96% (Figure 2.2B), which is in agreement with the 
results obtained by other authors (182,184). TB profiler and TGS-TB failed to predict resistance 
to RMP in two cases and TGS-TB and PhyResSE/Mykrobe predictor failed the prediction of INH-
resistance in one and two cases, respectively. For the remaining first line anti-TB drugs, the 
major differences occurred with the analysis of resistance to streptomycin, ethambutol and 
pyrazinamide, with accuracy rates ranging from 65-96%, 76-97% and 58-87%, respectively 
(Figure 2.2B). These high variations are in agreement with previous studies (182,190,192) 
showing overall accuracy rates on the range of 57-100%, 71-100% and 43-100% for STR, EMB 
and PZA, respectively. Such variations may be due to the lack of data on molecular mechanisms 
and mutations in genes that confer resistance to these drugs, as well as to the lack of 
standardization of phenotypic methodologies or drug concentrations for phenotypic DST, 
especially for PZA (182,188,189,194). Regarding the second-line anti-TB drugs, detection of 
100% of the fluoroquinolone and capreomycin resistant profiles was observed independently of 
the platform used (Figure 2.2B). These were more promising outcomes than the ones previously 
described in some studies (182,184) where prediction of fluoroquinolones (FLQ) resistance did 
not exceed 89.2%. With respect of the remaining aminoglycosides, we observed sensitivities 
ranging from 40-93% and 64-100% for kanamycin and amikacin, respectively, which is in line 
with previous studies, where sensitivity for prediction of resistance varied from 60-80% (182–
184,192). Globally, TB profiler showed up among the best ranked platforms to predict resistance 
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for almost all drugs, presenting, for instance, a considerably higher sensitivity (100%) to predict 
resistance to AMK than the other platforms (64%). A notable exception occurred for PZA for 
which TGS-TB was more sensitive (87%) than the other platforms (<65%). 
 
 
2.3.2 Analysis of discrepancies 
 
We found a total of 20 discrepancies (enrolling six phenotypes with no genotype and 14 
genotypes with no phenotype) involving resistance to three first-line (STR, EMB and PZA) and 
three second-line (ETH, AMK and KAN) anti-TB drugs (Figure 2.3A). 
 
Figure 2.3. Detailed analysis of discrepancies between phenotypes and genotypes found for all 54 MDR-
TB strains. (A) For each strain (upper row), only the discrepancies observed for a particular anti-TB drug 
are shown, as well as the respective locus and associate nucleotide mutations. The concordances among 
phenotypes and genotypes are not displayed in this figure (as they can be seen in Figure 2.1). For the 
cases where a resistance phenotype was observed but for which platforms did not point any genotype 
resistance hit, “candidate” mutations occurring in genes or promoter regions known to be associated with 
resistance are also shown. (B) Additional mutations (found solely by in-house bioinformatics) that 
occurred in parallel with other resistance mutations detected by online platforms. 
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These discrepancies were not due to mixed infections or heteroresistance, as no mixed 
SNP/indel calls were observed for any of the anti-TB drugs in analysis. Low-density inoculums or 
bad quality samples were also discarded, since almost all cases of failed correlation between 
genotype and phenotype occurred for a single drug. In parallel, considering that SNP/indel-
calling analysis is influenced by coverage, the later was inspected for each drug-resistance target 
identified in order to understand if coverage deficiencies/oscillations may underlie the observed 
discrepancies. This inspection was performed using both raw and trimmed read sequences 
(since TB Profiler and Mykrobe Predictor do not pre-process the raw data prior to the analysis) 
covering the 12 genes coding for drug targets and four promoter regions that were affected by 
the SNPs and indels identified by the four online platforms for all 54 MDR-TB strains. All genes 
displayed a coverage with medians from 62.6 to 82.6 for raw data and 52.4 to 66.9 for trimmed 
data, clearly exceeding the tenfold depth cut-off for almost all strains, regardless the pre-
processing of reads as well as the %GC content (Figure 2.4). The only exceptions (coverage depth 
of 8-10) occurred for three strains with lower genome coverage depth as result of a low WGS 
performance. Similar coverage depth results were observed for promoter regions (data not 
shown).  According to our confirmatory analyses, all genotypic discrepancies involved nucleotide 
sites whose coverage exceeded the tenfold depth, except for three positions, where a minimum 
of five reads was accepted to support polymorphism as all of them contained the same 
mutation. Also, the pre-processing of reads prior to the analysis by some platforms did not 
significantly impact the coverage depth (Figure 2.4) neither the respective SNP/indel calling 
analysis. 
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Figure 2.4. Evaluation of the WGS performance for the 12 loci associated with anti-TB resistance. The 
figure shows the coverage depth for the 12 drug-resistance genes affected by the SNPs and indels 
identified by the four online platforms for all 54 MDR-TB strains. Boxplot chart was generated using R 
statistical software v. 3.4.2, and consists of boxes (median and interquartile range) and whiskers that 
extend to the most extreme data points that were no more than 1.5 times the interquartile range from 
the box. Boxes represent the variability of coverage depth found for each gene among all strains using 
both raw and trimmed data. The horizontal black line within each box marks the median, while the lowest 
and the highest coverage values observed are represented by the extremes of the whisker below and 
above each box, respectively. Outliers are indicated by open circles. The red line represents the tenfold 
depth cut-off. The %GC of each gene is also shown above the respective boxplots. 
 
 
In opposition to resistance to isoniazid and rifampicin, assessing the activity of the other first-
line antituberculous drugs presents significant challenges (173–176). Regarding the resistance 
to streptomycin, four strains (TB16, TB34, TB51, TB53) were found to be exclusively classified as 
resistant by TB profiler (which highlighted mutations in gidB gene) although no resistance 
phenotype had been observed (Figure 2.3A). All the 37 STR phenotypically resistant strains (with 
the exception of TB27, TB28 and TB36) that had been correctly predicted as resistant at 
genotypic level, always exhibited mutations in rpsL independently of the existence of other 
mutations. For TB27 and TB 28 strains, the resistant phenotype was only confirmed by a gidB 
nonsynonymous mutation (Leu16Arg) (Supplementary Table S2.2). As phenotypic failures are 
known to occur for STR, these data are in agreement with what has been already described by 
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other authors (184,191), that mutations in gidB alone (in particular, Leu16Arg) are not sufficient 
to provide STR resistance in M. tuberculosis. These findings reinforce the assumption that these 
mutations in gidB are not resistance markers (195,196), but phylogenetic informative SNPs that 
have been historically misclassified. For TB36, besides the GidB Leu16Arg, we also found a C492T 
synonymous substitution in rrs, which has been described as a phylogenetic marker as well 
(184), pointing to a false phenotype. Since these platforms have also the parallel functionality 
to analyse the phylogenetic lineage, these gidB and rrs mutations may be miscalled from the 
shared databases. Interestingly, concerning TB25 strain, we found phenotypic resistance but, 
apparently, none of the platforms returned any hit mutation that could be responsible for this 
resistance. We have then verified the existence of “candidate” mutations in target genes already 
associated with drug resistance. TGS-TB and PhyResSE highlighted not only a “candidate” 
mutation in gidB gene that was different from any of the two hit mutations detected by TB 
profiler, but also a mutation in the promoter region of rpsL. This particular case constitutes an 
intriguing scenario, of whether the mutation in the promoter region of rpsL (Figure 2.3A) (for 
which mutations in the coding region have been associated with resistance to STR) is the 
responsible for the resistant phenotype or the gidB mutation (alone or in synergy with rpsL 
mutation) yields resistance to STR (180). On this regard, mutagenesis studies could be helpful to 
elucidate these hypotheses and further contribute to a revision of the current M. tuberculosis 
drug-resistance databases. 
Seven phenotypically sensitive strains revealed mutations associated with resistance to EMB 
(Figure 2.3A). Such discrepancies are not surprising as this anti-TB drug has been reported by 
other authors to frequently yield phenotypic failures (103,197,198), so these seven genotypic 
predictions are likely true positives that were phenotypically missed by routine laboratory 
procedures. These findings strongly point to an urgent re-evaluation of phenotypic laboratories 
methodologies for this anti-TB drug (199), highlighting the increasing need to perform 
confirmatory genotypic DST in the near future for treatment determination. Indeed, EMB 
resistance is closely associated with M/XDR-TB cases and Ethambutol is used in the treatment 
regimens only if M. tuberculosis strains are susceptible by DST results. Similar to what was 
observed for STR, there was one strain (TB8) phenotypically resistant to EMB but no known 
resistance-associated SNP or indel was detected by any of the platforms used for the analysis, 
not even “candidate” mutations. As no allelic variation was seen on currently known EMB-
resistance targets, we speculate that this may not be a true phenotype or it may be due to a not 
yet identified resistance marker. 
With respect to pyrazinamide, we found four strains with no phenotypic/genotypic correlation 
(Figure 2.3A), which, as above, is not surprising. In fact, on one hand, the routine drug 
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susceptibility testing is complicated as the growth of bacilli is dependent of the acidic conditions 
required for optimal drug activity (200–202). On the other hand, our understanding of the 
mechanisms of resistance to pyrazinamide remains limited (184,188,189). Therefore, the re-
evaluation of the laboratory technical procedures for the assessment of the resistance to 
pyrazinamide is needed. Additionally, DNA sequencing studies have revealed that mutations 
(SNPs and/or indels) are distributed throughout the entire length of the non-essential pncA, 
suggesting that sequencing the whole gene and respective promoter region would be essential 
to capture all possible mutations (134,189). Considering that pncA is responsible for the 
activation of the pro-drug pyrazinamide (133), any loss-of-function mutation can confer 
resistance and a wide variety of mutations were found clinically (191,199). We observed three 
putative loss-of-function scenarios, involving a 1bp frameshift insertion and large deletions 
affecting either the 5’ or the 3´ of pncA (Supplementary Table S2.2). Although none of the four 
platforms had returned positive results for TB20, when we analysed “candidate” mutations, we 
found one mutation in pncA (Figure 2.3A), detected by three platforms. We hypothesize that 
this mutation could be responsible for the PZA resistant phenotype, but further studies should 
be performed in order to evaluate if this “candidate” mutation can be in fact classified as a 
resistance marker.  For TB21, we did not find any mutation or “candidate” mutation that could 
be responsible for the observed resistance, suggesting a false positive phenotype. 
For the second-line anti-TB drugs, we verified that all platforms failed to detect resistance to 
ethionamide in strain TB1. As a structural analogue of pro-drug INH (203), ETH also inhibits the 
mycolic acid biosynthesis (204), sharing common molecular targets (205). However, we did not 
find mutations in inhA or within the inhA promoter for this specific strain, suggesting that we 
are not facing a cross resistance INH-ETH scenario (206,207). This strain was resistant to INH but 
such phenotype is supported by the highly prevalent Ser315Thr alteration in KatG (identified by 
all platforms) (180,181), which is not associated with ETH resistance (203). Nevertheless, we 
found a “candidate” 1-bp deletion in ethA with PhyResSE, leading to a premature stop codon. 
Curiously, it has been shown that mutations in ethA are associated with ETH resistance 
(208,209). Indeed, together with the regulatory protein EthR, EthA enzyme has been 
demonstrated to activate ETH (209,210), so that genetic alterations leading to reduced or even 
loss of EthA activity would be expected to result in increased ETH resistance (211). Still, whether 
this deletion is exclusively responsible for the observed ETH-resistant phenotype needs further 
investigation. In TB3, both TB profiler and TGS-TB found the synonymous mutation A514C in rrs 
gene as the only alteration associated with resistance to amikacin although this strain was 
phenotypical susceptible. In a recent review, this same mutation was considered as unlikely 
associated with aminoglycosides, based on expert knowledge (191), but strictly with STR.  In 
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fact, in our survey, this mutation was also identified by all platforms to confer STR resistance in 
TB3, so we may be facing a miscalling scenario for aminoglycosides as suggested in the literature. 
The resistant phenotype to kanamycin in TB28 was not genotypically confirmed by any platform 
(Figure 2.3A). Although a false phenotype cannot be discarded, KAN is known to yield phenotypic 
consistent data, so we have no reasonable explanation for the putative genotypic failure of all 
four platforms. 
For two first-line anti-TB drugs (RMP and EMB), although a phenotypic/genotypic correlation 
was found for six strains, we also detected (IGV analysis) additional mutations that were already 
described as resistance markers in the current M. tuberculosis drug-resistance databases (Figure 
2.3B). With exception of TGS-TB for TB27, all platforms failed in detecting these extra mutations. 
We have no reasonable explanation for that as no coverage depth deficiencies were found in 
these variant positions and surrounding regions. Although we do not have phenotypic evidence, 
we speculate that these additional mutations may confer higher levels of resistance since this 
phenomenon was already described for the major first-line anti-TB drug INH with inhA and katG 
genes (212). 
 
 
2.4 Discussion 
 
One of the major problems for TB control is the lack of accurate and rapid laboratory 
methodologies, hampering early diagnosis and the initiation of proper treatment regimen. In 
fact, the phenotypic methods for TB testing are expensive, technically complex and time-
consuming (8-15 weeks). It is current practice to initially test only for first-line antibiotics and to 
subsequently perform second- and third-line susceptibility testing in case of drug resistance 
(176,213). Although bacterial culture is still a roadblock (7-30 days), the ongoing advances in 
WGS technology and bioinformatics have expanded opportunities for TB drug resistance 
monitoring, allowing a faster prediction of resistance to the majority of anti-TB drugs used for 
treatment (1 to 3 days for sequencing and computational analysis, depending on the sequencing 
platform and number of samples). This is of considerable importance as it can be used to guide 
clinical decisions and significantly impact patients’ outcome. However, there is still a lack of 
exhaustive studies to assess their accuracy. In the present study, we simultaneously evaluated 
the performance of the four most used free online WGS-based platforms to predict resistance 
to first- and second-line anti-TB drugs, using a set of MDR-TB strains enrolling about 300 
phenotypic hits. As SNP/indel calling should reflect the real mutations occurring in the clinical 
isolates, it is of crucial importance to use WGS platforms less prone to errors. Accordingly, we 
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have chosen the MiSeq Illumina platform rather than others known to have higher error rates, 
such as the MinION. 
Overall, the sensitivity of resistance prediction ranged from 84.2% using Mykrobe predictor to 
95.2% using TB profiler, while specificity was higher and homogeneous among platforms 
(varying from 94.0% with TGS-TB to 100.0% with Mykrobe predictor) (Figure 2.2A). Our results 
are in line with previous published surveys performed by other authors around the world (181–
183,214). For some MDR-TB strains, a few lack of agreement between phenotype and genotype 
was observed (Figure 2.3A), but almost all of these cases involved anti-TB drugs known to cause 
frequent phenotypic failures (STR, EMB, PZA and ETH) (103,184,188,189,191,197,198), strongly 
pointing out to an urgent re-evaluation of phenotypic laboratories methodologies, and/or 
mutational hits that had been miscalled as resistance markers from the shared databases 
(184,191,195,196). Furthermore, we also detected some “candidate” mutations, in particular a 
SNP in the promoter region of rpsL that may be associated with resistance to STR as well as a 
1bp-deletion in ethA that may confer ETH resistance, highlighting the need to perform 
mutagenesis-based assays for confirmation purposes.   
TB profiler and TGS-TB showed-up as the best ranked platforms to predict resistance to almost 
all anti-TB drugs, with all performance parameters above 90%, appearing as highly promising 
tools to be implemented in the routine clinical practice of any microbiology laboratory. In fact, 
they provide an answer to the clinician at a reasonable cost and tremendously lower time frame 
when compared with phenotypic methods (183,213). It is rather complex to speculate about the 
relative importance of each of these performance values so we believe both sensitivity and 
specificity must be taken into account. Whereas a low sensitivity may discard the usefulness of 
a platform, a low specificity may impact the beginning of an inaccurate therapeutic regimen. Of 
worth note, although none of these platforms are licensed for clinical diagnostic use, its clinical 
impact in allowing the rapid detection of drug resistant TB led to the implementation of similar 
bioinformatics pipelines in England, in 2017, by the Public Health England Laboratory (215). 
Furthermore, all mutations described in our survey underlying a phenotype/genotype 
agreement had been described in other studies, as the patterns of drug resistance emergence 
seem conserved globally (180,181), which strengths the use of bioinformatics platforms for 
clinical decision guidance. Nevertheless, as also suggested by other authors 
(180,181,184,191,192,216,217) the genetic databases underlying M. tuberculosis resistance to 
anti-TB drugs should be reviewed, regularly updated, and likely reunited in a single public 
database. 
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2.5 Conclusion 
 
Our findings reinforce the role of WGS to revolutionize the diagnosis of M. tuberculosis infection. 
Using freely available online platforms, we believe that it is now feasible to start implementing 
WGS analysis in the clinical practice of any microbiology laboratory, with the potential to detect 
resistance weeks before traditional phenotypic culture methods, which will impact treatment 
options and prevent resistance dissemination. 
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3. Trends of MDR-TB clustering in Portugal 
 
Multidrug-resistant Tuberculosis (MDR-TB) represent a major threat for global TB control. In 
2017, World Health Organization (WHO) estimated 460 000 cases of MDR-TB cases, of which, 
8.5% were also extensively drug resistant cases (XDR-TB) (31). In Portugal, over the last decade, 
the decreasing tendency of TB cases is about 7% per year, and the proportion of MDR-TB cases 
remain steadily around 1% of the total TB cases.  In 2017 (151), the preliminary report of the 
Portuguese National TB program reported 1607 new cases of pulmonary TB with 12 MDR-TB 
cases. 
Since 2014, there are specific centres for the diagnosis, consultancy, monitoring, and treatment 
of the M/XDR-TB cases. Besides the clinical approach, these centres also aim to monitor these 
resistant cases linking the epidemiological survey performed within the community by Public 
Health Authorities (218) and systematic molecular genotyping performed by the National 
Reference Laboratory (NRL). Since the Portuguese NRL receives all the strains isolated from all 
the MDR-TB patients from Portugal (mandatory since 2007) (219), this approach can allow a very 
good correlation between the genetic and epidemiological information in order to detect both 
the resistance profiles as possible relations between strains due to occurring ongoing 
transmission (220,221). 
With this study, the authors intend to analyse MDR-TB clustering rate in Portugal. 
From a total of 78 M/XDR-TB strains identified and notified in the country during 2014-2017, 71 
(91.0%) were available for molecular analysis. From these 78 strains, seven were not available 
for further analysis due to contamination of the culture or MDR diagnosis based only in 
molecular biology methodologies (GeneXpert or other line-probe assays). The drug susceptibility 
profiles are described in table 3.1. 
For each strain, 24-loci MIRU-VNTR (Mycobacteria Insterspersed Repetitive Units – Variable 
Number of Tandem Repeats) genotyping was performed by standardized protocols using MIRU-
VNTR typing kit (Genoscreen) according to manufacturer´s instructions. Dendrograms were 
constructed using the online free software MIRU-VNTRplus (https://miru-
vntrplus.org/MIRU/miruinfo.faces). A molecular cluster was defined whenever different strains 
shared the exact MIRU-VNTR profile. All clusters identified were further analysed with the 
available epidemiological data. 
The majority of the MDR-TB cases were male (75,6%) with a median age of 44.3 years old 
(minimum 15 and maximum 75 years old). Most of these cases were notified in Lisbon and Tagus 
Valley (LTV) (64.0%) and North region (23.1%). XDR-TB cases were identified in 15 cases (19.2%), 
of which 86.7% were from LTV region (table 3.1). 
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Table 3.1 Microbiological and demographic characteristics of the patients enrolled in the study. 
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Using Miru-VNTR, seven different clusters were identified (table 3.1), ranging from 2 to 14 
strains. Overall, the proportion of MDR-TB cases attributable to recent transmission in the study 
period (2014-2017), on the basis of genetic data, was 63.4% (45/71). 
From the analysis of the molecular data we observed a decreasing tendency of the cases that 
can be potentially related to recent transmission. In fact, in 2014, we found 6 clusters ranging 
from 2 to 4 strains, corresponding to a clustering rate of 72,7%. The major cluster was from 
strains isolated in the North region and the remaining clusters were mainly from LTV strains. 
Regarding the MDR-TB strains isolated in 2015, 3 clusters were found, with a clustering rate of 
55,0%, ranging from 2 to 5 strains. All the clustered strains were from LTV with the exception of 
one strain that belonged to a patient from the North region. In 2016, only 2 clusters were found 
with 2 and 5 strains, with a clustering rate of 38,9%. The minor cluster was from a mother/child 
and the larger included strains from LTV and the North regions. Finally, in 2017, 2 clusters were 
identified with 2 strains each, all from LTV region, corresponding to a clustering rate of 36,4%. 
When linking the epidemiological and the molecular data, we did not find a good agreement. 
After adjustment for confirmed epidemiological links, the overall cluster rate (2014-2017) 
decreased to from to 63.4% to 14.9 %. 
This study has a limitation related to the possible heterogeneity of the epidemiological 
enquiries. It has however the strength of collecting all MDR-TB samples in the country for 4 years 
to be analyzed in the NRL. 
We observed, in the studied period, a decreasing tendency both in the number of MDR-TB cases 
and the clustering rates despite a poor agreement between laboratory and epidemiological 
data. The centralization of the MDR-TB cases in reference centres seems to be effective, 
although there is a need for a better molecular tool, with higher discriminatory power, and a 
better inclusion of epidemiological data when discussing these clusters. 
 
48 
 
 
49 
 
 
 
 
 
 
 
 
 
Chapter IV 
 
 
Development of genomic-based surveillance 
methodologies 
 
 
 
 
 
Evaluation of a gene-by-gene approach for prospective whole-genome sequencing-
based surveillance of multidrug resistant Mycobacterium tuberculosis 
 
 
Manuscript published with minor changes in 
2019, Tuberculosis, 115: 81-88 
DOI: 10.1016/j.tube.2019.02.006 
Rita Macedo, Miguel Pinto, Vítor Borges, Alexandra Nunes, Olena Oliveira, Isabel Portugal, 
Raquel Duarte, João Paulo Gomes 
Evaluation of a gene-by-gene approach for prospective whole-genome sequencing-
based surveillance of multidrug resistant Mycobacterium tuberculosis 
 
 
RM contributed to the design of the study, performed the experimental work, interpreted data 
and wrote the manuscript. 
50 
 
 
51 
 
4. Evaluation of a gene-by-gene approach for prospective 
whole-genome sequencing-based surveillance of multidrug 
resistant Mycobacterium tuberculosis 
 
 
Abstract 
Whole-genome sequencing (WGS) offer unprecedented resolution for tracking Mycobacterium 
tuberculosis transmission and antibiotic-resistance spread. Still, the establishment of 
standardized WGS-based pipelines and the definition of epidemiological clusters based on 
genetic relatedness are under discussion. We report the implementation of a dynamic gene-by-
gene approach, fully relying on freely available software, for prospective WGS-based 
tuberculosis surveillance. Its application for detecting transmission chains was demonstrated by 
retrospectively analysing all M/XDR strains isolated in 2013-2017 in Portugal. We observed a 
good correlation between genetic relatedness and epidemiological links, with strongly epilinked 
clusters displaying mean pairwise allele differences (AD)  always below 0.3% (ratio of mean AD 
over the total number of shared loci between same-cluster strains). This data parallels the 
genetic distances acquired by the core-SNV analysis, while providing higher resolution and 
epidemiological concordance than MIRU-VNTR genotyping. The dynamic analysis of strain sub-
sets (i.e., increasing the number of shared loci within each sub-set) also strengthens the 
confidence in detecting epilinked clusters. This gene-by-gene strategy offers several practical 
benefits (e.g., amenability to standardization, reliance on freely-available software, scalability 
and low computational requirements) and our data further consolidated it as the method of 
choice for a timely, standardized and robust prospective WGS-based laboratory surveillance of 
M/XDR-TB cases. 
 
Keywords 
Mycobacterium tuberculosis; Whole-genome sequencing; Surveillance; Gene-by-gene 
approach; Multidrug-resistance 
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4.1 Introduction 
 
In 2015, the World Health Organization (WHO) proposed to fight the global drug resistant 
tuberculosis (TB) crisis as one of its five high priority actions (169). In 2017, of the 10.4 million 
that fell ill with TB worldwide, 1.7 million died from the disease, with 460 000 cases caused by 
multidrug-resistant strains (MDR-TB; i.e., resistant to, at least, rifampicin and isoniazid) of which 
8.5% were also extensively drug-resistant (XDR-TB; i.e., MDR-TB with additional resistance to 
any fluoroquinolone and one or more of amikacin, kanamycin or capreomycin) (31). Globally, TB 
incidence is falling at a rate of about 2% per year but in order to reach the 2020 milestones of 
the “End TB Strategy” (31) this rate needs to accelerate to a 4–5% annual decline. In Portugal, 
TB incidence has been steadily decreasing in the last years, with an average of about 5% per year 
(151). From 2013 to 2017, about 10.000 new TB cases were reported to the Portuguese General 
Health Directorate (GHD), and the proportion of patients with MDR-TB remained stationary at 
1% of total cases (151,222). Considering that human-to-human transmission is the major cause 
of this epidemic, M/XDR-TB are more difficult and expensive to treat and have poorer survival 
rates when compared to drug sensitive TB, monitoring and controlling these multi-drug resistant 
cases is key for successful TB control programs and for achieving the targets of the “End-TB 
Strategy” (31). 
Targeted interventions to stop transmission, especially from M/XDR-TB cases, requires in depth 
epidemiological knowledge that can only be provided by a combination of effective genotyping 
with classical epidemiological enquiries. Concerning M. tuberculosis complex (MTBC) strains, 
there are three methods that are commonly used for typing purposes: IS6110 Restriction 
Fragment Length Polymorphism (RFLP) (152), spoligotyping (interspaced palindromic repeats) 
(153), and Mycobacterial Interspersed Repetitive Units-Variable Number of Tandem Repeats 
(MIRU-VNTR) (154). These methods have been widely applied to answer a variety of questions, 
from the investigation of cross-contamination in the laboratory to the investigation of outbreaks 
or population-based studies (161,223–227). Still, although traditional typing techniques provide 
standardized and easily computable typing results, these have limited discriminatory power. In 
this context, whole-genome sequencing (WGS) has emerged as a very powerful tool for the 
surveillance, outbreak investigation and drug resistance monitoring of human infectious 
pathogens including MTBC. As the ongoing technological developments are rapidly decreasing 
costs, WGS has the potential to become the ultimate tool for diagnostics and pathogen typing 
(161,228–230), providing comprehensive genetic information, virtually including all possible 
genomic targets, as well as additional valuable information on drug resistance, virulence and 
genome evolution (161,172,174,231). Additionally, efforts are being directed to overcome the 
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time-consuming M. tuberculosis growth prior to WGS, as recent developments show that 
acquisition of WGS data directly from clinical samples may be possible (232–234). 
The recent recommendations for TB molecular surveillance by the European Center for Disease 
Control and Prevention (ECDC) propose to introduce WGS-based surveillance methodologies in 
the National Reference Laboratories (NRL) of the EU/EEA regions. While the time between 
sample collection and WGS data analysis is increasingly being shortened, there is still a lack of 
standardized guidelines for the use of WGS for molecular epidemiological analysis, which is 
crucial for Public Health Authorities to act. In particular, two practical issues remain in order to 
sustain alerts for possible ongoing transmission and to maintain data sharing, either locally or 
globally: i) the definition of the more suitable approach to apply in a WGS-based surveillance 
era, and ii) the establishment of cut-offs of genetic relatedness that display the highest 
congruence with epidemiological data for cluster definition. While the latter will become more 
consistent as more WGS-based studies are being performed (for which consistent 
epidemiological data is essential), there is still a discussion regarding the methodology to use, 
namely gene-by-gene and single nucleotide polymorphism (SNP) based approaches 
(162,228,229,235). In addition, laboratories already performing WGS-based surveillance 
essentially rely on in-house command-line-based pipelines or commercial platforms (e.g., 
Bionumerics from Applied Maths or Ridom SeqSphere+ from Ridom Bioinformatics), which may 
not be accessible to all laboratories, thus potentially delaying the implementation of a 
harmonized and globally accepted strategy.   
In Portugal, since 2014, there are specific centres for the diagnosis, consultancy, monitoring, and 
treatment of the M/XDR-TB cases. As such, these centres constitute a major driving force for 
linking the epidemiological survey performed within the community by the Public Health 
Authorities (218) and the systematic molecular genotyping performed by the NRL at the National 
Institute of Health (NIH). Since the Portuguese NRL receives all the strains isolated from all the 
MDR-TB patients from Portugal (mandatory since 2007) (236), it is of utmost importance to set 
up a centralized and robust molecular typing system that potentiate the establishment of 
correlations between genetic and epidemiological information towards the 
detection/monitoring of the resistance profiles and transmission chains (220,221). In light of the 
transition to a WGS-based laboratory surveillance in Portugal, the present study reports the 
implementation of a dynamic gene-by-gene approach for WGS-based TB surveillance, through 
the evaluation of potential transmission chains among the M/XDR-TB cases isolated during the 
last 5 years (2013 to 2017). We also aimed to contribute for the understanding on how cut-offs 
of genetic relatedness can be applied to strengthen epidemiological investigation and public 
health actions. 
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4.2 Material and methods 
 
4.2.1 Sample dataset characterization and MIRU-VNTR genotyping 
 
All MDR-TB strains isolated in Portugal are mandatorily sent to the TB NRL from the Portuguese 
NIH for drug susceptibility testing (DST) and genotyping (236,237). Whenever a TB case is 
notified, public health services intervene in the community in order to identify other potentially 
associated TB cases or contacts at risk. An epidemiological enquiry is deployed and the 
information is stored in the Public Health Departments, at regional level. In addition, whenever 
a cluster is identified by molecular-based laboratory typing techniques, public health authorities 
are asked to confirm if there is an epidemiological link between the cases. This workflow was 
applied during the course of the present study with novel WGS-derived links being investigated 
retrospectively. 
From the NIH collection of ~10 000 TB strains isolated at country level from 2013 to 2017, a total 
of 96 M/XDR TB strains were identified and notified to the Portuguese GHD. From these, 83 
(86.5%) strains were available for molecular and genomic analysis (the remaining 13 were 
diagnosed based on molecular methods with no culture isolation). For 48 strains, DST, 24-loci 
MIRU-VNTR genotyping and WGS had been previously performed on behalf of a recent study 
focused on in silico prediction of antibiotic resistance (231). For the remaining isolates, DST was 
performed  for first- (isoniazid-INH, rifampicin-RMP, etambutol-EMB, streptomycine-STR and 
pyrazinamide-PZA) and second-line (amikacin-AMK, kanamycin-KAN, capreomycin-CAP, 
ofloxacin-OFX, moxifloxacin-MOX, ethionamide-ETH, linezolid-LNZ, cicloserine-CICLO and para-
aminosalicylic acid-PAS) anti-TB drugs, using MGIT960 system (Becton Dickinson), according to 
manufacturer´s instructions, or the proportion method using solid media (CICLO and PAS). 
For the traditional MIRU-VNTR genotyping and WGS, total DNA was extracted from solid 
cultures using commercial extraction kits (QIAmp, Qiagen) after an initial step of cell inactivation 
where samples were subjected to 95ºC for 1h followed by enzyme digestion for 3h with 
proteinase K. The 24-loci MIRU-VNTR experimental genotyping was performed, as previously 
described (231), by standardized protocols using MIRU-VNTR typing kit (Genoscreen) according 
to manufacturer´s instructions. Dendrograms were constructed using the online free software 
MIRU-VNTR plus (238,239). For WGS, high-quality DNA samples (quantified using Qubit, 
ThermoFisher) were subjected to dual-indexed NexteraXT Illumina library preparation using the 
KAPA HiFi Hot Start Ready Mix PCR Kit (KAPA Biosystems) in the indexing step to improve 
amplification of the GC-rich genome regions, as previously described (231). Libraries were 
subsequently subjected to cluster generation and paired-end sequencing (2×250bp) on an 
55 
 
Illumina MiSeq (Illumina), available at the Portuguese NIH. All data for isolates used in the 
present study, including drug susceptibility, genotyping and demographic data, are summarized 
in Supplementary Table S4.1. 
 
4.2.2 Genome de novo assembly 
 
All 83 genomes were de novo assembled using the INNUca v3.1 pipeline (https://github.com/B-
UMMI/INNUca), which consists of integrated modules for reads QA/QC, de novo assembly and 
post-assembly optimization steps. Briefly, after reads’ quality analysis (FastQC v0.11.5 - 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and cleaning (Trimmomatic 
v0.36) (240), genomes are assembled with SPAdes v3.11 (241) and subsequently improved using 
Pilon v1.18 (242). Based on a comparative analysis of the impact of performing “post-assembly 
polishment” of the assemblies using Pilon (data not shown), this step was skipped when Pilon 
introduced changes in more than 1/3 of the contigs. The affected genomes (n=8) were also 
among the ones presenting high genome fragmentation (i.e., more than 200 contigs). Draft 
genome sizes, mean depth of coverage, number of contigs and sequencing read size are 
described in Supplementary Table S4.1. In silico DST were performed using TB-profiler v0.3.0 
(184) as previously described (231). MIRU-VNTR profiles were also predicted in silico with a 
recently developed tool, MIRU-profiler (first release), using default parameters (243). 
 
4.2.3 Gene-by-gene analysis 
 
For gene-by-gene analysis, two panel of loci were retrieved (27th of July 2018) from the RIDOM 
Nomenclature Server (https://www.cgmlst.org/ncs), developed by Kohl and colleagues 
(228,229). These panels include 2891 genes from the M. tuberculosis complex “cgMLSTschema” 
and additional 755 “accessory” loci. In the present study, we inferred allelic diversity against 
either only the “short schema” (cgMLST 2891 loci) or the “extended schema” (cgMLST plus 
accessory loci; 3646 loci). For simplification purposes, the terms “short” and “extended” will be 
used throughout the manuscript to describe both schemas. 
Allele calling was performed for the 83 genomes against both schemas, using chewBBACA 
v2.0.11 (244) with default parameters and a training file generated by Prodigal v2.6.3 from the 
H37Rv reference genome (RefSeq Accession NC_000962.3). After allele calling using a Blast 
Score Ratio of 0.6, exact and inferred matches were used to construct an allelic profile matrix, 
where other allelic classifications (see https://github.com/B-UMMI/chewBBACA/wiki) were 
assumed as “missing” loci. 
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Genomes with less than 90% (2602 loci) called in the short schema were removed for 
subsequent phylogenetic inferences. This occurred only for 3 out of the 83 genomes under 
analysis (Supplementary Table S4.1). Minimum spanning trees (MST) were constructed taking 
advantage of goeBURST algorithm (245) implemented in the PHYLOViZ online web-based tool 
(246), based on 100% shared loci between all strains (i.e., shared-genome MLST). This approach 
was applied to both schemas and every cluster under evaluation. To take advantage of accessory 
genome loci, likely increasing the resolution power (which may be key for discriminating cases 
during outbreak investigation), we took advantage of PHYLOViZ online 2.0 Beta version 
(http://online2.phyloviz.net/), which allows maximizing the shared genome in a dynamic 
manner, i.e., for each sub-set of strains under comparison, the maximum number of shared loci 
between them is automatically used for tree construction. In this regard, all allelic distance 
thresholds used during cluster investigation were expressed as percentages of allele differences 
(AD) over the total number of shared loci under comparison. Initial potential clusters to explore 
were defined by applying an allelic distance cut-off of 0.56% to the initial tree enrolling 80 strains 
(i.e., 12 AD out of 2202 loci shared in the “short schema”; or 15 AD out of 2657 shared loci in 
the “extended schema”). The use of this conservative threshold relies on literature data that 
pointed out 12 AD as an accurate value for cluster investigation in gene-by-gene based 
surveillance era for M. tuberculosis (228,229). Finally, in order to evaluate the clustering 
agreement between MIRU-VNTR and the gene-by-gene approach, the Wallace's coefficient, 
with 95% confidence intervals, was calculated using the web-based framework “Comparing 
partitions” (http://www.comparingpartitions.info/) (247). 
 
 
4.2.4 Core-Single Nucleotide Variant (SNV)-based analysis 
 
A core-SNV-based analysis was also performed as it is one of the current methodologies used 
for MTB laboratory surveillance. For this, we applied Snippy v3.1 in the set of all 83 M. 
tuberculosis isolates.(https://github.com/tseemann/snippy). Briefly, quality improved read data 
(after Trimmomatic processing) of all isolates were individually mapped against the H37Rv 
reference genome (NC_000962.3), and SNP calling was performed on variant sites with the 
following criteria: minimum proportion of reads differing from the reference of 90%, a minimum 
mapping quality of 20 and a minimum coverage for SNP calling of 10. Core-SNPs were extracted 
using Snippy’s core module (snippy-core) ensuring that all genomes reached at least 95% of 
aligned bases with the reference. To achieve this, a minimum coverage of 6 was set for five out 
of the 83 genomes and one genome was excluded from the analysis (TB82). In summary, this 
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analysis enrols 82 strains (TB30 and TB35 had been excluded in gene-by-gene approach). Core-
SNV falling within known M. tuberculosis genomic regions with high GC content or repetitive 
elements (Supplementary Table S4.2), as well as known SNVs in resistance-associated positions, 
were excluded (compiled by Kohl and colleagues, available at https://github.com/ngs-
fzb/MTBseq_source/tree/master/var/res), as their inclusion would likely bias the phylogeny. 
Following the same rationale applied for gene-by-gene approach, initial potential clusters for 
investigation in core-SNV approach were defined based on a conservative maximum number of 
differences of 12 (228,229). 
 
 
4.2.5 Data availability 
 
All raw sequence reads used in the present study were deposited in the European Nucleotide 
Archive under the study accession number PRJEB29446 (detailed in Supplementary Table S1), 
which will be the Bioproject including all MTB strains analysed for prospective WGS-based 
surveillance in Portugal. As such, reads that were previously released (BioProject SRP131205) 
have also been deposited in PRJEB29446. 
 
 
4.3 Results 
 
4.3.1 MIRU-VNTR analysis 
 
Our first approach consisted in analyzing the M/XDR-TB strains by MIRU-VNTR genotyping, the 
conventional method used for the molecular epidemiology of MTBC strains. Overall, we found 
41 distinct MIRU-VNTR profiles, constituting 10 different genomic clusters involving 2 to 15 
strains each (Supplementary Table S4.1), thus yielding a clustering rate of 63.9% (53/83). 
Detailed analysis of these clusters will be integrated in the subsequent WGS-based analysis (see 
next sections). Although the in silico determination of VNTR profiles is challenging, a recently 
developed software (MIRU-profiler) was tested on our assembly data. This in silico approach 
correctly assigned a mean of ~15±3 (±SD) out of 24 VNTR profiles (ranging from 3 up to 20) for 
each strain, with a mean of 5±3 mismatched (ranging from 0 up to 16) and 4±3 “not detected” 
loci (ranging from 0 up to 16). In order to understand if these results correlate with the quality 
of WGS data, MIRU-profiler results were analysed against both the mean depth of coverage 
(after read quality improvement) (Supplementary Fig. S4.1A) and the number of contigs  
(Supplementary Fig. S4.1B). As expected, genomes relying on high depth of coverage and with 
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lower number of contigs yielded more correctly assigned loci. Still, while the number of correct 
assignments positively correlates with depth of coverage, decreasing this critical parameter 
seems to lead to more mismatches than loci not found. In an opposite scenario, high genome 
fragmentation (i.e., increasing number of contigs) seems to correlate mostly with high number 
of unassigned loci. 
 
 
4.3.2 Gene-by-gene analysis 
 
 
To investigate phylogenetic relationships between strains and their potential epidemiological 
link (“epilink”), we applied a gene-by-gene approach by taking advantage of publicly available 
schemas [using both a short (2891 loci) and an extended schema (3646 loci) (228,229)] and a 
freely available software for allele calling (chewBBACA) (244). As both schemas contain 
“accessory” genes, i.e., genes not present in M. tuberculosis spp tuberculosis, only genomes 
yielding more than 90% of called loci (80 out of 83 strains) in the short schema were subjected 
to gene-by-gene analysis (Supplementary Table S4.1). In a first step, a MST was generated for 
each schema based on allelic diversity found among the shared loci: 2202 for the short 
(Supplementary Fig. S4.2A) and 2657 for the extended schema (Fig. 4.1A). As a conservative 
approach to generate potential clusters to be subjected to the dynamic MST analysis, the same 
cut-off of 0.56% was applied for both short and extended schemas (i.e., strains with ≤ 12 and ≤ 
15 AD, respectively, were kept interconnected), resulting in seven (Supplementary Fig. S4.2A) 
and eight (Fig. 4.1A) clusters, respectively. The additional cluster in the extended schema 
(Cluster 4) was borderline in the short schema (the two enrolled strains, TB54 and TB11, 
displayed 14 AD; Supplementary Fig. S4.2). The content of the remaining clusters overlapped 
between both approaches. Of note, at the applied cut-off, the probability of two strains having 
the same MIRU-VNTR profile also belonging to the same cluster is about 85% (CI 69%-100%)  
(using either the short or the extended schema), while the probability of two strains that belong 
to the same cluster (using either the short or extended) also share the same MIRU-VNTR profile 
is around 50% (CI 35%-64%) (calculations using the Adjusted Wallace coefficient and 95% 
confidence intervals).
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Figure 4.1. Phylogeny of 80 M/XDR-
TB strains based on a dynamic 
gene-by-gene approach using an 
extended schema (3646 loci). A – 
Initial Minimum spanning tree 
(MST) constructed based on allelic 
diversity found among the 2657 
genes shared by 100% of the 
strains. Potential clusters defined 
for fine-tune analysis are 
highlighted by colored circles. B – 
Sub-MST reconstruction based on 
the maximum number of shared 
loci between strains within a 
potential cluster. Each circle (node) 
contains the strain’s designation 
and represents a unique allelic 
profile. Nodes are colored 
according to traditional MIRU-
VNTR profiles. The numbers in red 
on the connecting lines represent 
the allele differences (AD) between 
strains. MST were constructed 
using the goeBURST algorithm 
implemented in the PHYLOViZ 
Online platform, and are based on 
allelic profiles relying on distinct 
number of shared loci (indicated 
near the tree). 
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Figure 4.2. Allelic diversity with potential and confirmed clusters. A – Comparison of the mean percentage 
of allelic diversity (with standard deviation) observed within each potential cluster using the short and 
extended schemas, either with or without sub-minimum spanning tree (MST) reconstruction. B – Number 
of shared loci analyzed for each cluster detected by each approach. C – Comparison of the mean 
percentage of allelic diversity (with standard deviation) observed within each potential cluster, after its 
fragmentation into sub-sets according to the available epidemiological data. Calculations are presented 
when using the extended schema, with or without dynamic sub-MST reconstruction. Epilinks are 
highlighted by different colors. 
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Within each cluster, the mean percentage of pairwise AD (i.e., the ratio of mean AD over the 
total number of shared loci) fell within the same magnitude for the “initial MST” (containing all 
80 isolates) regardless of the schema used (Fig. 4.2A). A similar analysis after reconstruction of 
a sub-MST for each cluster, maximizing the number of shared loci between the sub-set of strains, 
revealed a general increase in mean percentage of AD, with this trend being more marked for 
the extended schema (Fig. 4.2A), indicating that accessory genes contributed to diversity. As the 
extended schema enrolls a much higher number of shared loci (Fig. 4.2B), this dynamic approach 
increases sensitivity, thus allowing a better evaluation of the close-relatedness of strains and, 
consequently, making cluster definition and exclusion of outliers more robust. For instance, the 
sub-MST of the additional cluster 4 in the extended schema consolidated the weak genetic link 
between the two enrolled strains (Fig. 4.1B). On the other hand, for cluster 5, despite the 
addition of almost 700 shared loci to the analysis, the absolute AD between strains increased by 
up to 4 AD, thus strengthening the potential link between the three strains. In general, 
regardless the schema that was used, the diversity within each cluster showed two patterns: 4 
clusters (clusters 1 to 4) with mean %AD of 0.4-0.7 and 4 clusters (clusters 5 to 8) with mean 
%AD of 0.0-0.3 (Fig. 4.2A). 
After correlating phylogenetic data with epidemiological data provided by the Public Health 
Authorities for each potential cluster, strong or weak epilinks could be established among strains 
within the analyzed clusters. In particular, while all strains within clusters 5 to 8 (with mean %AD 
below 0.3) had a strong epilink (the authorities confirmed these “strong” epi links as family 
members or very close contacts) (Fig. 4.2C), a weak epidemiological link was reported for some 
strains of cluster 2 and all strains of cluster 3 (representing strains from patients of the same 
geographic region and/or same chest clinic attendance), which could explain the higher mean 
pairwise %AD observed for the latter. In cluster 1, the largest cluster analyzed, while the overall 
mean %AD was high, very strong epilinks were reported for two clusters of patients (Fig. 4.2C; 
Fig. 4.1B). Concordantly, the mean %AD among epilinked strains was below 0.3%, while 
confirmed non-epilinked strains had %AD within ~0.3-0.5 (Fig. 4.2C). If we applied this empirical 
observed mean %AD (0.3%) as a linkage cut-off to the sub-MST of cluster 1, three sub-clusters 
would be obtained (Fig. 4.1B), including the two already confirmed and a novel cluster. In fact, 
this fine-tune analysis raises the hypothesis that not only TB5 and TB87 might also be epilinked, 
but also that TB80 and TB89 may be included in the confirmed epilinked cluster containing 
strains TB66, TB65, TB73 and TB8. Unfortunately, both potential epilinks could not be 
retrospectively traced. Regarding cluster 2 and 3, although only weak links or no data were 
retrieved, we cannot discard some possible links among the clustered strains, as observed when 
applying this cut-off. Of note, adjusted Wallace coefficient analysis at 0.3% threshold showed 
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that the probability of two strains having the same MIRU-VNTR profile also belonging to the 
same cluster decreased to about 28% (using either the short or the extended schema), while 
same-cluster strains have about 60% probability of belonging to the same MIRU-VNTR profile. 
Nevertheless, a proper inference of the level of congruence will require further large-scale 
studies with more diverse datasets. 
 
 
4.3.3 Core-SNP-based analysis 
 
A core-SNV-based approach matrix was used to infer phylogenetic relationships between 
isolates, after filtering repetitive loci and resistance-associated SNVs. The resulting MST, 
enrolling 82 strains, is presented in Supplementary Fig. S4.3. As expected, we observed a strong 
correlation between the mean %AD and the mean number of SNPs (Fig. 4.3) within each of the 
eight clusters investigated by the gene-by-gene approach (extended schema). Most importantly, 
when looking at the 10 clusters with epidemiological support (including eight with confirmed 
epilink and two with confirmed non-epilink), we observed two threshold patterns, where all 
clusters with strong epilinks have less than 6 SNPs/0.3 %AD, whereas the weak or confirmed 
non-epilinks have pairwise distances ranging from 6-16 SNPs/0.3-0.7 %AD, sustaining the 
parallelism with the gene-by-gene approach.
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Figure 4.3. Genetic diversity within clusters evaluated by the extended gene-by-gene and the core-SNV approach. Mean pairwise percentage of allelic diversity versus mean 
pairwise SNP distance within (A) each potential cluster defined in the extended gene-by-gene approach using a threshold of 0.56% (Fig. 4.1) and (B) their fragmentation 
according to the available epidemiological data. 
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4.4 Discussion 
 
The current study describes the implementation of a WGS-based laboratory workflow for TB 
surveillance in the Portuguese NRL, in the frame of the demanding supra-national short-term 
transition from traditional genotyping methods (MIRU-VNTR). A collection of 83 M/XDR-TB 
strains, isolated between 2013 and 2017, was characterized by traditional genotyping as well as 
by distinct methods for WGS data analysis (i.e., a gene-by-gene approach using both a short 
schema and an extended schema, and a core-SNV strategy) in order to set up a WGS-based TB 
surveillance focused on unveiling possible ongoing transmission chains to be flagged for action 
and further analysis by the health authorities. This study is the first to be performed in Portugal 
with these specific aims and involves the M/XDR strains isolated in the last 5 years. In general, 
the same clusters were essentially detected regardless the WGS-based approaches, both in 
strain number and content (Fig. 4.1; Supplementary Fig. S4.2; Supplementary Fig. S4.3). As 
expected, strains with the same MIRU-VNTR profile revealed high genetic relatedness at the 
genome level, even though we could unveil intricate genetic links between strains with distinct 
MIRU-VNTR patterns. Additionally, our attempt to extract MIRU-VNTR profiles in silico (using 
MIRU-profiler; (243)) yielded unsatisfactory results (Supplementary Fig. S4.1). Although we 
believe that efforts in this field are needed in order to maintain backward compatibility with 
traditional genotyping data, our results consolidate the expectation that repetitive genomic 
regions are still challenging to be extracted from short-read WGS data. 
Although similar results were obtained using a gene-by-gene analysis with both short and 
extended schemas, we observed that the increase in the number of shared loci analyzed may 
have an important role in the sensitivity (Fig. 4.2), which may be key for outbreak investigation. 
In fact, the introduction of accessory genes in the schema not only allows performing a dynamic 
analysis of epidemiological clusters, but also increases the confidence in results, as the link 
between strains is strengthened when AD decrease or remain very similar after generating sub-
MST. This concept of dynamically reconstructing phylogenies for sub-sets of strains, maximizing 
the number of shared loci, as well as the bioinformatics tools needed for its operationalization, 
have been set-up on behalf of a recent internationally collaborative project (INNUENDO; 
https://sites.google.com/site/theinnuendoproject/) that precisely aimed at developing 
analytical frameworks for the use of WGS in routine surveillance and epidemiologic 
investigations. Noteworthy, by providing an in-depth perspective on the accessory genomes 
content, this strategy also opens new possibilities to enrich our knowledge on MTBC biology and 
population genetics, by identifying for instance, lineage specific genetic markers to use for rapid 
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cluster identification (233,248,249) or by linking specific phenotypes with gene 
presence/absence profiles (250). 
In the present study, a good correlation was observed between the magnitude of strain genetic 
relatedness (defined both by gene-by-gene and core-SNV-based strategies) and the strength of 
the epidemiological link between patients, as reported by the Public Health Authorities. After 
conservatively defining potential clusters using the implemented dynamic gene-by-gene 
approach, we could subsequently observe that the mean pairwise distance among strongly 
epilinked strains was always below 0.3%AD, while confirmed non-epilinked and weakly epilinked 
strains had >0.3%AD. This trend strongly correlated with data acquired through the core-SNV 
strategy, with strains sharing strong epilinks displaying mean pairwise distances of less than 6 
SNPs and strains with weak or confirmed non-epilinks with up to 16 SNPs (Fig. 4.3). Of note, we 
found very close related strains within this threshold for which epidemiological data was not 
available, raising the hypothesis that some retrospective links may have been missed. These 
results are in agreement with previous studies, where genetic distance among strains from 
recent transmission chains reveal a maximum number of 12 SNPs/AD 
(143,183,228,229,251,252), and also corroborate the expectation that applying lower 
thresholds will increase the concordance with epidemiological data. Several studies have 
already applied even more stringent thresholds (234,235). Still, we believe that cut-offs should 
not be applied in a static manner, but instead should be dynamically fit to the sub-set of 
strains/lineages under investigation, which fits the evolutionary and epidemiological dynamics 
of M. tuberculosis that relies on a low mutation rate coupled with a long-term transmissibility. 
In fact, this can be operationally achieved with the gene-by-gene strategy described in this study 
as the maximum number of shared loci is automatically used for each potential cluster, with 
allelic distance thresholds being expressed as percentages of allele differences (AD) over the 
total number of shared loci under comparison. Moreover, this dynamic analysis should always 
be contingent on the epidemiological data, when available. In this context, this study illustrates 
the need to reinforce the conventional epidemiological tracing (e.g., by improving clinical 
inquiries and strengthening the communication workflow between stakeholders) in order to 
potentiate the benefits of an enhanced WGS-based laboratory surveillance focused on 
detecting/confirming more robust contact tracing investigation. 
While the advantages of WGS-based typing analysis are undeniable for routine TB laboratory 
surveillance, there are still several drawbacks that need to be overcome before a multi-country 
harmonized WGS-based surveillance (253), such as: i) the lack of standardized pipelines; ii) the 
need of empirical-derived thresholds for cluster definition and, iii) the existence of an 
internationally agreed nomenclature to be used in order to facilitate data sharing, especially for 
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cross-border outbreaks  (173,213). Also, there is still an ongoing debate on which approach will 
be the most reliable method, i.e., gene-by-gene-based, SNP-based or a combination of both 
(143,162,228,229,251,252). In opposition to core SNP-based approaches, our main method of 
choice for future WGS-based TB surveillance in the Portuguese NIH, the gene-by-gene strategy, 
offers several benefits such as: amenability to standardization, higher scalability, likely lower 
computational requirements and less constrains to implement a harmonized nomenclature 
(254,255). In addition, considering that our methodology fully relies on freely available software, 
in contrast with pay-per-use platforms (such as RIDOM SeqSphere) currently applied by several 
reference laboratories, we believe that the present study’s approach may constitute a valuable 
alternative for most laboratories, especially those with less resources. 
In summary, this study stands as the “starting point” for the application of a freely-available 
standardized routine WGS-based laboratory surveillance of M/XDR-TB cases. Together with the 
centralization of the diagnosis and molecular typing in the NIH and a strong articulation with the 
Public Health Authorities, the described framework constitutes the driving force towards a faster 
and robust prospective surveillance of M/XDR-TB cases, from antibiotic resistance prediction to 
transmission chain detection. As such, future studies based on this approach will be crucial to 
consolidate the benefits of this technological transition for Public Health. 
 
 
Acknowledgements 
We would like to thank to Prof. João A. Carriço and Bruno Ribeiro-Gonçalves for making the 
PHYLOViZ online 2.0 Beta version available for the analysis performed in the present study. 
O. Oliveira is supported by the Project NORTE-08-5369-FSE-000041, financed by the Operational 
Program NORTE 2020 and co-financed by the European Social Fund through a doctoral grant 
(grant number UMINHO/BD/47/2016). 
67 
 
 
 
 
 
 
 
 
 
Chapter V 
 
 
Whole-genome-sequencing of M. tuberculosis directly 
from clinical samples 
 
 
 
 
 
 
On-going work 
Rita Macedo, Bioinformatics team 
 
 
 
 
 
 
 
 
RM contributed to the design of the study, wrote the chapter and is performing most of the 
experimental work. 
 
68 
 
 
69 
 
5. Whole-genome-sequencing of Mycobacterium tuberculosis 
directly from clinical samples 
 
5.1 Introduction 
 
The gold standard for the routine clinical diagnosis and DST for M. tuberculosis is culture-based, 
which requires months for visible growth. As such, antimicrobial resistance detection can be 
delayed (until 6 months after culture becomes positive), leading to a potential prolonged 
suboptimal antibiotic treatment. As mentioned in the above chapters of this Ph.D. thesis, there 
are several molecular assays already endorsed by the WHO, but they fall short on targets and 
resistance-related regions or genes, to assure a correct prediction of resistance. The potential 
of WGS as a diagnostic assay has been repeatedly demonstrated and enables a comprehensive 
identification of all known-resistant mutations for all TB drugs as well as it can provide reliable 
contact tracing information (183,213,228,256–258).  For these reasons, we have implemented 
a WGS-based methodology as a routine for early positive cultures identification, resistance 
prediction and surveillance (231,259). Moreover, WGS approach performed at a comparable 
cost to phenotypic assays offering short turnaround times. 
However, as early positive cultures may still represent some weeks of bacterial growth, 
generating WGS information directly from samples avoiding the time-consuming need for 
culture would constitute a tremendous achievement. (Figure 5.1). But this approach has a major 
potential hurdle, because biological samples contain variable amounts of human cells (mixed 
with M. tuberculosis cells) that account for up to 99.9% of the total DNA present 
(166,167,260,261). 
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Figure 5.1. Diagnostics workflows and time-to-results shift using the traditional phenotypic 
methodologies and WGS-based approaches directly from cultures (A) or from smear-positive sputum 
samples (B). 
 
 
Several studies have already described the use a specific protocol, which uses SureSelect™ 
(Agilent) custom designed 120-mer RNA oligonucleotides that span the entire microbial 
genome, and can recover (by hybridization) low copy numbers of DNA directly from clinical 
samples with sufficiently high sensitivity and specificity to enable efficient WGS (262,263). 
M. tuberculosis is particularly appropriate for the use of diagnostic WGS with enrichment, since, 
unlike the majority of pathogenic organisms, it has a well characterized clonal nature, with low 
levels of sequence variation and does not undergo recombination or horizontal transfer (264); 
thus, a stable set of oligonucleotide baits can be created and sequence data can be mapped 
against a reference genome (167). However, mycobacterial cells may aggregate because of the 
high mucus content of respiratory samples, meaning that the volume and AFB count may not 
represent the total quantity of mycobacteria available (166,167,261). Direct samples therefore 
require pre-processing for homogenization and enrichment purposes, and to deplete other 
cells/DNA. 
The main objective of this study is to provide a proof-of-concept regarding the application of 
WGS-based methodologies directly from sputum samples, for resistance prediction and 
surveillance, in M. tuberculosis. 
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5.2 Materials and Methods 
 
5.2.1 Samples 
 
Smear-positive sputum samples retrieved from pulmonary TB patients and that were sent to the 
NRL-TB from the Portuguese NIH were tested. Samples were decontaminated using N-acetyl-l-
cysteine/NAOH (1% NaOH final concentration) and resuspended after centrifugation in 2 mL 
phosphate buffer (pH 6.8). After inoculation for phenotypic testing, all the remaining sputum 
specimens were kept frozen at −20°C until further use. Only samples with AFB scoring of 3+ 
(visually quantified according to WHO guidelines) were considered. 
 
 
5.2.2 Phenotypic resistance profiles 
 
All isolates were tested for susceptibility to first-line drugs rifampicin (RIF), isoniazid (INH), 
ethambutol (EMB), pyrazinamide (PZA), and streptomycin (STR). Isolates resistant to at least RIF 
and INH (i.e., representing multidrug-resistant TB [MDR-TB]) were additionally tested for 
susceptibility to kanamycin (KAN), amikacin (AMK), ofloxacin (OFL), capreomycin (CAP), 
ethionamide (ETH), prothionamide (PTH), and para-aminosalicylate sodium (PAS). Drug 
susceptibility testing (DST) was carried out on an automated liquid medium-based system, 
Bactec MGIT960 (Becton Dickinson), using standard drug concentrations (in micrograms per 
milliliter) as follows: for STR, 1.0; for INH, 0.1; for RIF, 1.0; for EMB, 5.0; for PZA, 100.0; for OFL, 
2.0; for AMK, 1.0; for CAP, 2.5; for KAN, 5.0; for ETH, 5.0; for PTH, 2.5; and for PAS, 4.0. 
 
 
5.2.3 DNA extraction 
 
In order to measure the effect of human DNA depletion prior to DNA extraction on the success 
of WGS directly from clinical samples, two DNA extraction protocols were tested in twin aliquots 
of each biological sample. These two protocols differed in the inclusion of an initial sonication 
step and treatment with a DNase/RNase solution. 
Briefly, the bacterial suspension used for inoculation was repelleted by centrifugation at 14,000 
× g for 10 min. Supernatants were decanted, and pelleted cells were resuspended in 0.2 mL PBS 
buffer. Microorganisms were heat killed at 95°C for 1 hour; after inactivation, the samples were 
subjected to two cycles of ultrasounds for 1 min each (S30 Elmasonic). After sonication, 0.2 mL 
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of a DNase/RNase solution was added and incubated for 30 minutes at 37ºC. The samples were 
then centrifuged at 14,000 × g for 10 min, the supernatant (containing the digested nucleic acids 
from the host cells) discarded and the pellet ressuspended in 0.2 mL of a DNase/RNase solution, 
subjected to 2 additional cycles of sonication for 1 min each (S30 Elmasonic) and incubated for 
30 minutes at 37ºC. The DNase/RNase solution was inactivated at 65ºC for 30 min followed by 
1 min on ice, centrifuged at 14,000 × g for 10 min and 0.2 mL PBS buffer was added to the pellet. 
TE 1X buffer (160 L) and lysozyme (40 L) were added and the samples were incubated for 1h 
at 37ºC. Next, 180 L lysis buffer (Bioline) and 20 L proteinase K were added to the samples, 
followed by incubation for 3h at 56ºC. The remaining protocol steps were performed according 
to manufacturer´s instructions using the Isolate II Genomic DNA kit (Bioline). 
In parallel, the twin aliquots of the same samples were extracted without the human DNA 
depletion steps, using the lysozyme solution, proteinase K and the Isolate II Genomic DNA kit 
(Bioline), as described above. At the end of the process, we proceeded with the subsequent 
experimental steps for four pairs of aliquots, corresponding to four different sputum samples. 
 
5.2.4 Generation of standard curves for real-time quantitative PCR (qPCR) 
 
To quantify the number of M. tuberculosis genomes in each sample, a plasmid standard curve 
was generated as previously described for other pathogens (263,265,266). Primers for the 
conserved MTBC single-copy gene katG were designed based on constant regions (primers KatG-
A TTACCGCTGGGCGTGTTC and KatG-B TCACGAAGAAGTCGTTGGTCAGT designed using Primer 
Express software; Applied Biosystems), according to the sequence of MTB H37Rv strain 
(Genbank # AL123456). Briefly, an amplified fragment (58 bp) of katG was cloned into the pCR® 
2.1 vector using the TOPO TA technology (Invitrogen, MA, USA) according to the manufacturer's 
instructions. After transformation of DH5α E. coli with the cloned vector and subsequent 
overnight propagation, plasmid DNA was purified and transformation was confirmed by PCR and 
sequencing. The plasmid copy number was calculated according to the formula: Nº plasmid/mL 
= (Avogadro's Nº x Plasmid conc. (g/mL))/MW of 1 mol of plasmids (g). The standard curve 
consisted of eight-serial plasmid dilutions (~1 to 1 x 108 plasmid copies/L). The number of 
human cells/sample was quantified by a similarly generated plasmid standard curve using an 
amplified fragment (73 bp) of a single copy human gene (b-actin) cloned in a similar vector, 
according to Gomes et al. 2006 (primers B-actin-3 GGTGCATCTCTGCCTTACAGATC and B-actin-4 
ACAGCCTGGATAGCAACGTACAT). 
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5.2.5 qPCR for quantification of MTB vs human cells 
 
The real-time quantification was performed using the Light-Cycler® 480 SYBR Green chemistry 
and optical plates (Roche Diagnostics, Basel, Switzerland). The qPCR reagents consisted of 2 x 
SYBR Green I Master Mix, 400 nM of each primer and 5 µL of DNA sample in a final volume of 
25 µL. The thermocycling profile was: 10 min/95 °C followed by 40 cycles of 15 s/95 °C and 1 
min/ 60 °C. Specificity was checked by generating the dissociation melting curves. Absolute 
quantification of bacterial and human genomes was calculated in relation to the respective 
plasmid standard curve. The relative load of MTBC cells in each sample was determined as the 
ratio between the number of katG and b-actin copies. 
 
 
5.2.6 DNA capture directly from clinical samples 
 
In order to capture the M. tuberculosis DNA, directly from clinical samples, complementary RNA 
oligonucleotide “baits”, 120 bp in size, were designed to span the ∼4.5 Mb of the M. tuberculosis 
genome. As such, the reference genome sequence of the MTBC H37Rv strain (Genbank 
#AL123456) was in silico fragmented into 120 bp sequences twice, to ensure an overlap of 60 bp 
between sequences. Due to their rich GC content, which could hamper DNA capture, all MTBC 
genes of the PE, PPE and PE-PGRS family were also independently fragmented into 120 bp 
sequences, in order to increase capture sensitivity. All resulting sequences were BLASTn 
searched against the Human Genomic + Transcript database to excluded homologous sequences 
to the human genome. Overall, a total of 42,278 RNA probes were generated and this custom 
bait library was then uploaded to the SureDesign software 
(https://earray.chem.agilent.com/suredesign/) and synthesized by Agilent Technologies. During 
synthesis, the 2199 sequences complementary to the PE, PPE and PE-PGRS family were 
unbalanced 8:1 to potentiate capture. Before enrichment and WGS, DNA samples were 
quantified using Qubit HS kit (Invitrogen, Life Technologies) to calibrate the input to 10-200 ng 
DNA. 
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5.2.7 SureSelectXT HS target enrichment: library preparation, hybridization, 
and whole genome sequencing   
 
Prior to the preparation of sequencing libraries, DNA was fragmented with an enzymatic 
procedure. 
For the libraries preparation we used SureSelectXT HS Target Enrichment System for Illumina 
Paired-End Multiplexed Sequencing Library (Agilent). Instead of the mechanical shearing 
(referred in Step 2 of the abovementioned protocol), we used the SureSelectXT HS Low input 
Enzymatic Fragmentation kit (Agilent) for DNA shearing, according to manufacturer´s 
instructions. We then continued the library preparation at “Step 3. Repair and dA-Tail the DNA 
Ends” of the protocol. 
 
 
Figure 5.2. Schematic protocol of the M. tuberculosis DNA enrichment SureSelectXT HS target enrichment 
prior to WGS. 
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5.2.8 WGS analysis 
 
To access the percentage of on-target reads, after quality analysis (FastQC v0.11.5 - 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and trimming (Trimmomatic 
v0.36) (240), the improved reads were mapped (Bowtie 2 v2.2.9) against the reference MTB 
H37Rv strain genome (Genbank #AL123456). Likewise, the reads were also mapped against the 
human reference genome GRCh38.p12 (assembly #GCA_000001405.27). 
All genomes were de novo assembled using the INNUca v4.0.1 pipeline (https://github.com/B-
UMMI/INNUca), which consists of integrated modules for reads QA/QC, de novo assembly and 
post-assembly optimization steps. Briefly, after reads’ quality analysis and cleaning, genomes 
are assembled with SPAdes v3.9.0 (241) and subsequently improved using Pilon v1.18 (242). To 
allow a higher horizontal coverage of the genomes, the parameters 
estimatedMinimumCoverage and assemblyMinCoverageContigs were set to the value 5. In 
order to access the suitability of the obtained genomes directly from the clinical samples for 
subsequent in silico DST and surveillance purposes, we subsequently used TB-profiler v0.3.0 
(267) as previously described (231), and performed gene-by-gene analysis, according to the 
study that is presented in the chapter IV of this PhD thesis (259). 
 
 
5.3 Results 
 
Four sputum samples were subjected to the workflow presented at the Methods section (point 
5.2.3), which includes two parallel DNA extraction protocols. As shown in Figure 5.3, the human 
DNA-depletion protocol was very successful for all samples analysed and did not compromise 
the yield of M. tuberculosis DNA extraction. One of the samples (TB 36163A) did not meet the 
concentration criteria required for further processing (10-200 ng) and was thus excluded. As 
such, four human DNA-depleted samples and three non-depleted were processed and analysed. 
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Figure 5.3. Results of the number of copies of human and M. tuberculosis after DNA extraction protocol 
with (B) or without (A) the human-DNA depletion step. 
 
 
 
The percentage of reads mapping against the reference MTB H37Rv strain genome ranged from 
56.69% to 97.22%, with 96.9-97.7% of the genome being covered by at least one read. 
Conversely, the percentage of reads mapping against the human genome ranged from 0.22% to 
5.1% (Figure 5.4). Although all the human DNA-depleted samples (labeled “B”) presented a 
lower level of human DNA when compared to their non-depleted pair, these values were not 
significantly lower and thus the success of the methodology seemed to be independent of this 
previous depletion. 
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Figure 5.4.  Percentage of reads mapping against the M. tuberculosis (Genbank #AL123456) and human 
(assembly #GCA_000001405.27) reference genomes. Samples labeled with “A” were extracted without 
human DNA depletion. Samples labeled with “B” were subjected to human DNA depletion. 
 
All samples were analysed using TB-profiler v0.3.0 and genotypic and phenotypic data were 
concordant. With the exception of TB36313, all the other samples were fully susceptible to all 
first-, second-, and third-line anti-TB drugs. TB36313 was phenotypically resistant to STR, which 
was confirmed genotypically by the identification of a mutation in the rrs gene. 
Since the main objective of this section was to establish a proof-of-concept on the efficiency of 
MTBC DNA capture directly from clinical sputum samples, for this preliminary assay, we decided 
to sequence the libraries in an Illumina MiSeq platform, using the Reagent Micro Kit v2 (300-
cycles). Surprisingly, given the high specificity of the RNA “baits” used for the capture and 
enrichment protocol (reflected in the high percentage of on-target reads), it was possible to 
assemble the genomes with a depth of coverage ranging from 21.2x to 32.4x, which was 
homogenously distributed throughout the genome (Figure 5.5). Hence, we can assume that if a 
higher output sequencing kit was used, the coverages would be significantly higher and 
comparable to those that are generally obtained from pure cultures. Furthermore, we were able 
to retrieve sequence data from GC-rich regions, namely, the PE/PPE family genes, for which the 
implemented routine WGS-based protocol (using pure cultures and mentioned in the previous 
chapters) does not yield sufficient depth of coverage sequencing (Figure 5.5). This is likely due 
to the specific enrichment of RNA “baits” spanning these regions, in a 8:1 ratio. The rRNA 
operon, however, presents a high coverage most likely because of the presence of several non-
MTB microorganisms in the sputum samples. The sequence conservation of this operon within 
bacteria may thus justify a high dedication of reads to this genomic region.
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Figure 5.5. Depth of coverage of the genomes sequenced directly from sputum samples. All sequences were mapped against the MTB H37Rv reference genome (Genbank 
#AL123456). An additional genome (PT_TB0105, in black), previously sequenced from a pure culture and published in a previous work (259), was added for comparison 
purposes. High depth of coverage peaks (presenting >3-fold the mean depth of coverage) in the sputum sequenced samples were inspected: peaks marked with an “*” refer 
to PE/PPE genes and the peak marked with a “†” indicates the rRNA genes operon.
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It was also possible to perform a gene-by-gene analysis, as described in Chapter IV of the present 
thesis (259). In order to frame these samples within the set of Portuguese MDR-TB strains 
previously analysed, after allele calling, and for simplicity purposes, we chose the assemblies 
that performed better from each pair of samples. This approach allowed the comparison of 
these four genomes with the remaining 112 strains, using a set 1709 shared loci, showing the 
potential of WGS directly from clinical samples for real-time surveillance purposes (Figure 5.6). 
 
 
 
 
 
Figure 5.6. MST of all MTBC strains used for surveillance purposes highlighting (marked as red dots) the 
phylogenetic position of the genomes that were captured directly from clinical samples. 
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5.4 Discussion / Perspectives 
  
The capture of large genomic sequences directly from clinical samples, such as the baits-based 
Agilent SureSelect procedure, has been widely used in genetic-related diagnoses such 
hemoglobinopathy cases (268) but, in the microbiology field, it has been used mostly for viruses 
(269). 
Here, we aimed to provide a proof-of-concept on the utility of WGS-based methodologies 
directly from sputum samples, for resistance prediction and surveillance, in M. tuberculosis 
using a similar enrichment approach. 
Overcoming the constraints of time-consuming laboratory procedures for the isolation of MTBC 
strains in culture, we were able to provide a methodology that allowed not only the 
identification and prediction of genotypic resistance, but also the possibility to integrate this 
approach in a “real-time” MDR-TB surveillance for the rapid articulation with the public health 
authorities. Within a 5-day wet-lab procedure, after DNA isolation directly from sputum 
samples, we were able to retrieve all the information needed for routine diagnostic purposes, 
skipping the 1-3 weeks period required for culture isolation. 
Furthermore, unlike WGS performed from DNA isolated from pure cultures, which potentially 
leads to the loss of information on the existence of MTBC sub-populations, targeted sequencing 
directly from clinical samples will likely provide information on the real scenario of the in vivo 
sub-populations that might co-exist during the infection period. Although this is a preliminary 
work, in which we have obtained relatively low coverage genomes exclusively due to the choice 
for a low output sequencing flow cell, future assays aiming for higher coverages will allow 
deeper and refined analysis, such as the potential prediction of transmission chains through the 
analysis of sub-populations. 
Furthermore, a rough estimation on the total cost of this methodology showed, comparing to 
culture WGS-based analysis, an increase of > 150 euros. Thus, an estimated final cost would 
roughly be between 180 and 220 euros per sample, depending on the desirable coverage and 
on the flow-cell that is used. Considering the improvement that is potentiated by a faster and 
accurate diagnostic, which will clearly result in proper therapeutic options and public health 
interventions, it is mandatory to perform a cost/benefit study in order to evaluate the usefulness 
of this approach. Also, and as it has already happened with WGS technology, it is expected a 
reduction in the costs of reagents in a near future. Overall, despite the important impact of the 
implementation of this approach in individual and public health and the quite promising results 
that we have obtained so far, more samples with heterogeneous M. tuberculosis loads will have 
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to be tested in order to obtain a more complete picture about its usefulness in laboratory 
practice for TB surveillance and diagnosis. We expect to provide results in the next couple of 
months. 
 
 
 
 
 
 
82 
 
 
83 
 
 
 
 
 
 
 
 
 
Chapter VI 
 
 
Identification of new mutations associated with 
decreased susceptibility to anti-TB drugs 
 
 
 
 
  
On-going work 
Rita Macedo, João Paulo Gomes. 
 
 
 
 
RM contributed to the design of the study, performed the experimental work, interpreted data 
and wrote the chapter. 
 
This study is being conducted after submission of the forms required by the Ethics Committee 
of the National Institute of Health Dr. Ricardo Jorge. All procedures are in accordance with the 
ethical standards and with the Helsinki Declaration, as revised in 2008. 
 
 
84 
 
 
85 
 
6. Identification of new mutations associated with decreased 
susceptibility to anti-TB drugs 
 
6.1 Introduction 
 
Although the molecular mechanisms responsible for the resistance to the first and some of the 
second-line drugs were already studied and are well documented, the same does not happen 
with most of second and third-line anti-TB drugs, such as linezolide (LZD), PAS, cycloserine and 
the recently acquired bedaquiline (BDQ) and delamanid (DLM). They are still poorer investigated 
and, as such, the correlation between genotypic and phenotypic DST has very low sensitivity. 
LZD, the first oxazolidinone approved for clinical use, has demonstrated excellent activity against 
drug-resistant strains of MTBC. LZD is rapidly absorbed after oral dosing. It readily distributes to 
well-perfused regions of the body, penetrates well into bronchoalveolar tissues, and acts by 
inhibiting protein synthesis at an early stage of translation (270). Recent case series have 
reported improvement among MDR-TB patients whose treatment regimens included LZD 
(271,272). However, the toxicities are severe, primarily including reversible myelosuppression 
and neuropathy, mainly determined by dose and duration, and require discontinuation of LZD 
in several cases (270). Mutations in the rplC and rrl target genes appear to be associated with 
either high or low-level LZD resistance respectively (273). 
BDQ and DLM are the first new anti-TB drugs to become available in 40 years and have recently 
received a marketing approval by the Food and Drug Administration and European Medicine 
Agency (77,274). 
BDQ-containing regimens increase by 12 times the probability of culture conversion in MDR-TB 
cases and prevent the emergence of further resistances to the drugs included in the backbone 
regimens. It has been shown to reduce the time to culture conversion in the first 6 months and 
the safety and tolerability profile seems to be good compared with other antituberculosis drugs 
(77,79). 
BDQ it is a diarylquinoline with potent activity against M. tuberculosis, including in vitro induced 
dormant cells, which targets the subunit c of the ATP synthase (275–277). Although it has been 
more recently introduced, some evidences points out that resistance to this drug appears to 
emerge rapidly. Three genes are so far known to be involved in the emergence of resistance to 
BDQ: atpE, Rv0678 and pepQ. atpE codes for the BDQ target and mutations in this gene are 
thought to abrogate the binding of this drug to its target, resulting in high-level resistance (276). 
DLM-containing regimens showed a short- and long-term efficacy in terms of culture conversion. 
The positive microbiological features are associated with the relevant improvement of a strong 
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epidemiological indicator- the reduction of mortality rates; the proportion of individuals who 
died after a ≥6 month´s exposure to DLM was 1% versus 8% in those not exposed (77). Also, the 
percentage of individuals who culture-converted at two months was about 45% versus nearly 
30% in the control group (77). 
DLM is a dihydro-nitroimidazooxazole derivative with a highly potent activity against either 
actively growing or dormant M. tuberculosis (278,279). As PZA or INH, DLM is a pro-drug that 
requires activation to its reactive form, which is catalysed by the deazaflavin(F420)-dependent 
nitroreductase (Ddn) and leads to the synthesis inhibition of methoxy-mycolic acids and keto-
mycolic acids (278,280,281). As such, loss of Ddn function by mutations on ddn gene is one of 
the main genetic mechanisms leading to DLM resistance. Other resistance mechanisms include 
non-synonymous mutations in fbiA, fbiB and fbiC, coding for enzymes involved in the synthesis 
of F420 that produce non-functional forms thereby compromising DLM bioactivation (281). 
Despite the identification of the above-cited genetic markers thought to be associated with the 
resistance to LZD, BDQ e DLM, since its regular use is only occurring in the present, more 
extensive research regarding the precise resistance mechanisms should be performed. As such, 
we aimed to disclose the genetic basis of resistance for these three drugs through the 
application of in vitro selective pressure scenarios, which have been accurately validated for 
other bacteria (282). 
 
 
6.2 Materials and Methods 
 
6.2.1. Bacterial strain and culture conditions 
 
A fully susceptible MTBC strain was subjected to sequential sub-MIC concentrations of LZD, BDQ 
and DLM using 7H9 liquid broth in the MGIT system according to manufacturer´s instructions. 
We started with concentrations corresponding to 1:8 MIC (1,0 g/L for LZD, 0,06 g/L for 
DLM and 1,0 g/L for BDQ) (171) and, after observing the fully adaptation of the strain, i.e., 
when the time of growth seemed to be independent of the introduction of the antibiotic, we 
duplicated the dosage until the strains were fully adapted at drugs concentrations higher than 
the pre-determined MIC. The procedure was stopped when no increase in MIC values were 
observed after three weeks of growth. Each test was performed in triplicate and using a control 
(with no antibiotic) and the aliquots were kept frozen after growth for further WGS analysis. 
Periodically, DST was performed to the “supposedly mutant” strain to confirm its susceptibility 
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and conversion to resistance. At the end of these selection procedures, the culture was plated 
onto solid media, single colonies were chosen for susceptibility testing and independent 
mutants from each reference drug were selected for sequencing. 
 
 
6.2.2 DNA extraction and quantification 
 
The bacterial cells were first resuspended in TE 1X buffer (160L) and lysozyme (40L) and were 
incubated for 1h at 37ºC. After this lysis step, 180 L lysis buffer (Bioline) and 20 L proteinase 
K were added and incubated for 3h at 56ºC. The remaining protocol was performed according 
to manufacturer´s instructions using the Isolate II Genomic DNA kit (Bioline). Quantification and 
quality assessment of the purified DNA was performed using Qubit Fluorometer with hsDNA 
Assay Kit (Thermo Fisher Scientific) and agarose gel electrophoresis (0,8%), respectively. 
 
 
6.2.3 WGS and genome assemblies 
 
For each strain, WGS was performed as previously described [28].   Briefly, high-quality DNA 
samples were used to prepare dual-indexed Nextera XT Illumina libraries using the KAPA HiFi 
HotStart ReadyMix PCR Kit (KAPA Biosystems) in the indexing step to improve amplification of 
the GC-rich genome regions. Libraries were subsequently subjected to cluster generation and 
paired-end sequencing (2×250bp) on a MiSeq Illumina platform (Illumina Inc.), according to the 
manufacturer’s instructions. 
All genomes were de novo assembled using the INNUca v3.1 pipeline (https://github.com/B-
UMMI/INNUca), which consists of integrated modules for reads QA/QC, de novo assembly and 
post-assembly optimization steps. Briefly, after reads’ quality analysis (FastQC v0.11.5 - 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and cleaning (Trimmomatic 
v0.36) (240), genomes are assembled with SPAdes v3.11 (241) and subsequently improved using 
Pilon v1.18 (242). 
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6.3 Preliminary results and future perspectives 
 
We started these experiments with LZD due to constraints regarding the acquisition of BDQ and 
DLM. So far, and after 9 months of sub-culturing, we have achieved a LZD dosage of 2xMIC, but 
the growth rate is still far from the expected if the cells were already fully adapted, so the 
experiments are still ongoing. The first passages were achieved in short periods of time, i.e., 
from the 1:8 MIC until 1:2 MIC we needed around 3 months; to achieve the MIC it took an extra 
2 months and, since then, we do not seem to be able to grow easy a 2xMIC M. tuberculosis 
culture. Although not comparable to other microorganisms, such as E. coli, which in only few 
weeks can convert to a resistant phenotype 1000X MIC (282), we must acknowledge that the 
means of in vitro evolution and adaptation are pretty much the same (i.e., random emergence 
of point mutations). The major hurdle is the fact that M. tuberculosis cells typically take as much 
as 24h to divide, making it extremely difficult to perform these experiments. This disadvantage 
is indeed potentiated under selective pressure scenarios (as the one in the present study), as 
the bacteria must adapt to a hostile environment created by the presence of antibiotics, which 
certainly strongly affects the duplication time. Nevertheless, we have already selected colonies 
growing at 2X MIC for future WGS analysis and screening for possible existing mutations. Even 
if these emergent clones are not yet the best fitted, the identification of their mutation profile 
will certainly help the understanding of the evolutionary pathway that takes place until a well-
adapted clone is established. 
The experiments with DLM and BDQ started this early february, and, so far, we have not been 
able to surpass the 1:8 MIC. 
Although really demanding, especially due to the constraints associated with M. tuberculosis 
species, we hope this work will contribute to the detection (and confirmation) of mutations 
associated with resistant phenotypes. This will contribute, not only to a better understanding of 
the resistance mechanisms, but also to the update of the mutations’ databases used by the 
bioinformatics platforms (as the ones used in Chapter II of this thesis) that allow a rapid in silico 
screening of resistance targets. 
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Final overview, concluding remarks and future directions 
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7. Final overview, concluding remarks and future directions 
 
 
The main goal of this PhD dissertation was to acknowledge the potential of the use of WGS-
based methodologies for routine diagnostic and epidemiological surveillance of M. tuberculosis 
strains and to develop specific pipelines to be implemented in the Portuguese NRL. As such, and 
given the major constraints regarding the isolation and time of growth of MTB strains, specially 
concerning the time to have a DST result, our first approach, as described in Chapter II, was to 
evaluate the efficiency of the available online-free software platforms for in silico resistance 
prediction. We conducted a study involving a set of 54 M/XDR- and five susceptible-TB strains, 
corresponding to about 300 phenotypic hits, simultaneously evaluating the major four free 
online platforms, TB Profiler, PhyResSE, Mykrobe Predictor and TGS-TB. Overall, the sensitivity 
of resistance prediction ranged from 84.3% using Mykrobe predictor to 95.2% using TB profiler, 
while specificity was higher and homogeneous among platforms. TB profiler revealed the best 
performance robustness (sensitivity, specificity, PPV and NPV above 95%), and thus it was the 
adopted platform for use in the NRL at the NIH as a tool for first-line clinical guidance for 
therapeutic decision. We have also observed a few discrepancies between phenotype and 
genotype, where, in some cases, it was possible to pinpoint some “candidate” mutations 
highlighting the need for their confirmation through mutagenesis assays and potential review of 
the anti-TB genetic databases. In addition, and specially with the introduction of new 
therapeutic options, it is mandatory to conduct these experiments (as it was pointed out in the 
Chapter VI of this thesis) for the revision and inclusion of new possible genetic markers 
underlying M. tuberculosis resistance in the available databases, so that they can reunite all 
possible mutations underlying antibiotic resistance. This tremendous development of the 
bioinformatics algorithms and reduced time frame for reporting a result to the clinician will 
certainly trigger the technological transition where WGS-based bioinformatics platforms could 
replace phenotypic drug susceptibility testing for TB. Although, at this stage, we have only 
implemented this approach at the culture level, studies are ongoing in order to use it directly 
from clinical samples isolated from TB patients (as it is demonstrated in Chapter V). This study 
resulted already in a paper that was published in an international scientific journal, as mentioned 
above. 
In chapter III, we studied the usefulness of the routinely and most widely used methodology for 
MTBC surveillance, MIRU-VNTR, in order to evaluate the rate of MDR-TB cases clustering and 
the possible association links that could underlie a direct transmission. We have evaluated the 
activity, since 2014, of specific reference centres for the diagnosis, consultancy, monitoring, and 
92 
 
treatment of the M/XDR-TB cases. Besides the clinical approach, these centres also link the 
information on molecular genotyping performed by the NRL with the epidemiological surveys 
performed by the Public Health Authorities. Although, with this analysis, we have observed a 
decreasing tendency both in the number of MDR-TB cases and the clustering rates, there is a 
poor agreement between laboratory and epidemiological data. The centralization of the MDR-
TB cases in reference centres seems to be effective, but there is certainly a need for a better 
molecular tool, with higher discriminatory power, and a better inclusion of epidemiological data 
when discussing these clusters. This “better molecular tool” was already developed and 
described in Chapter IV of this thesis and it will be discussed in the next paragraphs. To better 
understand the transmission patterns from all culture-confirmed MDR-TB cases notified in 
Portugal from 2014 to 2017, we  started a collaboration with a group from Universidade do 
Minho to deeper investigate this phenomenon. The results showed a unique MDR-TB 
transmission scenario, where MDR strains likely arose and are being transmitted within local 
chains despite the efforts from the Public Health authorities to identify and control all the cases. 
With 63% of these cases in cluster (using MIRU-VNTR molecular methodology), it appoints to a 
very high degree of primary transmission. An evolutionary analysis of these same strains 
suggested that clustered strains arose locally from endemic strains (still under investigation). 
While in Europe LAM strains are more common and Beijing sub-lineages are mostly associated 
with MDR-TB, in Portugal LAM is the common MTBC lineage clade but also associated with 
higher prevalence of MDR cases. One hypothesis is that MDR-TB in Portugal is evolving within 
an autochthonous chain of transmission. In fact, according to the MIRU-VNTR profiles, we have 
found clusters that have been previously identified (283,284) and associated with MDR-TB cases, 
such as cluster Q1, Lisboa3-A and Lisboa3-B, in the LTV region. Despite the efforts to track and 
contain MDR-TB strains in Portugal, their transmission remain to be disclosed, stressing the need 
to reinforce surveillance and Public Health containment strategies. This specific work is also part 
of a PhD thesis from a colleague from Universidade do Minho and will be soon submitted for 
publication. 
As stated above, there is a need for a more accurate molecular surveillance tool that can allow 
a better match between the laboratory and the epidemiological information. For this reason, in 
Chapter IV, we aimed to report the implementation of a dynamic gene-by-gene approach, fully 
relying on freely available software, for prospective WGS-based tuberculosis surveillance. It is 
well established that WGS offers unprecedented resolution for tracking MTBC transmission and 
antibiotic-resistance prediction, however, standardized pipelines and the definition of 
epidemiological cut-offs for cluster detection are still under discussion. Our implemented 
approach and its application for detecting transmission chains was demonstrated by 
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retrospectively analysing all M/XDR strains isolated between 2013 and 2017 in Portugal. We 
observed a good correlation between genetic relatedness and epidemiological links, obtaining 
mean pairwise allele differences (AD) below 0.3% for strongly epi-linked clusters. We observed 
the same scenario by applying the core-SNV analysis, while providing higher resolution and 
epidemiological concordance than MIRU-VNTR genotyping. In addition, “zooming in” each 
strains’ sub-set (i.e., increasing the number of shared loci within each sub-set) also strengthens 
the confidence in detecting epi-linked clusters. This gene-by-gene strategy offers several 
practical benefits (e.g., amenability to standardization, reliance on freely-available software, 
scalability and low computational requirements) and our data further consolidated it as the 
method of choice for a timely, standardized and robust prospective WGS-based laboratory 
surveillance of M/XDR-TB cases. 
In Chapter V, we intended to overcome the limitations of performing our WGS-based 
approaches only after isolation of MTBC strains in culture. As such, we aimed at capturing the 
genomes of MTBC directly from the sputum positive clinical samples, without the need for 
culture propagation. To achieve this, we bioinformatically designed RNA baits that span the 
entire genome, and can recover (by hybridization) low copy numbers of DNA directly from the 
samples with sufficiently high sensitivity and specificity to enable efficient WGS. Although, at 
this stage, we simply aimed at establishing a proof-of-concept, the results were quite surprising 
in the sense that we were able to recover the full MTBC genomes from all tested sputum 
samples. In fact, the percentage of dedicated reads to this bacterium ranged from 56,7% to 
96,7% and all samples had 99% of their genome covered by, at least, one read. Surprisingly, 
these results are comparable with the ones obtained with pure cultures, raising tremendous 
expectations about its applicability in the routine practice of the NRL. We anticipate that, if the 
extension of this study to many more samples yields similar results, this approach shows-up as 
a cutting-edge laboratory procedure for determination of the antibiotic resistance profiles and 
even for epidemiological surveillance. The potential decrease in the time-to-results to about five 
days after receiving the biological sample will constitute a hallmark in the TB diagnosis practice, 
as it would yield unequivocal gains both in the individual and in the Public Health strategies. 
Finally, in chapter VI, we aimed to disclose the genetic basis of resistance for the newest 
introduced drugs for TB treatment, LZD, BDQ and DLM, through the application of in vitro 
selective pressure scenarios. It has taken many years to create a database with most of the 
mutations associated with the susceptibility decrease to the currently used TB drugs. Even 
though it is believed that many mutations remain to be disclosed, as several studies have 
pointed additional putative genetic markers of resistance that not belong to the available 
databases, this issue becomes even more relevant for the drugs that were introduced in the 
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treatment procedures only very recently. As such, we used in vitro selective pressure scenarios, 
for which the proof-of-concept for this purpose was already demonstrated for some bacteria, 
to disclose the genetic basis of resistance to these drugs. This approach consisted on the 
propagation of a fully susceptible MTBC strain using increasing dosages (starting with sub-MIC 
concentrations) of each drug until it fully adapts to concentrations two or three times higher 
than the MICs defined for DST analysis. This study is still ongoing and the time when the first 
resistant clones will emerge cannot be predicted at this stage. 
Overall, we believe this PhD dissertation contributes for a better understanding of how WGS-
based methodologies can surpass the difficulties of TB diagnosis and surveillance and, in 
particular, the ability to provide the clinicians with a much more rapid information regarding 
resistance prediction and an eventual transmission chain. 
As immediate future perspectives, we will continue the work underlying the use of WGS directly 
on clinical samples in order to be fully validated and implemented as routine as the culture WGS-
based approach already is. Additionally, the propagation of the strains using antibiotic selective 
pressure is also ongoing with the ultimate goal of the enrichment of the publicly available 
databases of genetic markers of resistance. 
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Supplementary Figure 4.1. Performance of the in silico determination of MIRU-VNTR profiles using MIRU-profiler software (243). The number of correctly assigned and mismatched loci refer 
to the comparison between traditional genotyping and in silico prediction. Not detected loci refer to loci flagged as such by MIRU-profiler. Results are plotted in correlation with (A) genome 
mean depth of coverage after read quality improvement using Trimmomatic (240), and (B) with the number of contigs generated after genome assembly. 
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Supplementary Figure 4.2. Phylogeny of 80 M/XDR-TB strains based on a dynamic gene-by-gene approach using a short schema (2891 loci). A – Initial Minimum spanning tree (MST) constructed 
based on allelic diversity found among the 2202 genes shared by 100% of the strains. Potential clusters defined for fine-tune analysis are highlighted by colored circles. B – Sub-MST 
reconstruction based on the maximum number of shared loci between strains within a potential cluster. Each circle (node) contains the strain’s designation and represents a unique allelic 
profile. Nodes are colored according to traditional MIRU-VNTR profiles. The numbers in red on the connecting lines represent the allele differences (AD) between strains. MST were constructed 
using the goeBURST algorithm implemented in the PHYLOViZ Online platform, and are based on allelic profiles relying on distinct number of shared loci (indicated near the tree). 
129 
 
Supplementary Figure 4.3.  M/XDR-TB core-SNV-based phylogenetic tree. Core-SNV–based MST of 82 MTBC strains reconstructed by using 5274 variant sites identified when mapping to the 
reference genome H37Rv (RefSeq NC_000962.3) and filtered out for SNVs falling within known genomic regions with high GC content or repetitive elements, as well as resistance-associated 
positions. Each circle (node) contains the strain’s designation and represents a unique SNP profile. Nodes are colored according to traditional MIRU-VNTR profiles. The numbers in red on the 
connecting lines represent the SNP differences between strains. MST were constructed using the goeBURST algorithm implemented in the PHYLOViZ Online platform. 
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Supplementary Table 4.1. Sample dataset characterization. *Previously published under BioProject SRP131205. For better visualization of the information on this table, please refer to the 
internet link: https://www.sciencedirect.com/science/article/pii/S1472979218304748 
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TB01 TB25429-14 2014 M 41 Lisbon and Tagus Valley M R R R R R R S S R S S S S S S SRR6511596 PT_TB0001 ERR2864235 244233352644425153353823 9 4352623 250 169.8 132 2726 94.29 3364 92.27 6
TB02 1595-14 2014 M 37 Lisbon and Tagus Valley M R R R R S R S S R S S S S S S SRR6511595 PT_TB0002 ERR2864288 244213132324114142532822 1 4300244 250 119.3 119 2748 95.05 3394 93.09 2
TB03 1279-14 2014 F 31 Lisbon and Tagus Valley M R R R R R R S S R S S S R S S SRR6511594 PT_TB0003 ERR2864247 132254322224125153322622 --- 4339519 250 75.8 169 2751 95.16 3397 93.17 ---
TB04 1428-14 2014 M 48 Lisbon and Tagus Valley M R R R R S R S S R S S S S S S SRR6511593 PT_TB0004 ERR2864239 244213132324114142532822 1 4335856 250 89.7 68 2751 95.16 3396 93.14 ---
TB05 1378-14 2014 M 50 Lisbon and Tagus Valley XDR R R R R R S S R R R S R S S SRR6511592 PT_TB0005 ERR2864298 244213232424116143532822 4 4290760 150 33.3 165 2744 94.92 3387 92.9 ---
TB06 TB24818-14 2014 F 32 Lisbon and Tagus Valley M R R R R R S S S S S S S S S S SRR6511591 PT_TB0006 ERR2864238 244233352644425173343723 10 4373724 250 30.7 93 2723 94.19 3360 92.16 5
TB07 1599-14 2014 M 43 Lisbon and Tagus Valley M R R R R R S S S S S S S S S S SRR6511590 PT_TB0007 ERR2864296 244233352644425153353823 9 4356270 150 65.8 100 2725 94.26 3363 92.24 6
TB08 187-14 2014 M 58 Lisbon and Tagus Valley M R R R R R R S S R S S S S S S SRR6511589 PT_TB0008 ERR2864263 244213232324116143532822 3 4336178 250 81.4 88 2747 95.02 3393 93.06 1b
TB09 88-14 2014 M 63 North region M R R R R S S S S S S S S S S S SRR6511588 PT_TB0009 ERR2864291 243244331234424153334332 6 4364003 250 139.3 115 2740 94.78 3393 93.06 3
TB10 1536-14 2014 M 23 North region M R R R R S S S S S S S S S S S SRR6511587 PT_TB0010 ERR2864265 243244331234424153334332 6 4379658 250 47.6 69 2739 94.74 3394 93.09 3
TB11 729-14 2014 M 47 North region M R R R R S S S S S S S S S S S SRR6511635 PT_TB0011 ERR2864233 223235321432423153332522 --- 4381013 250 57.1 77 2747 95.02 3392 93.03 ---
TB12 1928-15 2015 M 61 Lisbon and Tagus Valley M R R R R R R S S R S S S S S S SRR6511634 PT_TB0012 ERR2864218 244213132324114142532822 1 4333002 250 36.3 70 2751 95.16 3396 93.14 2
TB13 1229-15 2015 M 39 Lisbon and Tagus Valley XDR R R R R R R R R R R S R S S SRR6511637 PT_TB0013 ERR2864225 244213132324114142532822 1 4328223 250 138.6 104 2748 95.05 3392 93.03 ---
TB14 1876-15 2015 M 55 Lisbon and Tagus Valley XDR R R R R R R S R R R S R S S SRR6511636 PT_TB0014 ERR2864234 244213232424116143532822 4 4332370 250 39.2 82 2751 95.16 3397 93.17 1a
TB15 1926-15 2015 M 52 Lisbon and Tagus Valley XDR R R R R R R R R R R S R S S SRR6511631 PT_TB0015 ERR2864240 244213132324114142532822 1 4336664 250 141.1 110 2749 95.09 3393 93.06 ---
TB16 2829-15 2015 M 44 Lisbon and Tagus Valley M R S R R S S S S R S S S S S S SRR6511630 PT_TB0016 ERR2864264 244213132324114142532822 1 4290704 250 101.9 131 2749 95.09 3395 93.12 ---
TB17 2184-15 2015 M 75 Lisbon and Tagus Valley M R R R R R R R R R S S S R S S SRR6511633 PT_TB0017 ERR2864250 244213132324114142532822 1 4306787 250 89.6 104 2748 95.05 3395 93.12 ---
TB20 2058-15 2015 M 57 Lisbon and Tagus Valley M R R R R S R S S R S S S S S S SRR6511642 PT_TB0020 ERR2864292 244213232424116143532622 --- 4294971 250 54.1 180 2746 94.98 3387 92.9 ---
TB21 TB24737-15 2015 M 44 Lisbon and Tagus Valley XDR R R R R R R R S R R S R S R SRR6511610 PT_TB0021 ERR2864261 244223352634425153353823 --- 4364988 250 17,0 139 2708 93.67 3341 91.63 ---
TB22 1585-15 2015 F 42 Lisbon and Tagus Valley M R R R R R S S S R S S S S S S SRR6511611 PT_TB0022 ERR2864256 244213232424116143532822 4 4292967 250 175.4 158 2745 94.95 3387 92.9 ---
TB23 2354-15 2015 F 27 Lisbon and Tagus Valley M R R R R R R R R S S S S R S S SRR6511612 PT_TB0023 ERR2864242 235237232244425113323632 5 4360251 250 96.3 243 2720 94.09 3368 92.38 ---
TB25 2579-15 2015 M 35 Lisbon and Tagus Valley M R R R R R R S S R S S S S S S SRR6511614 PT_TB0025 ERR2864270 244211232424116143632822 --- 4388702 250 22.4 93 2746 94.98 3403 93.34 ---
TB26 2452-15 2015 M 57 North region M R R R R S S S S R S S S S S S SRR6511615 PT_TB0026 ERR2864257 244213232424116143532822 4 4329104 250 45.5 111 2749 95.09 3394 93.09 ---
TB27 982-15 2015 M 37 North region M R R R R R R S S S S S S S S S SRR6511616 PT_TB0027 ERR2864254 214213232225126153332322 --- 4334560 250 125.1 102 2740 94.78 3391 93.01 ---
TB28 1880-15 2015 M 58 North region M R R R R S S S S S S S S R S S SRR6511617 PT_TB0028 ERR2864295 214213232225126153332222 --- 4260761 150 42.4 287 2714 93.88 3354 91.99 ---
TB29 2353-15 2015 M 21 Island of M adeira M R S R R R S S S R S S S S S S SRR6511608 PT_TB0029 ERR2864231 244233352644425183353823 8 4353529 250 101.4 177 2722 94.15 3360 92.16 8
TB30 27-15 2015 M 44 Algarve M R S R R S S S S R S S S S S S SRR6511609 PT_TB0030 ERR2864278 223235332534425153333632 --- 4221968 250 137.3 476 2498 86.41 3081 84.5 ---
TB31 308144-16 2016 M 41 Lisbon and Tagus Valley XDR R R R R R R S R R R S R S S SRR6511645 PT_TB0031 ERR2864267 244213232424116143532822 4 4224372 250 137,0 310 2646 91.53 3252 89.19 ---
TB32 309968-16 2016 F 41 North region M R R R R S S S S S S S S S S S SRR6511644 PT_TB0032 ERR2864221 243244331234424153334332 6 4378927 250 44.4 72 2742 94.85 3397 93.17 3
TB33 310368-16 2016 M 42 North region XDR R R R R R R S R R R S R S S SRR6511601 PT_TB0033 ERR2864276 244213232424116143532822 4 4210994 250 118.2 375 2604 90.07 3201 87.79 ---
TB34 312205-16 2016 F 63 Lisbon and Tagus Valley M R S R R S R R R R S S S R S S SRR6511626 PT_TB0034 ERR2864289 244213132324114142532822 1 4234612 250 162.4 246 2677 92.6 3290 90.24 ---
TB35 314371-16 2016 M 15 Lisbon and Tagus Valley M R R R R R S S S R S S S S S S SRR6511641 PT_TB0035 ERR2864244 244233352644425153353823 9 4246999 250 116,0 391 2571 88.93 3159 86.64 ---
TB36 324134-16 2016 M 61 Centre region M R R R R R R S S S S S S R S S SRR6511640 PT_TB0036 ERR2864224 234244322424226133131722 --- 4385993 250 83,0 94 2752 95.19 3412 93.58 ---
TB37 326551-16 2016 M 40 Lisbon and Tagus Valley M R R R R R R S S S S S S S S S SRR6511639 PT_TB0037 ERR2864290 244233352633425153353823 --- 4367138 250 34.5 87 2726 94.29 3365 92.29 ---
TB38 327889-16 2016 F 22 Lisbon and Tagus Valley XDR R R R R R R S R R R S R S S SRR6511638 PT_TB0038 ERR2864216 244213232424116143532822 4 4335738 250 80.2 84 2752 95.19 3397 93.17 1a
TB39 320857-16 2016 M 43 Lisbon and Tagus Valley M R R R R R R S S S S S S S S S SRR6511619 PT_TB0039 ERR2864217 2542s12232224125153332622 --- 4339057 250 35.3 75 2746 94.98 3397 93.17 ---
TB40 316569-16 2016 M 54 North region M R R R R S S R R S S S S R S S SRR6511618 PT_TB0040 ERR2864248 235237132244425113323532 --- 4308129 250 145.1 287 2672 92.42 3297 90.43 ---
TB44 TB31393-16 2016 F 40 Lisbon and Tagus Valley M R R R R S S S S S S S S S S S SRR6511620 PT_TB0044 ERR2864219 214213232225126153332422 --- 4341106 250 84.9 73 2745 94.95 3395 93.12 ---
TB45 332846-16 2016 M 70 Centre region M R R R R S R S S S S S S S S S SRR6511606 PT_TB0045 ERR2864279 134262332224126153322722 --- 4371371 250 78.4 82 2743 94.88 3399 93.23 ---
TB46 347401-16 2016 F 20 Lisbon and Tagus Valley M R R R R R S S S R S S S S S S SRR6511607 PT_TB0046 ERR2864246 214213232225126163332422 --- 4327468 250 24.6 128 2690 93.05 3333 91.42 ---
TB47 TB31250-16 2016 M 62 North region M R R R R S S S S R S S S S S S SRR6511604 PT_TB0047 ERR2864249 244213232424116143532822 4 4329390 250 21.2 88 2747 95.02 3393 93.06 ---
TB48 348387-16 2016 M UNK Centre region M R S R R S S S S S S S S S S S SRR6511605 PT_TB0048 ERR2864259 243244332334425153334732 --- 4384558 250 78.8 74 2744 94.92 3402 93.31 ---
TB49 352139-17 2017 F 22 Centre region M R R R R R R S S S S S S S S S SRR6511598 PT_TB0049 ERR2864252 244233352644425153353823 9 4363470 250 54,0 95 2724 94.22 3363 92.24 6
TB50 375001-17 2017 F 22 Centre region M R S R R R S S S R S S S S S S SRR6511599 PT_TB0050 ERR2864272 244233352644425183353823 8 4376598 250 49,0 127 2723 94.19 3362 92.21 8
TB51 374686-17 2017 F 34 Lisbon and Tagus Valley M R S R R R R S S R S S S S S S SRR6511623 PT_TB0051 ERR2864236 254214232224125163333622 --- 4342099 250 52.5 118 2747 95.02 3400 93.25 ---
TB52 381277-17 2017 M 30 North region M R R R R R S S S S S S S S S S SRR6511622 PT_TB0052 ERR2864260 254214232224125163332622 --- 4346252 250 77.9 94 2749 95.09 3402 93.31 ---
TB53 TB33470LB-17 2017 M 52 Lisbon and Tagus Valley M R S R R R R S S R S S S S S S SRR6511625 PT_TB0053 ERR2864294 244213132324114142532822 1 4336120 250 89.8 99 2751 95.16 3396 93.14 ---
TB54 389865-17 2017 F 59 North region M R R R R R R S S S S S S S S S SRR6511624 PT_TB0054 ERR2864223 223235321432423153333522 7 4380694 250 54.3 132 2747 95.02 3389 92.95 ---
TB55 157108-13 2013 M 24 Lisbon and Tagus Valley M R R R R S S S S R S S S R S S --- PT_TB0055 ERR2864220 235237232244425113323632 5 4405717 250 85.7 139 2743 94.88 3401 93.28 ---
TB56 157637-13 2013 F 16 North region XDR R R R R R R R R R R S S S S --- PT_TB0056 ERR2864243 243244231234424153334332 --- 4342056 250 100.6 166 2734 94.57 3386 92.87 3
TB57 159528-13 2013 M 42 North region M R R R R R S R S S S S S R S S --- PT_TB0057 ERR2864286 234233352644425153353623 --- 4348454 250 98.7 165 2728 94.36 3363 92.24 ---
TB58 163-14 2014 M 53 Lisbon and Tagus Valley XDR R R R R R R S R R R S R S S --- PT_TB0058 ERR2864293 244213232424116143532822 4 4308144 250 95.3 165 2746 94.98 3388 92.92 ---
TB59 163761-13 2013 F 32 Lisbon and Tagus Valley XDR R R R R R R R R R R S R S S --- PT_TB0059 ERR2864283 244213132324114142532822 1 4312712 250 126.3 143 2748 95.05 3394 93.09 ---
TB60 171591-13 2013 M 47 Lisbon and Tagus Valley XDR R R R R R R S R S S S S S S --- PT_TB0060 ERR2864227 244234332224226153141512 --- 4348211 250 132.1 228 2736 94.64 3392 93.03 ---
TB61 178958-13 2013 F 24 Lisbon and Tagus Valley XDR R R R R R R R R S R S S S S --- PT_TB0061 ERR2864271 244213132324114142532822 1 4279065 250 126.2 218 2742 94.85 3377 92.62 2
TB62 180161-13 2013 M 50 North region M R R R R R R S S R S S S S S S --- PT_TB0062 ERR2864229 244213232324116143532822 3 4303856 250 83,0 196 2737 94.67 3378 92.65 ---
TB63 180198-13 2013 M 34 North region M R R R R R R S S S S S S S S S --- PT_TB0063 ERR2864275 223235321432423153333522 7 4327660 250 97.2 292 2719 94.05 3341 91.63 ---
TB64 199228-14 2014 M 42 Lisbon and Tagus Valley XDR R R R R R R R R R R S S S S --- PT_TB0064 ERR2864253 244213132324114142532722 2 4267296 250 97.3 261 2732 94.5 3365 92.29 2
TB65 1994-15 2015 M 41 Lisbon and Tagus Valley M R R R R S R S S R S S S S S S --- PT_TB0065 ERR2864268 244213232324116143532822 3 4329740 250 97.3 141 2745 94.95 3391 93.01 1b
TB66 207797-14 2014 M 53 Lisbon and Tagus Valley M R R R R S R S S R S S S S S S --- PT_TB0066 ERR2864226 244213232324116143532822 3 4228239 250 48.2 454 2609 90.25 3205 87.9 1b
TB67 211891-14 2014 M 36 Lisbon and Tagus Valley M R R R R R S S S R S S S S S S --- PT_TB0067 ERR2864255 244233352644425173343723 10 4362169 250 124.3 173 2723 94.19 3358 92.1 5
TB68 2471-15 2015 M 34 Lisbon and Tagus Valley M R R R R R S S S R S S S S S S --- PT_TB0068 ERR2864245 244213232424116143532822 4 4337289 250 99.3 118 2752 95.19 3398 93.2 ---
TB69 2624-15 2015 M 28 Lisbon and Tagus Valley M R R R R R S S S R S S S S S S --- PT_TB0069 ERR2864228 244233352644425173343723 10 4351551 250 111.3 207 2716 93.95 3349 91.85 5
TB70 291-14 2014 M 28 Lisbon and Tagus Valley M R R R R R S S S S S S S S S S --- PT_TB0070 ERR2864232 242236442774225163353843 --- 4356216 250 103.7 186 2730 94.43 3374 92.54 ---
TB71 292-14 2014 F 41 North region M R R R R S S S S S S S S S S S --- PT_TB0071 ERR2864258 243244331234424153334332 6 4372065 250 87.1 148 2740 94.78 3394 93.09 3
TB72 340-14 2014 M 48 Centre region XDR R R R R S R S R S R S R S S --- PT_TB0072 ERR2864277 244213232424116143532822 4 4306675 250 24.3 127 2743 94.88 3383 92.79 ---
TB73 340248-16 2016 M 20 Lisbon and Tagus Valley M R R R R S R S S R S S S S S S --- PT_TB0073 ERR2864273 244213232324116143532822 3 4327253 250 138.3 146 2746 94.98 3390 92.98 1b
TB74 356-14 2014 M 42 North region M R S R R S S S S S S S S S S S --- PT_TB0074 ERR2864285 223154342434425153333812 --- 4383915 250 121.6 130 2745 94.95 3404 93.36 ---
TB75 387683-17 2017 M 56 Lisbon and Tagus Valley XDR R R R R R R S R R R S R S S --- PT_TB0075 ERR2864241 244213232424116143532822 4 4324855 250 149.3 130 2748 95.05 3392 93.03 ---
TB76 396397-17 2017 M 51 Lisbon and Tagus Valley XDR R R R R R R R R S S S R S S --- PT_TB0076 ERR2864269 244213132324114142532822 1 4330853 250 243.1 126 2751 95.16 3398 93.2 2
TB77 399045-17 2017 F 41 North region M R R R R S S S S R R R S S S S --- PT_TB0077 ERR2864237 133224332224127153322622 --- 4376744 250 197.9 132 2748 95.05 3404 93.36 ---
TB78 399986-17 2017 M 58 Lisbon and Tagus Valley M R R R R R S S S R R R S S S S --- PT_TB0078 ERR2864262 244213232424116143532822 4 4327232 250 224.8 154 2749 95.09 3394 93.09 ---
TB79 423-14 2014 F 75 North region M R R R R S S S S S S S S S S S --- PT_TB0079 ERR2864222 243244331234424153334332 6 4366225 250 114.6 130 2740 94.78 3395 93.12 3
TB80 884-15 2015 M 61 Lisbon and Tagus Valley M R R R R S R S S R S S S S S S --- PT_TB0080 ERR2864230 244213232324116143532822 3 4287079 250 107,0 226 2732 94.5 3368 92.38 ---
TB81 92-14 2014 M 59 Centre region M R R R R S S S S R S S S S S S --- PT_TB0081 ERR2864251 244213232324116143532822 3 4323098 250 124.2 159 2749 95.09 3392 93.03 ---
TB82 TB22229-13 2013 F 38 Lisbon and Tagus Valley XDR R R R R R R R R R R S S S S --- PT_TB0082 ERR2864297 244213132324114142532722 2 4091146 150 22.9 1313 2077 71.84 2561 70.24 ---
TB83 TB22634-13 2013 M 50 Lisbon and Tagus Valley XDR R R R R R R R R R R S S R S --- PT_TB0083 ERR2864280 244213232424115143532822 --- 4248079 250 48.8 396 2646 91.53 3254 89.25 ---
TB84 TB23204-13 2013 M 35 Lisbon and Tagus Valley M R R R R R S S S S S S S S S S --- PT_TB0084 ERR2864266 223235332432423163331732 --- 4361159 250 80.4 132 2741 94.81 3380 92.7 ---
TB85 TB23392-13 2013 M 41 Lisbon and Tagus Valley M R R R R R S S S S S S S S S S --- PT_TB0085 ERR2864282 234334-22434236143343522 --- 4352831 250 115.4 160 2748 95.05 3402 93.31 7
TB86 TB24007-13 2013 M 37 Lisbon and Tagus Valley M R R R R R S S S R S S S S S S --- PT_TB0086 ERR2864274 234333322434236143333522 --- 4359274 250 119,0 140 2749 95.09 3406 93.42 7
TB87 TB24207-13 2013 F 29 Lisbon and Tagus Valley XDR R R R R R R S R R R S S R S --- PT_TB0087 ERR2864287 244213232424116143532822 4 4336319 250 117.4 125 2752 95.19 3398 93.2 ---
TB88 TB25380-13 2013 M 42 Lisbon and Tagus Valley XDR R R R R R R R R R R R S R S --- PT_TB0088 ERR2864284 244233162324114142532822 --- 4282031 250 56.4 203 2741 94.81 3377 92.62 ---
TB89 TB34192-17 2017 M 62 Lisbon and Tagus Valley M R R R R S S S S R S S S S S S --- PT_TB0089 ERR2864281 244213232224116143532822 --- 4325767 250 98,0 146 2745 94.95 3391 93.01 ---
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Supplementary Table 4.2. List of loci masked from core-SNV-based analysis. As currently done by several studies, regions with 
high GC content or repetitive elements are excluded for SNV-based phylogenetic analysis. The list used in the present study 
included a recently compiled list available in a   pipeline under construction (MTBSeq), as well as additional loci described by 
Merker 2013 (*). Locus tags, gene names, products and positions refer to the H37Rv reference genome (NC_000962.3). 
 
 
  
 
 
Locus tag Gene name Product Position
Rv0031 --- Possible remnant of a transposase 33582 - 33794
Rv0096 PPE1 PPE family protein PPE1 105324 - 106715
Rv0109 PE_PGRS1 PE-PGRS family protein PE PGRS1 131382 - 132872
Rv0124 PE_PGRS2 PE-PGRS family protein PE PGRS2 149533 - 150996
Rv0151c PE1 PE family protein PE1 179309 - 177543
Rv0152c PE2 PE family protein PE2 180896 - 179319
Rv0159c PE3 PE family protein PE3 188839 - 187433
Rv0160c PE4 PE family protein PE4 190439 - 188931
Rv0256c PPE2 PPE family protein PPE2 309547 - 307877
Rv0278c PE_PGRS3 PE-PGRS family protein PE PGRS3 336310 - 333437
Rv0279c PE_PGRS4 PE-PGRS family protein PE PGRS4 339073 - 336560
Rv0280 PPE3 PPE family protein PPE3 339364 - 340974
Rv0285 PE5 PE family protein PE5 349624 - 349932
Rv0286 PPE4 PPE family protein PPE4 349935 - 351476
Rv0297 PE_PGRS5 PE-PGRS family protein PE PGRS5 361334 - 363109
Rv0304c PPE5 PPE family protein PPE5 372764 - 366150
Rv0305c PPE6 PPE family protein PPE6 375711 - 372820
Rv0335c PE6 PE family protein PE6 400050 - 399535
Rv0354c PPE7 PPE family protein PPE7 424694 - 424269
Rv0355c PPE8 PPE family protein PPE8 434679 - 424777
Rv0387c --- Conserved hypothetical protein 467406 - 466672
Rv0388c PPE9 PPE family protein PPE9 468001 - 467459
Rv0442c PPE10 PPE family protein PPE10 532214 - 530751
Rv0453 PPE11 PPE family protein PPE11 543174 - 544730
Rv0532 PE_PGRS6 PE-PGRS family protein PE PGRS6 622793 - 624577
Rv0578c PE_PGRS7 PE-PGRS family protein PE PGRS7 675916 - 671996
Rv0741 --- Probable transposase (fragment) 832534 - 832848
Rv0742 PE_PGRS8 PE-PGRS family protein PE PGRS8 832981 - 833508
Rv0746 PE_PGRS9 PE-PGRS family protein PE PGRS9 835701 - 838052
Rv0747 PE_PGRS10 PE-PGRS family protein PE PGRS10 838451 - 840856
Rv0754 PE_PGRS11 PE-PGRS family protein PE PGRS11 846159 - 847913
Rv0755c PPE12 PPE family protein PPE12 850040 - 848103
Rv0755A --- Putative transposase (fragment) 850527 - 850342
Rv0795 --- Putative transposase for insertion sequence element IS6110 (fragment) 889072 - 889398
Rv0796 --- Putative transposase for insertion sequence element IS6110 889347 - 890333
Rv0797 --- Putative transposase for insertion sequence element IS1547 890388 - 891482
Rv0832 PE_PGRS12 PE-PGRS family protein PE PGRS12 924951 - 925364
Rv0833 PE_PGRS13 PE-PGRS family protein PE PGRS13 925361 - 927610
Rv0834c PE_PGRS14 PE-PGRS family protein PE PGRS14 930485 - 927837
Rv0850 --- Putative transposase (fragment) 947312 - 947644
Rv0872c PE_PGRS15 PE-PGRS family protein PE PGRS15 970244 - 968424
Rv0878c PPE13 PPE family protein PPE13 978203 - 976872
Rv0915c PPE14 PPE family protein PPE14 1021329 - 1020058
Rv0916c PE7 PE family protein PE7 1021643 - 1021344
Rv0920c --- Probable transposase 1026816 - 1025497
Rv0922 --- Possible transposase 1027685 - 1029337
Rv0977 PE_PGRS16 PE-PGRS family protein PE PGRS16 1090373 - 1093144
Rv0978c PE_PGRS17 PE-PGRS family protein PE PGRS17 1094356 - 1093361
Rv0980c PE_PGRS18 PE-PGRS family protein PE PGRS18 1096451 - 1095078
Rv1034c --- Probable transposase (fragment) 1159307 - 1158918
Rv1035c --- Probable transposase (fragment) 1160061 - 1159375
Rv1036c --- Probable IS1560 transposase (fragment) 1160433 - 1160095
Rv1039c PPE15 PPE family protein PPE15 1162472 - 1161297
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Rv1040c PE8 PE family protein PE8 1163376 - 1162549
Rv1041c --- Probable is like-2 transposase 1165435 - 1164572
Rv1042c --- Probable is like-2 transposase 1165499 - 1165092
Rv1047 --- Probable transposase 1169423 - 1170670
Rv1054 --- Probable integrase (fragment) 1176928 - 1177242
Rv1067c PE_PGRS19 PE-PGRS family protein PE PGRS19 1190424 - 1188421
Rv1068c PE_PGRS20 PE-PGRS family protein PE PGRS20 1192148 - 1190757
Rv1087 PE_PGRS21 PE-PGRS family protein PE PGRS21 1211560 - 1213863
Rv1088 PE9 PE family protein PE9 1214513 - 1214947
Rv1089 PE10 PE family protein PE10 1214769 - 1215131
Rv1091 PE_PGRS22 PE-PGRS family protein PE PGRS22 1216469 - 1219030
Rv1135c PPE16 PPE family protein PPE16 1264128 - 1262272
Rv1149 --- Possible transposase 1277893 - 1278300
Rv1168c PPE17 PPE family protein PPE17 1299804 - 1298764
Rv1169c lipX PE family protein. Possible lipase LipX. 1300124 - 1299822
Rv1172c PE12 PE family protein PE12 1302681 - 1301755
Rv1195 PE13 PE family protein PE13 1339003 - 1339302
Rv1196 PPE18 PPE family protein PPE18 1339349 - 1340524
Rv1199c --- Possible transposase 1342605 - 1341358
Rv1214c PE14 PE family protein PE14 1357625 - 1357293
Rv1243c PE_PGRS23 PE-PGRS family protein PE PGRS23 1386677 - 1384989
Rv1313c --- Possible transposase 1469505 - 1468171
Rv1325c PE_PGRS24 PE-PGRS family protein PE PGRS24 1489965 - 1488154
Rv1361c PPE19 PPE family protein PPE19 1533633 - 1532443
Rv1369c --- Probable transposase 1542980 - 1541994
Rv1370c --- Putative transposase for insertion sequence element IS6110 (fragment) 1543255 - 1542929
Rv1386 PE15 PE family protein PE15 1561464 - 1561772
Rv1387 PPE20 PPE family protein PPE20 1561769 - 1563388
Rv1396c PE_PGRS25 PE-PGRS family protein PE PGRS25 1573857 - 1572127
Rv1430 PE16 PE family protein PE16 1606386 - 1607972
Rv1441c PE_PGRS26 PE-PGRS family protein PE PGRS26 1619684 - 1618209
Rv1450c PE_PGRS27 PE-PGRS family protein PE PGRS27 1634627 - 1630638
Rv1452c PE_PGRS28 PE-PGRS family protein PE PGRS28 1638229 - 1636004
Rv1468c PE_PGRS29 PE-PGRS family protein PE PGRS29 1656721 - 1655609
Rv1548c PPE21 PPE family protein PPE21 1753333 - 1751297
Rv1573 --- Probable PhiRv1 phage protein 1779314 - 1779724
Rv1574 --- Probable PhiRv1 phage related protein 1779930 - 1780241
Rv1575 --- Probable PhiRv1 phage protein 1780199 - 1780699
Rv1576c --- Probable PhiRv1 phage protein 1782064 - 1780643
Rv1577c --- Probable PhiRv1 phage protein 1782584 - 1782072
Rv1578c --- Probable PhiRv1 phage protein 1783228 - 1782758
Rv1579c --- Probable PhiRv1 phage protein 1783623 - 1783309
Rv1580c --- Probable PhiRv1 phage protein 1783892 - 1783620
Rv1581c --- Probable PhiRv1 phage protein 1784301 - 1783906
Rv1582c --- Probable PhiRv1 phage protein 1785912 - 1784497
Rv1583c --- Probable PhiRv1 phage protein 1786310 - 1785912
Rv1584c --- Possible PhiRv1 phage protein 1786528 - 1786307
Rv1585c --- Possible phage PhiRv1 protein 1787099 - 1786584
Rv1586c --- Probable PhiRv1 integrase 1788505 - 1787096
Rv1646 PE17 PE family protein PE17 1855764 - 1856696
Rv1651c PE_PGRS30 PE-PGRS family protein PE PGRS30 1865382 - 1862347
Rv1705c PPE22 PPE family protein PPE22 1932654 - 1931497
Rv1706c PPE23 PPE family protein PPE23 1933878 - 1932694
Rv1753c PPE24 PPE family protein PPE24 1984775 - 1981614
Rv1756c --- Putative transposase 1988731 - 1987745
Rv1757c --- Putative transposase for insertion sequence element IS6110 (fragment) 1989006 - 1988680
Rv1763 --- Putative transposase for insertion sequence element IS6110 (fragment) 1996152 - 1996478
Rv1764 --- Putative transposase 1996427 - 1997413
Rv1765A --- Putative transposase (fragment) 1999357 - 1999142
Rv1768 PE_PGRS31 PE-PGRS family protein PE PGRS31 2000614 - 2002470
Rv1787 PPE25 PPE family protein PPE25 2025301 - 2026398
Rv1788 PE18 PE family protein PE18 2026477 - 2026776
Rv1789 PPE26 PPE family protein PPE26 2026790 - 2027971
Rv1790 PPE27 PPE family protein PPE27 2028425 - 2029477
Rv1791 PE19 PE family protein PE19 2029904 - 2030203
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Rv1800 PPE28 PPE family protein PPE28 2039453 - 2041420
Rv1801 PPE29 PPE family protein PPE29 2042001 - 2043272
Rv1802 PPE30 PPE family protein PPE30 2043384 - 2044775
Rv1803c PE_PGRS32 PE-PGRS family protein PE PGRS32 2046842 - 2044923
Rv1806 PE20 PE family protein PE20 2048072 - 2048371
Rv1807 PPE31 PPE family protein PPE31 2048398 - 2049597
Rv1808 PPE32 PPE family protein PPE32 2049921 - 2051150
Rv1809 PPE33 PPE family protein PPE33 2051282 - 2052688
Rv1818c PE_PGRS33 PE-PGRS family protein PE PGRS33 2062674 - 2061178
Rv1840c PE_PGRS34 PE-PGRS family protein PE PGRS34 2089518 - 2087971
Rv1917c PPE34 PPE family protein PPE34 2167311 - 2162932
Rv1918c PPE35 PPE family protein PPE35 2170612 - 2167649
Rv1983 PE_PGRS35 PE-PGRS family protein PE PGRS35 2226244 - 2227920
Rv2013 --- Transposase 2260665 - 2261144
Rv2014 --- Transposase 2261098 - 2261688
Rv2105 --- Putative transposase for insertion sequence element IS6110 (fragment) 2365465 - 2365791
Rv2106 --- Probable transposase 2365740 - 2366726
Rv2107 PE22 PE family protein PE22 2367359 - 2367655
Rv2108 PPE36 PPE family protein PPE36 2367711 - 2368442
Rv2123 PPE37 PPE family protein PPE37 2381071 - 2382492
Rv2126c PE_PGRS37 PE-PGRS family protein PE PGRS37 2387972 - 2387202
Rv2162c PE_PGRS38 PE-PGRS family protein PE PGRS38 2424838 - 2423240
Rv2167c --- Probable transposase 2431145 - 2430159
Rv2168c --- Putative transposase for insertion sequence element IS6110 (fragment) 2431420 - 2431094
Rv2177c --- Possible transposase 2439947 - 2439282
Rv2278 --- Putative transposase for insertion sequence element IS6110 (fragment) 2550065 - 2550391
Rv2279 --- Probable transposase 2550340 - 2551326
Rv2328 PE23 PE family protein PE23 2600731 - 2601879
Rv2340c PE_PGRS39 PE-PGRS family protein PE PGRS39 2618908 - 2617667
Rv2352c PPE38 PPE family protein PPE38 2634098 - 2632923
Rv2353c PPE39 PPE family protein PPE39 2635592 - 2634528
Rv2354 --- Probable transposase for insertion sequence element IS6110 (fragment) 2635628 - 2635954
Rv2355 --- Probable transposase 2635903 - 2636889
Rv2356c PPE40 PPE family protein PPE40 2639535 - 2637688
Rv2371 PE_PGRS40 PE-PGRS family protein PE PGRS40 2651753 - 2651938
Rv2396 PE_PGRS41 PE-PGRS family protein PE PGRS41 2692799 - 2693884
Rv2408 PE24 Possible PE family-related protein PE24 2706017 - 2706736
Rv2424c --- Probable transposase 2721777 - 2720776
Rv2430c PPE41 PPE family protein PPE41 2727920 - 2727336
Rv2431c PE25 PE family protein PE25 2728266 - 2727967
Rv2479c --- Probable transposase 2785643 - 2784657
Rv2480c --- Possible transposase for insertion sequence element IS6110 (fragment) 2785918 - 2785592
Rv2487c PE_PGRS42 PE-PGRS family protein PE PGRS42 2797385 - 2795301
Rv2490c PE_PGRS43 PE-PGRS family protein PE PGRS43 2806236 - 2801254
Rv2512c --- Transposase for insertion sequence element IS1081 2829803 - 2828556
Rv2519 PE26 PE family protein PE26 2835785 - 2837263
Rv2591 PE_PGRS44 PE-PGRS family protein PE PGRS44 2921551 - 2923182
Rv2608 PPE42 PPE family protein PPE42 2935046 - 2936788
Rv2615c PE_PGRS45 PE-PGRS family protein PE PGRS45 2944985 - 2943600
Rv2634c PE_PGRS46 PE-PGRS family protein PE PGRS46 2962441 - 2960105
Rv2646 --- Probable integrase 2970551 - 2971549
Rv2648 --- Probable transposase for insertion sequence element IS6110 (fragment) 2972160 - 2972486
Rv2649 --- Probable transposase for insertion sequence element IS6110 2972435 - 2973421
Rv2650c --- Possible PhiRv2 prophage protein 2975234 - 2973795
Rv2651c --- Possible PhiRv2 prophage protease 2975775 - 2975242
Rv2652c --- Probable PhiRv2 prophage protein 2976554 - 2975928
Rv2653c --- Possible PhiRv2 prophage protein 2976909 - 2976586
Rv2654c --- Possible PhiRv2 prophage protein 2977234 - 2976989
Rv2655c --- Possible PhiRv2 prophage protein 2978658 - 2977231
Rv2656c --- Possible PhiRv2 prophage protein 2979052 - 2978660
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Rv2657c --- Probable PhiRv2 prophage protein 2979309 - 2979049
Rv2659c --- Probable PhiRv2 prophage integrase 2980818 - 2979691
Rv2666 --- Probable transposase for insertion sequence element IS1081 (fragment) 2983071 - 2983874
Rv2741 PE_PGRS47 PE-PGRS family protein PE PGRS47 3053914 - 3055491
Rv2768c PPE43 PPE family protein PPE43 3078078 - 3076894
Rv2769c PE27 PE family protein PE27 3078985 - 3078158
Rv2770c PPE44 PPE family protein PPE44 3080457 - 3079309
Rv2791c --- Probable transposase 3101581 - 3100202
Rv2810c --- Probable transposase 3116142 - 3115741
Rv2812 --- Probable transposase 3116818 - 3118227
Rv2814c --- Probable transposase 3121552 - 3120566
Rv2815c --- Probable transposase 3121827 - 3121501
Rv2853 PE_PGRS48 PE-PGRS family protein PE PGRS48 3162268 - 3164115
Rv2885c --- Probable transposase 3195548 - 3194166
Rv2892c PPE45 PPE family protein PPE45 3202020 - 3200794
Rv2943 --- Probable transposase for insertion sequence element IS1533 3288464 - 3289705
Rv2943A --- Possible transposase 3289705 - 3290235
Rv2944 --- Possible transposase for insertion sequence element IS1533 3289790 - 3290506
Rv2961 --- Probable transposase 3313283 - 3313672
Rv2978c --- Probable transposase 3335164 - 3333785
Rv3018c PPE46 PPE family protein PPE46 3378243 - 3376939
Rv3018A PE27A PE family protein PE27A 3378415 - 3378329
Rv3021c PPE47 PPE family protein PPE47 3380452 - 3379376
Rv3022c PPE48 PPE family protein PPE48 3380682 - 3380440
Rv3022A PE29 PE family protein PE29 3380993 - 3380679
Rv3023c --- Probable transposase 3382622 - 3381375
Rv3115 --- Probable transposase 3481451 - 3482698
Rv3125c PPE49 PPE family protein PPE49 3491651 - 3490476
Rv3135 PPE50 PPE family protein PPE50 3501334 - 3501732
Rv3136 PPE51 PPE family protein PPE51 3501794 - 3502936
Rv3144c PPE52 PPE family protein PPE52 3511317 - 3510088
Rv3159c PPE53 PPE family protein PPE53 3529163 - 3527391
Rv3184 --- Probable transposase for insertion sequence element IS6110 (fragment) 3551281 - 3551607
Rv3185 --- Probable transposase 3551556 - 3552542
Rv3186 --- Probable transposase for insertion sequence element IS6110 (fragment) 3552764 - 3553090
Rv3187 --- Probable transposase 3553039 - 3554025
Rv3191c --- Probable transposase 3558345 - 3557311
Rv3325 --- Probable transposase for insertion sequence element IS6110 (fragment) 3710433 - 3710759
Rv3326 --- Probable transposase 3710708 - 3711694
Rv3327 --- Probable transposase fusion protein 3711749 - 3713461
Rv3343c PPE54 PPE family protein PPE54 3736935 - 3729364
Rv3344c PE_PGRS49 PE-PGRS family protein PE PGRS49 3738438 - 3736984
Rv3345c PE_PGRS50 PE-PGRS family protein PE PGRS50 3742774 - 3738158
Rv3347c PPE55 PPE family protein PPE55 3753184 - 3743711
Rv3348 --- Probable transposase 3753765 - 3754256
Rv3349c --- Probable transposase 3755033 - 3754293
Rv3350c PPE56 PPE family protein PPE56 3767102 - 3755952
Rv3367 PE_PGRS51 PE-PGRS family protein PE PGRS51 3778568 - 3780334
Rv3380c --- Probable transposase 3796086 - 3795100
Rv3381c --- Probable transposase for insertion sequence element IS6110 (fragment) 3796361 - 3796035
Rv3386 --- Possible transposase 3800092 - 3800796
Rv3387 --- Possible transposase 3800786 - 3801463
Rv3388 PE_PGRS52 PE-PGRS family protein PE PGRS52 3801653 - 3803848
Rv3425 PPE57 PPE family protein PPE57 3842239 - 3842769
Rv3426 PPE58 PPE family protein PPE58 3843036 - 3843734
Rv3427c --- Possible transposase 3844640 - 3843885
Rv3428c --- Possible transposase 3845970 - 3844738
Rv3429 PPE59 PPE family protein PPE59 3847165 - 3847701
Rv3430c --- Possible transposase 3848805 - 3847642
Rv3474 --- Possible transposase for insertion element IS6110 (fragment) 3890830 - 3891156
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Rv3475 --- Possible transposase for insertion element IS6110 [second part] 3891105 - 3892091
Rv3477 PE31 PE family protein PE31 3894093 - 3894389
Rv3478 PPE60 PE family protein PPE60 3894426 - 3895607
Rv3507 PE_PGRS53 PE-PGRS family protein PE PGRS53 3926569 - 3930714
Rv3508 PE_PGRS54 PE-PGRS family protein PE PGRS54 3931005 - 3936710
Rv3511 PE_PGRS55 PE-PGRS family protein PE PGRS55 3939617 - 3941761
Rv3512 PE_PGRS56 PE-PGRS family protein PE PGRS56 3941724 - 3944963
Rv3514 PE_PGRS57 PE-PGRS family protein PE PGRS57 3945794 - 3950263
Rv3532 PPE61 PPE family protein PPE61 3969343 - 3970563
Rv3533c PPE62 PPE family protein PPE62 3972453 - 3970705
Rv3539 PPE63 PPE family protein PPE63 3978059 - 3979498
Rv3558 PPE64 PPE family protein PPE64 3997980 - 3999638
Rv3590c PE_PGRS58 PE-PGRS family protein PE PGRS58 4033158 - 4031404
Rv3595c PE_PGRS59 PE-PGRS family protein PE PGRS59 4038050 - 4036731
Rv3621c PPE65 PPE family protein PPE65 4061889 - 4060648
Rv3622c PE32 PE family protein PE32 4062198 - 4061899
Rv3636 --- Possible transposase 4075752 - 4076099
Rv3637 --- Possible transposase 4076484 - 4076984
Rv3638 --- Possible transposase 4076984 - 4077730
Rv3640c --- Probable transposase 4079749 - 4078520
Rv3650 PE33 PE family protein PE33 4091233 - 4091517
Rv3652 PE_PGRS60 PE-PGRS family-related protein PE PGRS60 4093632 - 4093946
Rv3653 PE_PGRS61 PE-PGRS family-related protein PE PGRS61 4093940 - 4094527
Rv3738c PPE66 PPE family protein PPE66 4190232 - 4189285
Rv3739c PPE67 PPE family protein PPE67 4190517 - 4190284
Rv3746c PE34 Probable PE family protein PE34 (PE family-related protein) 4196506 - 4196171
Rv3751 --- Probable integrase (fragment) 4198874 - 4199089
Rv3798 --- Probable transposase 4252993 - 4254327
Rv3812 PE_PGRS62 PE-PGRS family protein PE PGRS62 4276571 - 4278085
Rv3827c --- Possible transposase 4302789 - 4301563
Rv3844 --- Possible transposase 4318775 - 4319266
Rv3872 PE35 PE family-related protein PE35 4350745 - 4351044
Rv3873 PPE68 PPE family protein PPE68 4351075 - 4352181
Rv3892c PPE69 PPE family protein PPE69 4375683 - 4374484
Rv3893c PE36 PE family protein PE36 4375995 - 4375762
Rv0287* esxG ESAT-6 like protein EsxG (conserved protein TB9.8) 351525 - 351818
Rv1037c* esxI Putative ESAT-6 like protein EsxI (ESAT-6 like protein 1) 1160828 - 1160544
Rv1038c* esxJ ESAT-6 like protein EsxJ (ESAT-6 like protein 2) 1161151 - 1160855
Rv1197* esxK ESAT-6 like protein EsxK (ESAT-6 like protein 3) 1340659 - 1340955
Rv1198* esxL Putative ESAT-6 like protein EsxL (ESAT-6 like protein 4) 1341006 - 1341290
Rv1792* esxM ESAT-6 like protein EsxM 2030347 - 2030643
Rv1793* esxN Putative ESAT-6 like protein EsxN (ESAT-6 like protein 5) 2030694 - 2030978
Rv2346c* esxO Putative ESAT-6 like protein EsxO (ESAT-6 like protein 6) 2626172 - 2625888
Rv2347c* esxP Putative ESAT-6 like protein EsxP (ESAT-6 like protein 7) 2626519 - 2626223
Rv3017c* esxQ ESAT-6 like protein EsxQ (TB12.9) (ESAT-6 like protein 8) 3376852 - 3376490
Rv3019c* esxR Secreted ESAT-6 like protein EsxR (TB10.3) (ESAT-6 like protein 9) 3379001 - 3378711
Rv3020c* esxS ESAT-6 like protein EsxS 3379329 - 3379036
Rv3444c* esxT Putative ESAT-6 like protein EsxT 3862926 - 3862624
Rv3445c* esxU ESAT-6 like protein EsxU 3863264 - 3862947
Rv3619c* esxV Putative ESAT-6 like protein EsxV (ESAT-6 like protein 1) 4060268 - 4059984
Rv3620c* esxW Putative ESAT-6 like protein EsxW (ESAT-6 like protein 10) 4060591 - 4060295
Rv3875* esxA 6 kDa early secretory antigenic target EsxA (ESAT-6) 4352609 - 4352896
Rv3890c* esxC ESAT-6 like protein EsxC (ESAT-6 like protein 11) 4374013 - 4373726
Rv3891c* esxD Possible ESAT-6 like protein EsxD 4374372 - 4374049
Rv3904c* esxE Putative ESAT-6 like protein EsxE (hypothetical alanine rich protein) (ESAT-6 like protein 12) 4390709 - 4390437
Rv3905c* esxF Putative ESAT-6 like protein EsxF (hypothetical alanine and glycine rich protein) (ESAT-6 like protein 13) 4391031 - 4390720
Rv2543* lppA Probable conserved lipoprotein LppA 2866468 - 2867127
Rv2544* lppB Probable conserved lipoprotein LppB 2867124 - 2867786
Rv2048c* pks12 Polyketide synthase Pks12 2306986 - 2294531
